ビジネスワイヤ(バフェットのBerkshire Hathaway group）
Synchronoss Cloud Analytics Prototype Helps NTT Plala Ident… 2017年06月27日 23時10分
Platform delivers cutting edge insights to meet business objectives
with industry leading service provider partners
TOKYO--(BUSINESS WIRE)--Synchronoss Technologies, Inc. (NASDAQ:SNCR), has been selected by NTT
Plala, a major Japanese internet service provider (ISP), to implement an
advanced analytics prototype to generate data insights that will
increase the effectiveness of cross-selling and upselling services to
their existing subscribers. Synchronoss’ Cloud Analytics platform
delivers proactive, data-driven insights derived from NTT Plala’s
customers’ preferences. This data will enable NTT Plala to achieve sales
and service enhancements that effectively engage customers and boost
product penetration.
“We were impressed by the depth and granularity of the insights
delivered by the Synchronoss Cloud Analytics platform, making it easier
to target our audiences with new and enhanced services to improve the
overall customer experience,” said Katsumi Nagata, Executive Director of
NTT Plala. “The platform enables us to engage directly with existing
customers, and to use powerful analytics and targeting to deliver
further value and meet business objectives.”
Through data science, machine learning, and artificial intelligence,
Synchronoss employs a prescriptive approach that includes targeting,
advanced segmentation and market analysis, optimization, distribution,
as well as campaign measurement. By delivering relevant insights to the
appropriate business teams through a user-friendly interface, NTT Plala
will be able to identify which customers are more likely to buy specific
services, gain insight into why these customers are being targeted
(based on contextual information, behavior and interaction), and inform
which campaigns to launch in order to best upsell their customers.
“ISPs need a data-driven way to identify new monetization opportunities
with existing and potential customers, and our Cloud Analytics platform
offers impressive depth and powerful capabilities that enable NTT Plala
to achieve tangible results,” said Charlie Thomas, executive vice
president and general manager at Synchronoss Technologies. “The new
platform is poised to quickly create new revenue streams and enhance
existing ones for carriers around the globe.”
Learn more about Synchronoss Cloud Analytics here:
http://synchronoss.com/products/cloud/cloud-analytics/
About Synchronoss Technologies, Inc.
Synchronoss (NASDAQ:SNCR) helps service providers to transform their
business by providing scalable and secure mobile software solutions for
communications, content, and collaboration. By providing simple,
powerful and flexible technology, we enable our customers to realize and
execute their goals for mobile transformation. Synchronoss white label
solutions allow service providers and enterprises to streamline
operations and drive new revenue across channels, devices and platforms.
In our 20+ year history, we have earned the trust and business of Tier 1
service providers across the globe with an unparalleled reputation for
security, scalability, and support that positively create profitable
business results. For more information, visit www.synchronoss.com.
The Synchronoss logo, Synchronoss and Synchronoss Integrated Life are
trademarks of Synchronoss Technologies, Inc. All other trademarks are
property of their respective owners.
Contacts
Investor and Media:
Synchronoss Technologies, Inc.
Daniel
Ives, 908-524-1047
daniel.ives@synchronoss.com
NEC Tests Facial Recognition with U.S. Customs and Border P… 2017年06月27日 23時00分
A fast-photo match at the gate on select Emirates Airline flights
will help expedite boarding experience while providing biometrics-based
exit verification
IRVING, Texas & TOKYO--(BUSINESS WIRE)--NEC Corporation and NEC Corporation of America (NEC) today announced a
pilot to test NEC’s commercial-off-the-shelf (COTS) NeoFace®
Express device and cloud-based NeoFace matching as key facial
recognition components of a frictionless biometric exit process in
Dulles International Airport.
Started earlier this month on flights from Dulles International Airport
in Washington, D.C., to Dubai, United Arab Emirates (UAE), at a gate
operated by Emirates Airlines, passengers will simply step up to a
NeoFace Express device which captures the photo for matching.
The Dulles International pilot, which follows an earlier Atlanta
Hartsfield pilot, is one of several CBP pilots to implement the federal
government’s mandated Biometric Exit Program to verify the identity of
travelers leaving the United States.
“NEC is pleased to have participated in the Dulles and Atlanta pilots
with CBP and we are glad that our technology can potentially be used to
help achieve CBP’s greater missions,” said Raffie Beroukhim, Senior Vice
President, NEC Corporation of America, Advanced Recognition Systems
Division.
NEC Advanced Recognition Systems information: www.necam.com/ARS
NEC
information: www.necam.com
Blog: www.NECToday.com
LinkedIn: www.linkedin.com/company/nec-corporation-of-america
YouTube: www.youtube.com/interactiveNEC
Facebook
fan page: www.necam.com/facebook
Twitter:
@NEC
About NEC Corporation of America
NEC Corporation of America (NEC) is a leading technology integrator
providing solutions that improve the way people work and communicate.
NEC delivers integrated Solutions for Society that are aligned with our
customers' priorities to create new value for people, businesses and
society, with a special focus on safety, security and efficiency. We
deliver one of the industry's strongest and most innovative portfolios
of communications, analytics, security, biometrics and technology
solutions that unleash customers' productivity potential. Through these
solutions, NEC combines its best-in-class solutions and technology, and
leverages a robust partner ecosystem to solve today's most complex
business problems. NEC Corporation of America is a wholly-owned
subsidiary of NEC Corporation, a global technology leader with a
presence in 160 countries and $25 billion in revenues. For more
information, please visit www.necam.com.
About NEC Corporation
NEC Corporation is a leader in the integration of IT and network
technologies that benefit businesses and people around the world. By
providing a combination of products and solutions that cross utilize the
company’s experience and global resources, NEC’s advanced technologies
meet the complex and ever-changing needs of its customers. NEC brings
more than 100 years of expertise in technological innovation to empower
people, businesses and society. For more information, visit NEC at http://www.nec.com.
© 2017 NEC Corporation of America. NEC and NeoFace are registered
trademarks of NEC Corporation. All Rights Reserved. Other product or
service marks mentioned are the trademarks of their respective owners.
Contacts
NEC Corporation of America
John Wise, 214-262-6385
Senior
Manager, Marketing Communications
john.wise@necam.com
QS Pharma Receives Approval from European Medicines Agency … 2017年06月27日 17時50分
QS Pharma, a Quotient Clinical business, is now approved to
manufacture medicinal products for the US, Europe and Japan
PHILADELPHIA & NOTTINGHAM, England--(BUSINESS WIRE)--#ClinicalPharmacology--QS Pharma, the Contract Development and Manufacturing Organisation
(CDMO), which was acquired by Quotient Clinical (“Quotient”) in February
2017, today announced it has received approval from the European
Medicines Agency (EMA) to manufacture certain medicinal products for
commercial use in Europe.
QS Pharma’s manufacturing facility in Boothwyn, Pennsylvania, was
inspected in February 2017 by the Dutch Health Care Inspectorate (IGZ)
at the request of the EMA. The assessment focused on two NDA filed
products, and the overall quality systems of QS Pharma. Following the
successful outcome of the inspection, added to past approvals from the
FDA and PDMA, QS Pharma is now approved to manufacture medicinal
products for the US, Europe and Japan.
Nutan Gangrade, Managing Director, QS Pharma, said: “QS Pharma is
dedicated to maintaining a robust quality system, underpinned by our
excellent regulatory history. This approval by the EMA ensures we are
able to support customers with interests in Europe, creating further
growth opportunities for the business.”
Mark Egerton, Chief Executive Officer, Quotient Clinical, said:
“QS Pharma is becoming a major global player in the commercial
manufacture of market products, with a focus on high potency
manufacturing, and niche therapies and markets such as orphan drugs, for
tablets, capsules and oral liquids. This latest inspection and approval
adds further value to the business.”
ENDS
About QS Pharma http://www.qspharma.com
Founded
in 2002, QS Pharma specialises in the formulation development and
manufacturing of small molecule drug products, and is capable of
supporting customer programs through all stages of development and
commercialisation. Of particular relevance is QS Pharma’s capability to
work with high potency molecules, which is a fast-growing market need.
QS Pharma was acquired by Quotient Clinical in February 2017. Further
details of the announcement can be viewed here.
About Quotient Clinical http://www.quotientclinical.com
Quotient
Clinical is a drug development services provider, focused on helping
clients reduce the time and cost of bringing a drug to market. We
deliver integrated capabilities including formulation development, GMP
drug product manufacturing and clinical pharmacology services to biotech
and pharmaceutical clients globally.
We employ over 600 staff and operate from state-of-the-art manufacturing
and clinical facilities in the UK and USA. We can support our clients,
working under FDA or MHRA guidelines, and offer a full range of support
services, from study set-up right through to data analysis and reporting.
Contacts
Zyme Communications
Katie Odgaard
Tel: +44
(0)7787 502 947
Email: katie.odgaard@zymecommunications.com
or
Quotient
Clinical
Robin Bodicoat
Marketing Director
Tel:
+44 (0)115 931 5102
Email: robin.bodicoat@quotientclinical.com
有名韓国キャラクター日本上陸…ライセンシングジャパンで会いま… 2017年06月27日 17時17分
韓国・京畿道富川--(BUSINESS WIRE)--#GCA--（ビジネスワイヤ） -- 京畿コンテンツ振興院（Gyeonggi
Content Agency）は6月28日から30日まで東京で開かれる‘ライセンシングジャパン’に参加して京畿道館を運営する計画を明らかにした。京畿コンテンツ振興院は韓国コンテンツ産業の中心地である京畿道の文化コンテンツ産業を育成および支援する公共機関で、道内コンテンツ産業の海外進出を支援している。
今年で7回目を迎える‘ライセンシングジャパン(Licensing
Japan)’は日本最大のコンテンツビジネス総合展示会‘コンテンツ東京(Content
Tokyo)’を構成する専門展示会のひとつで、日本国内のライセンシング専門マーケットで最大規模のキャラクターライセンシング展示会だ。
振興院は今年初めて日本展示会に参加して、京畿道館を運営する計画で6つの京畿道のキャラクター企業が参加してブース展示およびビジネスミーティングを行う。参加企業はアートライセンシング(ARTLicensing、代表
イヨンス)、トリデザイン(TORI
DESIGN、代表 ユンヨンチョル)、クリスピ(XrisP、大行
ソンデギュン)、ヒョンソルエヌ(代表
ジャンジンヒョック)、ケミカルエディション(CHEMICAL
EDITION、代表 イムジョンミヌ)、ガビア(Gabia、代表
キムホンクグ)だ。
アートライセンシングは根強い人気を博しているかわいいワンちゃんキャラクターの‘パンア’と地上波MBCで放送されている‘私の友達マカダ’を展示する予定で、すでに海外展示会で参加して成果を挙げたトリデザインは愛されるキャラクター‘トリちゃん’と新しいキャラクター蛍妖精
‘ルシポン’のライセンシングビジネス拡大を目指している。
クリスピはKBS2で放送されているTVアニメーション ‘ローラーコースターボイ,
ノリ’の配給およびライセンシング事業を継続する方針で、ヒョンソルエヌは韓国的なキャラクター
‘黒いゴム靴’と根強い人気を博しているかわいいキャラクター‘ポグリ’で日本販路を開拓しようとしている。またケミカルエディションは乳幼児層はもちろんキダルトまで攻略する洗練されたデザイン‘ロングイアバップ’を、ガビアは‘アム’という独特で差別化されたキャラクターを披露する予定だ。
上記以外にも、振興院はキャラクターライセンシング強国の日本市場に進出するため、8月末から開かれる第84回東京インターナショナル・ギフト・ショー(Tokyo
International Gift
Show)にも参加して道内のキャラクターの優秀性を宣伝し、道内企業が日本市場に本格的に進出するための足場を固めるつもりだ。
Contacts
For 京畿コンテンツ振興院
AVING NEWS
Judy Yu, +82.2.856.3276
globalpr@aving.net
Nomura Files Annual Report on Form 20-F 2017年06月27日 16時12分
TOKYO--(BUSINESS WIRE)--Nomura Holdings, Inc. (TOKYO:8604) filed its Annual Report on Form 20-F
(for the fiscal year ended March 31, 2017) with the U.S. Securities and
Exchange Commission on June 26, 2017. The report can be accessed via
Nomura’s website at:
http://www.nomuraholdings.com/investor/library/sec/
The shareholders of Nomura Holdings, Inc. (including holders of its
American Depositary Receipts) may receive a printed copy of the Annual
Report on Form 20-F, which contains Nomura’s most recent audited
consolidated financial statements, free of charge upon request via:
https://www.nomuraholdings.com/cgi-bin/investor/ar/request.cgi
Nomura
Nomura is an Asia-headquartered financial services group with an
integrated global network spanning over 30 countries. By connecting
markets East & West, Nomura services the needs of individuals,
institutions, corporates and governments through its three business
divisions: Retail, Asset Management, and Wholesale (Global Markets and
Investment Banking). Founded in 1925, the firm is built on a tradition
of disciplined entrepreneurship, serving clients with creative solutions
and considered thought leadership. For further information about Nomura,
visit www.nomura.com.
Contacts
For further information please contact:
Nomura Holdings, Inc.
Joey
Wu / Michael Lintaro Yasuhara, 81-3-3278-0591
Group Corporate
Communications Dept.
SAISON INFORMATION SYSTEMS : SCSK Asia Pacific Becomes Cert… 2017年06月27日 14時27分
Strengthening the sales, implementation, and technical support for
HULFT's IT integration offerings in the ASEAN region
TOKYO--(BUSINESS WIRE)--SCSK Asia Pacific becomes Certified HULFT Partner, strengthening the
sales, implementation, and technical support for HULFT's IT integration
offerings in the ASEAN region.
SCSK Asia Pacific Pte. Ltd. (Managing Director: Shu Wei; Herein: SCSK
Asia Pacific) is the Singaporean subsidiary of SCSK Corporation
(Headquarters: Tokyo, Japan; CEO: Tooru Tanihara; Herein: SCSK).
HULFT Pte. Ltd. (Herein: HULFT Pte) is the Singaporean subsidiary of
Saison Information Systems Co., Ltd. (Headquarters: Tokyo, Japan; CEO:
Kazuhiro Uchida; Herein: Saison Information Systems). The company makes
middleware products including HULFT (managed file transfer, MFT) and
DataSpider Servista (enterprise data integration, EDI).
HULFT Pte certified SCSK Asia Pacific as a HULFT Implementation Partner*
in May 2017.
* A specific designation within the HULFT Partner Program (HPP), which
certifies participants to provide various services for the HULFT family
of data management middleware products.
Background
SCSK has been offering data integration solutions since the late 1990s,
and has a track record of over 250 successful implementation projects.
Since its establishment in 2007, SCSK Asia Pacific has provided
strategic IT support as a business partner of Japanese companies in the
ASEAN region. In response to the rapidly changing global economy,
interest in data integration is increasing in the region, particularly
in the financial and manufacturing industries.
These developments lead to it being ideal timing to establish
capabilities to provide consistent sales, implementation services, and
support for HULFT and DataSpider Servista. These middleware products
enable end users to take advantage of new business opportunities by
ensuring reliable and secure integration of devices, clouds, and
applications.
Future Developments
SCSK Asia Pacific has already received orders from several companies and
started providing support services with the aim of functioning as a
one-stop solution provider for customers in the ASEAN region.
Using Singapore as their base, HULFT Pte will work closely with SCSK
Asia Pacific to develop business in several markets including Indonesia,
Thailand. The companies will also cooperate to assist customers entering
the ASEAN region with data integration.
About HULFT
Compatible with an ever-growing range of platforms since its launch in
1993, HULFT is managed file transfer (MFT) middleware equipped with all
the functionality enterprises need to share data between business
systems. As of March 2017, there are 189,600 HULFT licenses in use by
8,700 companies in 43 countries worldwide, spanning a broad range of
industries. In addition to sending, receiving and managing file transfer
jobs, HULFT also includes peripheral functions essential to transferring
files, including security and integration of data before and after
transfer.
Product Details: https://www.hulft.com/en/hulft-mft/
About DataSpider Servista
As of March 2017, DataSpider Servista has been installed by over 3,000
companies. In Japan, it has been ranked No. 1 in customer satisfaction
for four years running*. Its GUI enables quick and easy setup without
the need for coding. Its many adapters can connect a wide variety of
systems, applications, databases, and other data sources hosted either
on-premise or in the cloud. It can be used to automate a broad range of
processes, thereby greatly improving an organization’s operational
efficiency.
Product Details: https://www.hulft.com/en/dataspider-servista
* Source: EAI Software survey by Nikkei BP Consulting, April 2017.
SCSK Corporation
Headquarters: Toyosu Front, 3-20 Toyosu, Koto-ku, Tokyo 135-0061, Japan
Establishment: October 1969
Representative: Tooru Tanihara (Representative Director and President,
Executive Officer)
Website: http://www.scsk.jp/index_en.html
SCSK Asia Pacific Pte. Ltd.
Headquarters: #05-04 Mapletree Anson, 60 Anson Road, Singapore 079914
Establishment: November 2007
Representative: Shu Wei
Website: http://www.scskap.com/english/index.html
Saison Information Systems Co., Ltd.
Headquarters: Sunshine 60 (21F), 3-1-1 Higashi-Ikebukuro, Toshima-ku,
Tokyo 170-6021, Japan
Established: September 1970
President: Kazuhiro Uchida (President & CEO)
Website: http://home.saison.co.jp/english/
Notes:
* HULFT and related product names are registered trademarks
or trademarks of Saison Information Systems Co., Ltd.
* DataSpider
and DataSpider Servista are registered trademarks or trademarks of
Appresso K.K.
* Other company names, product names and service
names are registered trademarks or trademarks of their respective
companies.
Contacts
Product Inquiries:
SCSK Corporation
+81-3-5166-1960
IT
Engineering Division Middleware Department
hulft-sales@ml.scsk.jp
or
Saison
Information Systems Co., Ltd.
Masaaki Takayama, +81-3-3988-5301
HULFT
Division
info@hulft.com
or
Press
Inquiries:
SCSK Corporation
Kurioka, +81-3-5166-1150
Public
Relations Department
or
SCSK Asia Pacific Pte. Ltd.
Hasegawa,
+65-6530-5687
Business Solution Team
Enterprise Solution
Department
contacts@scskap.com
or
Saison
Information Systems Co., Ltd.
Akane Toyota / Seiko Yokoi,
+81-3-3988-3477
Corporate Planning Department
kikaku@saison.co.jp
LEDを自然な光に回帰させるソウル半導体の新技術“SunLike” 2017年06月27日 10時51分
ソウル半導体のLEDチップに関する特許技術と東芝マテリアルの蛍光体技術“TRI-R”を組み合わせたLED製品のSunLikeシリーズは、次世代LEDとして世界最高レベルの光の質を提供し、サーカディアンリズムに合わせて最適化されたヒューマンセントリックな照明を実現します。
韓国安山市--(BUSINESS WIRE)--（ビジネスワイヤ） -- LED製品および技術の世界的なイノベータのSeoul Semiconductor Co., Ltd.
(本社：韓国安山市、代表理事：李貞勲、以下「ソウル半導体」)は、太陽光のスペクトルにほぼ完全に一致した光を発するLEDの新技術を開発した。2017年6月26日、ドイツ・フランクフルトでメディア向けに開催された新技術説明会で、ソウル半導体は、東芝マテリアル株式会社(本社：神奈川県横浜市)と自然光スペクトルのLED技術の「サンライク（SunLike）」シリーズを共同開発したと発表した。
自然な光に回帰
人類は何万年もの間、自然な太陽光の下で生活してきた。そして、紀元前3世紀になって初めてランタンが使われ始めた、一般照明用途に白色LEDが使われるようになってから、まだ20年にもならないが、LED照明は、高効率で、コストセーブになるため世界中で急速に普及した。しかし、低コスト化と高効率化にばかり注目が集まり、光の質は二の次の扱いになっていた。そのため、従来のLEDが放つ光は、人間のバイオリズムの基本となっている太陽光とは異なる特性を持っている。
SunLike技術によるLEDは、人類が何千年もの間、慣れ親しんできた太陽光のスペクトルにほぼ完全に一致している。SunLike技術は、自然光の長所を最大化し、人工的な光源の短所を最小化することによって、より自然光に近い光を実現している。太陽光とほぼ同等のスペクトルは、ソウル半導体の世界トップレベルのLEDチップ技術と、東芝マテリアルの蛍光体材料に関する先進的なTRI-R技術が融合して誕生した。
東芝マテリアルの小林薫平社長は、「ソウル半導体のようなLEDの世界トップメーカーと協業し、自然光スペクトルLEDのSunLikeシリーズを発表する運びとなって満足しています。人間にとってより親しみがあり、自然な光による明かりの環境を作る先進技術の代表となるでしょう」と語った。
ソウル半導体の李貞勲代表理事は、「太陽光のスペクトルに限りなく近い光を発するLEDのSunLikeシリーズを発表することによって、新たに韓国発のLED技術のイノベーションを世に送り出すことができて喜ばしい。LEDのパッケージング工程に革命を起こしたソウル半導体のパッケージレスLEDのWICOPシリーズと同様に、SunLikeシリーズも、自然光スペクトルのLED照明を具現化する上で革命となるでしょう。SunLikeシリーズのLEDは、照明分野に応用され、人類のより健康的な生活に寄与することでしょう。また、植物育成の分野にも応用可能で、遺伝子組み換えよりも安全で、理想的な植物育成環境を作り出すことができます」とコメントしている。
李代表理事は、「東芝マテリアルと手を携え、朝日の明るさに始まり、昼間光のエネルギーへと続き、夕暮れの日没の暖かい光に至る、太陽光の自然なスペクトルを実現する光源をお客様にお届けすることができて光栄です。ヒューマンセントリックな照明技術の新たな時代を切り開くことによって、SunLikeシリーズのLEDが人々の生活の質を高めると信じています」と続けた。
ブルーライトの副作用を最小化
SunLikeシリーズのLEDは、太陽光のスペクトルに限りなく一致する光を発するように作られているため、自然光の恩恵を最大化するヒューマンセントリックな照明のための光源として最適化されていると言える。一方、人工光源のマイナス面の影響は最小化されている。
ハーバード大学など、著名な大学による近年の研究によると、可視光を生成する一般的なLEDに使われている青色LEDチップの光は、昼間に見ると、注意力を高め、ムードを盛り上げる正の刺激を人に目に与えるが、青色LEDは、LEDの光出力に青の波長の「スパイク」を含んでおり、夜間に長時間見ると、負の影響を与えることがあり、人間のバイオリズムを干渉することがあるという。SunLikeシリーズの自然光スペクトルLED技術は、紫色LEDを採用しており、TRI-R蛍光体技術と組み合わせて、一般的なLED光源の特性であるブルーライトの「スパイク」を最小化している。これにより、太陽光のスペクトルに限りなく近い光出力を実現し、より健康的な照明体験を提供することができる。
*Blue Light Articles (Source: Harvard Medical School)
http://www.health.harvard.edu/staying-healthy/blue-light-has-a-dark-side
SunLikeの世界トップクラスの色の再現性
Natureなど、学術論文誌に掲載された研究結果によると、人間は、何千年もの間、太陽の下で生活してきた歴史があるため、人間の器官やバイオリズムは太陽光に対して最も適切に反応するように進化している。色に関する光の入力を解釈して、それに反応する人間の網膜細胞は、赤・緑・青の錐体細胞で構成されており、青の受容体の割合はわずか5.7%である。
人間の目が受容することができる青い光の量は限られているため、青い光が限度を超えて目に入ってくると、その光は散乱する。散乱現象が起こると、光は拡散し、結果として、物体の質感と色は歪められる。また、過剰な青い光は、目の網膜細胞に過剰な刺激を与えることがあり、目の疲れや注意力喪失などを引き起こすことがある。一方、SunLikeシリーズのLEDは、太陽光とほぼ同等のスペクトルを持っているため、自然光の中での物体の質感と色を正確に再現し、過剰な青い光が目や生物リズムに与える負の影響はほとんどなくなる。東芝マテリアルのTRI-R技術が採り入れられた製品は、すでにミラノコレクション(Milan
Fashion Week)や、美術館の絵画の照明などに採用されている。
アプリケーションおよび市場の見通し
SunLikeは、百貨店や、宝石店など、太陽光の下で見えるのとまったく同じ製品の色を演出する必要のある商業施設や、植物を屋内で育成するための植物工場、美術館や展示会などの展示施設、試着室や化粧室など美容関連施設などで応用されると見込まれている。
世界の照明市場は870億ドルと推定されており、そのうちLED照明は350億ドル程度を占めると言われている。SunLikeシリーズのLED製品が応用されると考えられる市場は170億ドルと見られる。自然光スペクトルLEDのSunLikeシリーズは、高品質照明のアプリケーションから始まり、最終的には一般照明市場にまで採用が進んで行くと予想される。
ソウル半導体について
ソウル半導体は、自動車、一般照明、特殊照明、およびバックライト市場に向けて発光ダイオード(LED)を開発、販売している。LEDメーカーとして世界4位のソウル半導体は、12,000件以上の特許を保有し、幅広い技術を提供しながら、”Wicop”
(市場トップの色の均一性を誇り、高いルーメン密度と設計自由度で器具コストを低減可能な、シンプルな構造のパッケージレスLED)、” Acrich"
(2005年に開発された世界初の高電圧AC駆動LED技術であり、チップからモジュール、回路製造工程、マルチジャンクションテクノロジー(MJT)を含むあらゆるAC
LED関連技術)、”nPola"
(従来のLEDよりも10倍以上の光出力を実現するGaN基板をベースとする新技術)、ソウル半導体に関する最新情報は http://www.seoulsemicon.com/jp/
を参照。
*東芝マテリアルについて
東芝マテリアル株式会社(http://www.toshiba-tmat.co.jp)は、2003年に株式会社東芝から分離独立。材料設計技術を中核として、社会の発展をサポートする主要材料と核心部品を供給している。主な製品は、金属材料、部品、精密セラミック部品、化学材料。2017年3月31日現在の売上高は、140億円である。
WicopおよびAcrichはSeoul Semiconductor Co., Ltd.の商標です。
TRI-Rは東芝マテリアル株式会社の商標です。
Contacts
報道関係者お問い合わせ先：
日本支社：ジャパンソウル半導体株式会社
広報担当
03-5360-7620
リミニストリートが革新的な顧客サービスで 2017 Asia-Pacific … 2017年06月27日 09時00分
今年10個目のスティービーアワード受賞、 業界をリードする顧客サービスで世界的評価をふたたび獲得
ラスベガス発--(BUSINESS WIRE)--（ビジネスワイヤ） --
Oracle®およびSAP®などエンタープライズソフトウェア向けの独立系保守サービスを提供するグローバルリーディングカンパニーのリミニストリートは、本日、2017
Asia-Pacific Stevie Awardsの「Innovation in Customer Service Management,
Planning &
Practice」部門で、名誉あるスティービーアワードを受賞したことを発表しました。これで今年に入って10個目のスティービーアワード受賞の栄誉に輝き、2017
American Business AwardsSM の「Most
Innovative Tech Company of the Year」、2017 Stevie Awards for Sales &
Customerの「Customer
Service Department of the Year」など7部門でスティービーアワードを獲得しました。
世界規模の優れたカスタマーサービスが再度評価を受ける
リミニストリートのグローバルサポート部門は、OracleやSAPのエンタープライズソフトウェアを運用しているお客様にプレミアムレベルの独立系サポートモデルを提供しており、今回のスティービーアワードの受賞は、同部門の顧客サービスの卓越性と革新性が優れたレベルに達していることが評価されたものです。サポートモデルには、カスタマイズ部分のサポート、相互運用性、パフォーマンスのチューニング、平均15年の経験を持つ専任サポートエンジニア（PSE）の任命、最重要ケース（P1）については15分以内の応答の保証といった、ベンダーの標準的な保守サービスでは提供されない、より包括的なサービスが組み込まれており、これらがすべてベンダーの年間保守料金の半分の価格で提供されます。
サポートをリミニストリートに切り替えたお客様も受賞
独立系の保守サポートに切り替え、迅速なサポートによって運用効率と柔軟性を高めている企業は、これによって大幅に削減された費用をビジネスの革新に再投資し、成長と優位性をもたらすより戦略的なイニシアチブを推進できます。この好例として、熊谷組が挙げられます。
ゼネコンのひとつである熊谷組は、リミニストリートに切り替えたことで、即座にERPソフトウェアのアップグレードに伴うITコストを1億円削減しました。同社はまた、年間4000万円の運用コストと保守費用の削減を実現する一方で、より迅速なサポート対応をリミニストリートから得ることができました。これにより、iPadを800台導入して企業全体の業務効率を向上させるなど、節約した資金を新しいプロジェクトに振り向けることを可能にしました。その結果、熊谷組は今年初めに企業情報化協会（IT協会）のIT特別賞を受賞しました。
リミニストリートのアジア・太平洋地域担当のマネージャーAndrew
Powellは次のように述べています。
「名誉あるAsia-Pacific Stevie
Awardを受賞したことを光栄に思っています。今回の受賞によって、顧客サービスにおけるリミニストリートのリーダーとしてのポジションと、サポートを提供する企業にイノベーションをもたらすリミニストリートの能力の高さがさらに明確なものとなりました。リミニストリートは、お客様がコスト削減を実現できるようにするだけでなく、優れたシステムサポートを提供し、削減した資金の再投資によってビジネスの成長促進を可能にすることでお客様に大きな価値をもたらします。」
Asia-Pacific Stevie
Awardは、アジア・太平洋地域22か国内の企業を対象とし、審査の重点はビジネスにおけるイノベーションの評価に置きました。審査委員会は、世界中から集められた50人以上のエグゼクティブによって組織され、各地の企業から選出された700以上の候補の審査を務めました。
授賞式は6月2日に東京のヒルトンホテルで行われました。
リミニストリートについて
リミニストリートは、エンタープライズソフトウェア向けの独立系保守サービスを提供するグローバルリーディングカンパニーです。2005年以来、受賞歴を持つ革新的プログラムにより、エンタープライズ向けサポートサービスのあり方を塗り替えてきました。こうしたプログラムにより、Oracle、SAP、IBM®、Microsoft®、その他のエンタープライズソフトウェアのベンダーの総サポート費用の最大90%を削減することが可能になります。そして、現行のソフトウェアリリースを、アップグレードなしに少なくとも15年間使い続けることが出来る環境が整います。多様な業界のグローバル企業、フォーチュン500企業、中規模企業、公共セクター組織を含む約1,300社の顧客が、ソフトウェアベンダーから独立した信頼できるサポートプロバイダーとして、リミニストリートを利用しています。
詳細はhttp://www.riministreet.comをご覧ください。またTwitter（@riministreet）、Facebook、LinkedInでリミニストリートをフォローしてください。
将来見通しに関する記述
本プレスリリースには、Oracle、IBM DB2、Microsoft SQL Server、およびSAPのHANA、ASE、IQ、SQL
Anywhere、Advantage
Serverのデータベース向けサポートに関する記述など、将来見通しに関する記述が含まれる場合があります。「考える」、「かもしれない」、「だろう」、「計画する」、「推定する」、「継続する」、「期待する」、「意図する」、「見込む」という文言および同様の表現は、将来見通しに関する記述の特定を意図したものです。これらの将来見通しに関する記述にはリスクおよび不確実性が伴い、さまざまな想定に基づいています。リスクが実現または当社の想定の誤りが判明された場合、実際の結果はこれらの将来見通しに関する記述によって暗示された結果と大きく異なる可能性があります。リミニストリートは、本プレスリリースの発表時点の内容に過ぎない将来見通しに関する記述または情報を更新する義務を一切負いません。
© 2017 Rimini Street, Inc. All rights reserved. Rimini
Streetは、米国およびその他の国におけるリミニストリートの登録商標です。Rimini Street、Rimini
Streetロゴ、およびその組み合わせ、その他TMの付いたマークは、リミニストリートの商標です。その他のすべての会社名および製品名は、それぞれの所有者の商標です。特に規定がない限り、リミニストリートはこれらの商標保有者またはここに記載されているその他の企業に提携、支持、または協力を求めることはありません。
本プレスリリースの公式バージョンはオリジナル言語版（英語版）です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。
Contacts
本件に関する報道関係のお問い合わせ先
船見厚宏
日本リミニストリート PR担当
rimini@wizbrains.com
LINE Corporation Issues Stock Options (Warrants) 2017年06月26日 23時54分
TOKYO--(BUSINESS WIRE)--LINE Corporation (NYSE:LN) (TOKYO:3938) (Headquarters: Shinjuku-ku,
Tokyo, Japan; President & CEO: Takeshi Idezawa; “the Company”) announces
that it determined at its board meeting held today the terms and
conditions of warrants that are to be issued in the form of stock
options to directors and executive officers of the Company and the
director of a subsidiary, and passed a resolution to solicit subscribers
for the warrants, among others, as follows.
1. Reason for issuance of stock options (warrants)
The purpose of the issuance is to provide the Company’s directors and
executive officers and its subsidiary director with an incentive to
improve corporate earnings and enhance corporate value.
2. Specific details of stock option (warrant) issuance to the
Company’s directors
(1) Name of warrants
LINE Corporation 20th Warrants.
(2) Total number of warrants
12,621 warrants.
The above total number of warrants is the number of warrants planned to
be allotted. If the number of warrants to be allotted declines, such as
where applications for subscription are not made, then the total number
of warrants to be allotted shall be the total number of warrants to be
issued.
(3) Amount of payment for warrants
The amount to be paid in upon allotment of each warrant shall be the
amount obtained using the following formula: (x) the option price
(fractions less than 1 yen being rounded off) per Company share
calculated by the Black-Scholes Model based on various conditions as of
the date on which warrants are to be allotted, as set forth in (10)
below (the “Allotment Date”), multiplied by (y) the number of shares
subject to each warrant (the “Number of Allotted Shares”). Any person
who is allotted a warrant shall, instead of paying the amount to be
paid-in, offset the payment with his/her remuneration claim that he/she
has against the Company.
(4) Class and number of shares to be issued upon exercise of warrants
The class of shares to be issued upon exercise of warrants shall be
shares of common stock of the Company and the Number of Allotted Shares
shall be 100 shares. However, if the Company conducts a share split
(including gratuitous allotment of shares of common stock of the
Company; the same applies below to the description of a share split) or
share consolidation of shares of common stock of the Company, the
Company shall adjust the Number of Allotted Shares using the following
formula; and any fractions less than 1 share arising due to such
adjustment shall be rounded down.
Number of Allotted Shares After Adjustment
= Number of Allotted
Shares Before Adjustment × Share split or share consolidation ratio
Number of Allotted Shares After Adjustment shall be applied, in the case
of a share split, on or after the record date of the share split (if no
record date is determined, the effective date of the share split); and
in the case of a share consolidation, on or after the effective date of
the share consolidation. However, if a share split is conducted on
condition that a proposal is passed at the Company’s shareholders’
meeting to reduce the amount of surplus and increase the amount of
stated capital or capital reserve, and where the date of the close of
that shareholders’ meeting or any date before that is to be the record
date for the share split, then the Number of Allotted Shares After
Adjustment shall be applied on or after the date immediately following
the date on which the shareholders’ meeting is closed.
When adjusting the Number of Allotted Shares, the Company shall notify
or publicly notify such parties holding each warrant as stated in the
warrant register (“Warrant Holder(s)”) of necessary matters up to the
date immediately before the date of application of the Number of
Allotted Shares After Adjustment. However, if the Company is unable to
notify or publicly notify up to that date, it shall notify or publicly
notify it promptly after the application.
(5) Value of assets to be contributed upon exercise of warrants
1) The value of assets to be contributed when each warrant is exercised
shall be the Number of Allotted Shares multiplied by the amount paid per
share that can be delivered by exercise of that warrant (the “Exercise
Price”). The Exercise Price shall be obtained by multiplying 1.05 by the
average closing price in ordinary trading of the Company’s shares of
common stock on the Tokyo Stock Exchange for each day (excluding any day
on which no trade is executed) of the month preceding the month in which
the Allotment Date belongs, and any fraction less than 1 yen arising due
to such calculation will be rounded up. However, when the amount of the
Exercise Price calculated this way is less than the closing price (or
closing price of the immediately preceding trading day when there is no
closing price) of the shares of the Company’s common stock on the
Allotment Date, the Exercise Price shall be that closing price.
2) If the Company falls under any of the following items (a) to (c)
after the Allotment Date with respect to its common stock, it shall
adjust the Exercise Price using each of the respective formulas (the
“Exercise Price Adjustment Formula”) set forth below; and any fractions
less than 1 yen arising due to the adjustment shall be rounded up.
(a) When conducting a share split or a share consolidation
| = |
| × | 1 | |||||||||
|
Exercise Price After Adjustment shall be applied, in the case of a share
split, on or after the record date of the share split (if no record date
is determined, the effective date of the share split); and in the case
of a share consolidation, on or after the effective date of the share
consolidation. However, if a share split is conducted on condition that
a proposal is passed at the Company’s shareholders’ meeting to reduce
the amount of surplus and increase the amount of stated capital or
capital reserve, and where the date of the close of that shareholders’
meeting or any date before that is to be the record date for the share
split, then the Number of Allotted Shares After Adjustment shall be
applied on or after the date immediately following the date on which the
close of the shareholders’ meeting took place.
(b) When issuing new shares of the Company’s common stock or disposing
of treasury shares at a price lower than the market value (excluding
where the foregoing is conducted by exercising warrants)
| ＋ |
| × |
| |||||||||||||||||
| = |
| × | Market Value Per Share | |||||||||||||||||
Number of Shares Already Issued
| |||||||||||||||||||||
(i) The “Market Value” used in the above Exercise Price Adjustment
Formula shall be the average (calculated to the second decimal place and
rounded off to the first decimal place) closing price (including
indicated quotation; the same below) in ordinary trading of the
Company’s shares of common stock on a listed financial instruments
exchange (if the Company’s common stock is listed on more than one
financial instruments exchange, the principal exchange that is
determined to be the most appropriate, considering the trading volume,
pricing ratio, and other factors concerning the Company’s common stock,
during the period mentioned later) in 30 trading days (excluding days
without a closing price) starting on the 45th trading day before the
application date of the Exercise Price After Adjustment.
(ii) The “Number of Shares Already Issued” in the above Exercise Price
Adjustment Formula shall be the amount obtained by deducting the number
of treasury shares concerning the Company’s common stock, from the total
number of issued shares of the Company’s common stock as of the date one
month before the application date of the Exercise Price After Adjustment
(if there is no record date), or as of the record date (if there is a
record date). If the Company disposes of treasury shares of its common
stock, the “Number of Shares to be Newly Issued” in the above formula
shall be replaced by the “Number of Treasury Shares to be Disposed of”.
(iii) The Exercise Price After Adjustment shall be applied on or after
the date immediately following the date on which the relevant amount is
paid-in (if the period for pay-in is determined, the last day of that
period), or if there is a record date for the subscription, on or after
the date immediately following the record date.
(c) In addition to the above, if it is appropriate to adjust the
Exercise Price because of the Company’s merger with another company,
among others, after the Allotment Date, the Company shall adjust the
Exercise Price as necessary to a reasonable extent.
(d) When adjusting the Exercise Price, the Company shall notify or
publicly notify the Warrant Holders of necessary matters up to the date
immediately before the date of application of the Exercise Price After
Adjustment. However, if the Company is unable to notify or publicly
notify it up to that date, it shall notify or publicly notify it
promptly after the application.
(6) Exercise period for warrants
The exercise period for warrants shall be from July 18, 2018 to July 18,
2027 (the “Exercise Period”). However, if the last day of the Exercise
Period falls on a Company holiday, the immediately preceding business
day shall be the last day.
(7) Matters regarding stated capital and capital reserve that are to
increase when shares are issued upon the exercise of warrants
1) The amount of stated capital to increase when shares are issued upon
the exercise of warrants shall be the amount equivalent to half of the
maximum amount of increase in stated capital calculated according to
Article 17, Paragraph 1 of the Rules of Corporate Accounting. If
fractions less than 1 yen arise due to the calculation, then the
fractions shall be rounded up.
2) The amount of capital reserve to increase when shares are issued upon
the exercise of warrants shall be the amount obtained by deducting (x)
the amount of stated capital to be increased set forth in 1) above from
(y) the maximum amount of increase in stated capital mentioned in 1)
above.
(8) Restriction on acquisition of warrants by transfer
Acquisition of warrants by transfer shall be subject to approval by
resolution of the Company’s board of directors.
(9) Conditions for exercise of warrants
1) In the case of death of a Warrant Holder, an heir of that holder
cannot exercise that holder’s warrants. However, the foregoing shall not
apply if the Company’s board of directors approves such exercise.
2) Warrant Holders must be in the position of director of the Company or
its associated companies (i.e., the associated companies as set forth in
the Ordinance on Terminology, Forms, and Preparation Methods of
Financial Statements, etc.) when exercising the warrants. However, this
shall not apply in cases of the retirement of a director of the Company
or its associated companies due to the expiration of his or her term of
office, or other cases determined to have a reason to be justified by
the Company’s board of directors.
3) Each warrant cannot be exercised partially.
(10) Allotment date of warrants
July 18, 2017
(11) Date of payment of money to be made in exchange for warrants
July 18, 2017
(12) Matters regarding acquisition of warrants
If a proposal under the following items 1), 2), 3), 4), or 5) is
approved at the Company’s shareholders’ meeting (in the case where a
resolution at a shareholders’ meeting is not required, if a resolution
is passed by the Company’s board of directors or a determination is made
by a delegated executive officer in accordance with Article 416,
paragraph 4 of the Companies Act), the Company may acquire a warrant
without compensation on a date separately determined by the board of
directors (or by a delegated executive officer in accordance with
Article 416, paragraph 4 of the Companies Act):
1) a proposal to approve a merger agreement by which the Company will be
a disappearing company;
2) a proposal to approve a split agreement or a split plan by which the
Company will be a splitting company;
3) a proposal to approve a share exchange agreement or a share transfer
plan by which the Company will be a wholly-owned subsidiary;
4) a proposal to approve an amendment to the Company’s articles of
incorporation establishing a provision, with respect to all issued
shares of the Company, that an acquisition of those shares by transfer
shall require the Company’s approval; or
5) a proposal to approve an amendment to the Company’s articles of
incorporation establishing a provision, with respect to shares of the
class subject to the warrants, that an acquisition of those shares by
transfer shall require the Company’s approval, or with respect to the
shares of that class, that the Company shall acquire all of those shares
by a resolution of the Company’s shareholders’ meeting.
(13) Matters regarding delivery of warrants in conjunction with
organizational restructuring
If the Company conducts a merger (limited to where the Company will
disappear in a merger), absorption-type split or incorporation-type
split (in each case, limited to where the Company becomes a splitting
company), or share exchange or share transfer (in each case, limited to
where the Company becomes a wholly-owned subsidiary) (collectively, the
“Organizational Restructuring”), the Company shall deliver to Warrant
Holders who hold the remaining warrants (the “Remaining Warrants”) at
the time immediately preceding the effective date of the Organizational
Restructuring (i.e., in each case, the date on which the absorption-type
merger becomes effective, the date on which a stock company is
incorporated through the consolidation-type merger, the date on which
the absorption-type split becomes effective, the date on which a stock
company is incorporated through the incorporation-type split, the date
on which the share exchange becomes effective, or the date on which a
wholly-owning parent company is incorporated through the share transfer;
the same below) warrants of any of the stock companies listed in
Article 236, Paragraph 1, Item (viii), (a) to (e) of the Companies Act
(the “Restructured Company”), upon the respective Organizational
Restructuring. In this case, the Remaining Warrants shall disappear, and
the Restructured Company shall newly issue warrants. However, an
absorption-type merger agreement, consolidation-type merger agreement,
absorption-type split agreement, incorporation-type split plan, share
exchange agreement, or share transfer plan shall state that warrants of
the Restructured Company shall be delivered according to each of the
following:
1) Number of warrants of the Restructured Company to be delivered
The number equivalent to the number of the Remaining Warrants held by
the respective Warrant Holders shall be delivered.
2) Class of shares of the Restructured Company subject to warrants
Common stock of the Restructured Company.
3) Number of shares of the Restructured Company subject to warrants
To be determined according to (4) above by taking into consideration the
conditions and the like for the Organizational Restructuring.
4) Value of assets to be contributed upon the exercise of warrants
The value of assets to be contributed upon the exercise of each warrant
to be delivered shall be the amount obtained by taking into
consideration the conditions and the like of the Organizational
Restructuring, and by multiplying (x) the Exercise Price after the
Organizational Restructuring, which is obtained by adjusting the
Exercise Price determined according to (5) above by (y) the number of
shares of the Restructured Company subject to the warrants, which is
determined according to 3) above.
5) Exercise period of warrants
The exercise period shall be from the later of either (i) the
commencement date of the period in which warrants may be exercised as
set forth in (6) above, or (ii) the effective date of the Organizational
Restructuring, to the expiration date of the period in which warrants
may be exercised as set forth in (6) above.
6) Matters regarding stated capital and capital reserve that are to
increase when shares are issued upon the exercise of warrants
To be determined according to (7) above.
7) Restriction on acquisition of warrants by transfer
The acquisition of warrants by transfer shall require the approval of
the board of directors of the Restructured Company.
8) Other conditions for exercising warrants
To be determined according to (9) above.
9) Clauses regarding acquisition of warrants
To be determined according to (12) above.
(14) Arrangement concerning fractions less than 1 share arising due to
the exercise of warrants
If the number of shares to be delivered to Warrant Holders exercising
their warrants includes any fractions less than 1 share, the fractions
shall be rounded down.
(15) People who are to be allotted warrants, the number thereof, and the
number of warrants to be allotted
Allottee | Number | Number of warrants | |||||||
Directors of the Company | Four (4) |
| |||||||
3. Specific details of stock option (warrant) issuance to
executive officers of the Company and the director of a subsidiary
(1) Name of warrants
LINE Corporation 21st Warrants.
(2) Total number of warrants
11,419 warrants.
The above total number of warrants is the number of warrants planned to
be allotted. If the number of warrants to be allotted declines, such as
where applications for subscription are not made, then the total number
of warrants to be allotted shall be the total number of warrants to be
issued.
(3) Amount of payment for warrants
The amount to be paid in upon allotment of each warrant shall be the
amount obtained using the following formula: (x) the option price
(fractions less than 1 yen being rounded off) per Company share
calculated by the Black-Scholes Model based on various conditions as of
the date on which warrants are to be allotted, as set forth in (10)
below (the “Allotment Date”), multiplied by (y) the number of shares
subject to each warrant (the “Number of Allotted Shares”). Any person
who is allotted a warrant shall, instead of paying the amount to be
paid-in, offset the payment with his/her remuneration claim that he/she
has against the Company.
(4) Class and number of shares to be issued upon exercise of warrants
The class of shares to be issued upon exercise of warrants shall be
shares of common stock of the Company and the Number of Allotted Shares
shall be 100 shares. However, if the Company conducts a share split
(including gratuitous allotment of shares of common stock of the
Company; the same applies below to the description of a share split) or
share consolidation of shares of common stock of the Company, the
Company shall adjust the Number of Allotted Shares using the following
formula; and any fractions less than 1 share arising due to such
adjustment shall be rounded down.
Number of Allotted Shares After Adjustment
= Number of Allotted
Shares Before Adjustment × Share split or share consolidation ratio
Number of Allotted Shares After Adjustment shall be applied, in the case
of a share split, on or after the record date of the share split (if no
record date is determined, the effective date of the share split); and
in the case of a share consolidation, on or after the effective date of
the share consolidation. However, if a share split is conducted on
condition that a proposal is passed at the Company’s shareholders’
meeting to reduce the amount of surplus and increase the amount of
stated capital or capital reserve, and where the date of the close of
that shareholders’ meeting or any date before that is to be the record
date for the share split, then the Number of Allotted Shares After
Adjustment shall be applied on or after the date immediately following
the date on which the shareholders’ meeting is closed.
When adjusting the Number of Allotted Shares, the Company shall notify
or publicly notify such parties holding each warrant as stated in the
warrant register (“Warrant Holder(s)”) of necessary matters up to the
date immediately before the date of application of the Number of
Allotted Shares After Adjustment. However, if the Company is unable to
notify or publicly notify up to that date, it shall notify or publicly
notify it promptly after the application.
(5) Value of assets to be contributed upon exercise of warrants
1) The value of assets to be contributed when each warrant is exercised
shall be the Number of Allotted Shares multiplied by the amount paid per
share that can be delivered by exercise of that warrant (the “Exercise
Price”). The Exercise Price shall be obtained by multiplying 1.05 by the
average closing price in ordinary trading of the Company’s shares of
common stock on the Tokyo Stock Exchange for each day (excluding any day
on which no trade is executed) of the month preceding the month in which
the Allotment Date belongs, and any fraction less than 1 yen arising due
to such calculation will be rounded up. However, when the amount of the
Exercise Price calculated this way is less than the closing price (or
closing price of the immediately preceding trading day when there is no
closing price) of the shares of the Company’s common stock on the
Allotment Date, the Exercise Price shall be that closing price.
2) If the Company falls under any of the following items (a) to (c)
after the Allotment Date with respect to its common stock, it shall
adjust the Exercise Price using each of the respective formulas (the
“Exercise Price Adjustment Formula”) set forth below; and any fractions
less than 1 yen arising due to the adjustment shall be rounded up.
(a) When conducting a share split or a share consolidation
| = |
| × | 1 | |||||||||
|
Exercise Price After Adjustment shall be applied, in the case of a share
split, on or after the record date of the share split (if no record date
is determined, the effective date of the share split); and in the case
of a share consolidation, on or after the effective date of the share
consolidation. However, if a share split is conducted on condition that
a proposal is passed at the Company’s shareholders’ meeting to reduce
the amount of surplus and increase the amount of stated capital or
capital reserve, and where the date of the close of that shareholders’
meeting or any date before that is to be the record date for the share
split, then the Number of Allotted Shares After Adjustment shall be
applied on or after the date immediately following the date on which the
close of the shareholders’ meeting took place.
(b) When issuing new shares of the Company’s common stock or disposing
of treasury shares at a price lower than the market value (excluding
where the foregoing is conducted by exercising warrants)
| ＋ |
| × |
| |||||||||||||||||
| = |
| × | Market Value Per Share | |||||||||||||||||
Number of Shares Already Issued
| |||||||||||||||||||||
(i) The “Market Value” used in the above Exercise Price Adjustment
Formula shall be the average (calculated to the second decimal place and
rounded off to the first decimal place) closing price (including
indicated quotation; the same below) in ordinary trading of the
Company’s shares of common stock on a listed financial instruments
exchange (if the Company’s common stock is listed on more than one
financial instruments exchange, the principal exchange that is
determined to be the most appropriate, considering the trading volume,
pricing ratio, and other factors concerning the Company’s common stock,
during the period mentioned later) in 30 trading days (excluding days
without a closing price) starting on the 45th trading day before the
application date of the Exercise Price After Adjustment.
Contacts
LINE Global PR
Icho Saito, +81-3-4316-2104
dl_gpr@linecorp.co
Read full story here
Line Corporation Introduces Employee Stock Ownership Plan (… 2017年06月26日 23時53分
TOKYO--(BUSINESS WIRE)--LINE Corporation (NYSE:LN) (TOKYO:3938) (Headquarters: Shinjuku-ku,
Tokyo, Japan; President & CEO: Takeshi Idezawa; hereinafter the
“Company”) announced on February 23, 2017, the introduction of an
Employee Stock Ownership Plan (J-ESOP; hereinafter called the “Plan”;
and the trust to be established based on the trust agreement concluded
with Mizuho Trust & Banking Co., Ltd. for the Plan, hereinafter called
the “Trust”) and has now determined the details, including the date of
establishment of the Trust, etc. at the Board of Directors Meeting held
today.
In conjunction with the introduction of the Plan, the Company has
simultaneously decided to assign 1,007,810 new shares (3,999,997,890
yen) to Trust & Custody Services Bank, Ltd. (Trust E). For details,
please refer to “Notice Regarding the Offering of Shares to Be Issued
through Third-Party Allotment in Accordance with the Introduction of the
Employee Stock Ownership Plan” dated today.
| ||||
(1) Type of Trust: Trust of money other than money trust (third-party trust) | ||||
(2) Purpose of Trust: | To provide stock of the Company and other assets to beneficiaries, in accordance with the Regulations on Stock Compensation | |||
(3) Trustor: The Company | ||||
(4) Trustee: Mizuho Trust & Banking Co., Ltd. | ||||
(Mizuho Trust & Banking Co., Ltd. will conclude a comprehensive trust agreement with Trust & Custody Services Bank, Ltd., which will become the successor trustee) | ||||
|
|
| ||
(6) Trust Agreement Date: June26, 2017 | ||||
(7) Trust Period: From June 26, 2017 to the termination of the Trust | ||||
(The Trust termination date is not yet decided; the Trust will continue as long as the Plan continues.) | ||||
(8) Plan Start Date: July 18, 2017 (tentative) | ||||
(9) Share Acquisition Date: July 18, 2017 (tentative) | ||||
(10) Share Acquisition Amount: 3,999,997,890 yen (tentative) | ||||
Notice Regarding the Offering of Shares to Be Issued through
Third-Party Allotment in Accordance with the Introduction of the
Employee Stock Ownership Plan
LINE Corporation (Headquarters: Shinjuku-ku, Tokyo, Japan; President &
CEO: Takeshi Idezawa; the “Company”) announces that it passed a
resolution at its board meeting held today to conduct an offering of
shares by means of a third-party allotment (the “Third-Party
Allotment”), in accordance with the introduction of an Employee Stock
Ownership Plan (J-ESOP; the “Plan”) that was announced on February 23,
2017, as follows.
| |||||
|
| Tuesday, July 18, 2017 | |||
|
| 1,007,810 shares of common stock | |||
|
| 3,969 yen per share | |||
|
| 3,999,997,890 yen | |||
|
| Third-party allotment | |||
|
| Trust & Custody Services Bank, Ltd. (Trust E) | |||
|
| The offering is subject to notification in accordance with the Financial Instruments and Exchange Act being effective. | |||
2. Purpose and reasons for the offering
The Company announced its introduction of the Plan on February 23, 2017,
and then passed a resolution regarding detailed matters of the Plan at
its board meeting held today. (For a summary of the Plan, please see the
“Notice Regarding Introduction of Employee Stock Ownership Plan
(Determination of the Details)” announced today.
The new shares to be issued through the Third-Party Allotment will be
allotted to Trust & Custody Services Bank, Ltd. (Trust E) (the successor
trustee entrusted by Mizuho Trust & Banking Co., Ltd., the trustee for
the Plan) that is in charge of holding and disposing of the Company’s
shares and is established upon introduction of the Plan.
3. Amount, use, and scheduled timing of use of funds to be procured
| ||||||
Total amount to be paid (yen) |
|
| ||||
3,999,997,890 yen | － | 3,999,997,890 yen | ||||
|
|
| ||||
|
| |||||
(2) Use of the funds to be procured
The estimated net amount after expenses of 3,999,997,890 yen mentioned
above will be appropriated entirely to operating funds, including
payment of expenses on and after the payment date. The funds will be
managed in the Company’s bank account until they are used for the above
purpose.
4. View on reasonableness of use of funds
The Company believes that the planned use of the funds to be procured by
issuing new shares through the Third-Party Allotment is reasonable, as
it will contribute to the operation of the Company’s business.
5. Reasonableness of issuance terms and conditions
(1) Basis for calculation of issue price and details thereof
In order to determine the issue price non-arbitrarily, the Company set
the issue price at 3,969 yen (any fraction less than one yen is rounded
off), the average closing price of the Company’s common stock traded on
Tokyo Stock Exchange, Inc. during the one-month period from May 24,
2017, to the day immediately preceding the Board of Directors meeting at
which the resolution for the Third-Party Allotment was passed (June 23,
2017). The reason for adopting the average closing price of the
Company’s common stock traded on the Tokyo Stock Exchange during the
one-month period immediately preceding the resolution at the Board of
Directors meeting is because the Company considers that it is more
objective and reasonable as a calculation base to use the leveled value
of the average share price over a certain period, rather than using the
price at a specific point, since special factors such as temporary
fluctuations in the share price are eliminated. In addition, the reason
why the Company has adopted the most recent one-month period as the
calculation period is that the Company believes it is more reasonable to
adopt a certain period in which the average share price is closest to
the most recent market price than to adopt the most recent three or six
months.
The issue price of 3,969 yen is equal to (i) the closing price (3,995
yen) of the Company’s stock on the business day immediately preceding
the date of the resolution at the board meeting multiplied by 99.35%;
(ii) the average of the closing prices (3,988 yen, any fraction less
than one yen is rounded off) of the Company’s stock during the three
months starting from the business day immediately preceding the date of
resolution at the board meeting multiplied by 99.52%, and (iii) the
average of the closing prices (3,935 yen, any fraction less than one yen
is rounded off) of the Company’s stock during the six months starting
from the business day immediately preceding the date of resolution at
the board meeting multiplied by 100.86%. Taking these into
consideration, the Company believes that the issue price for the
Third-Party Allotment is not especially favorable to the prospective
allottee and is reasonable.
Regarding the issue price stated above, 3 Corporate Auditors who
attended the board meeting (2 of which are outside Corporate Auditors)
have expressed their opinion that the price is not especially favorable
to the prospective allottee.
(2) Basis for assessing that the number of shares to be issued and level
of share dilution are reasonable
The number of shares to be issued through the Third-Party Allotment
corresponds to the number of shares expected to be granted to the
employees of the Company and those of its subsidiaries (“Relevant
Employees”) during the trust period in accordance with the Regulations
on Stock Compensation; and it will be 0.46% of the total issued and
outstanding shares (219,309,500 shares) as of May 31, 2017 (rounded off
to two decimal places) and 0.46% of the total voting rights (2,192,959
voting rights) as of May 31, 2017 (rounded off to two decimal places).
It is unlikely that the shares involving the Third-Party Allotment may
be placed on a stock market all at once. In addition, the Third-Party
Allotment will enhance morale and motivation of the Relevant Employees
and contribute to securing excellent human resources and their long-term
success, thereby enhancing the Company’s corporate value. As such, the
Company believes that the level of share dilution is reasonable, and
there will only be a minor effect on the secondary market.
6. Reason for selection of prospective allottee
(1) | Overview of the prospective allottee | |||
1) | Name: | Trust & Custody Services Bank, Ltd. (Trust E) | ||
2) | Details of Trust Agreement (J-ESOP Agreement): | |||
Type of Trust: | Trust of money other than monetary trust (third-party trust) | |||
Purpose of Trust: | To provide stock of the Company and other assets to beneficiaries, in accordance with the Regulations on Stock Compensation | |||
Trustor: | The Company | |||
Trustee: | Mizuho Trust & Banking Co., Ltd. | |||
Mizuho Trust & Banking Co., Ltd. will conclude a comprehensive trust agreement with Trust & Custody Services Bank, Ltd., which will become the successor trustee. | ||||
Beneficiaries: | Persons who have acquired the right to receive assets pursuant to the provisions of the Regulations on Stock Compensation | |||
Trust Agreement Date: | June 26, 2017 | |||
Trust Period: | From June 26, 2017 to the termination of the Trust | |||
Share Acquisition Date: | July 18, 2017 (tentative) | |||
3) | Relationship between the listed company and the prospective allottee: | |||
There is no capital relationship, personnel relationship or business relationship between the Company and the prospective allottee. The prospective allottee is not a related party of the Company. | ||||
(1) Name | Trust & Custody Services Bank, Ltd. | |||||||
(2) Address | Tower Z, Harumi Triton Square, 8-12, Harumi 1-chome, Chuo-ku, Tokyo | |||||||
| Akira Moriwaki, President & CEO | |||||||
(4) Business description | Master trust services, asset administration services for securities, asset administration services for defined contribution pensions | |||||||
(5) Capital | 50,000 million yen | |||||||
(6) Date of establishment | January 22, 2001 | |||||||
| 1,000,000 shares | |||||||
(8) Fiscal year end | March 31 | |||||||
(9) Number of employees | 653 (as of September 30, 2016) | |||||||
(10) Main business partners | Business corporations and financial corporations | |||||||
(11) Main banks | - | |||||||
| Mizuho Financial Group, Inc. 54%
| |||||||
| Capital relationship: N/A | |||||||
Personnel relationship: N/A | ||||||||
Business relationship: N/A | ||||||||
Ties to related parties: N/A | ||||||||
(14) Business results and financial conditions over the last three fiscal years (unit: million yen, unless otherwise specified) | ||||||||
Fiscal year ended | March 31, 2015 | March 31, 2016 | March 31, 2017 | |||||
Net assets | 59,419 | 60,385 | 60,771 | |||||
Total assets | 1,993,528 | 5,473,232 | 11,424,703 | |||||
Net assets per share (yen) | 59,419 | 60,385 | 60,771 | |||||
Ordinary revenue | 23,785 | 24,500 | 23,462 | |||||
Ordinary income | 1,792 | 1,721 | 990 | |||||
Net income | 1,129 | 1,129 | 674 | |||||
Net income per share (yen) | 1,129.20 | 1,129.27 | 674.44 | |||||
Dividends per share (yen) | 230.00 | 230.00 | 135.00 | |||||
* | Trust & Custody Services Bank, Ltd. is a subsidiary of Mizuho Financial Group, Inc.; based on our research on public information posted on Mizuho’s website and disclosure materials (such as the Business Code of Conduct), the Company confirmed that none of the prospective allottee nor its officers or major shareholders (major contributors) have any connection with anti-social forces, and submitted a confirmation letter to that effect to Tokyo Stock Exchange, Inc. | |
(2) Reason for selecting the prospective allottee
In accordance with the introduction of the trust to be created under the
trust agreement to be executed with Mizuho Trust & Banking Co., Ltd.
regarding the Plan, the Company allots the shares to the Trust E opened
at Trust & Custody Services Bank, Ltd., the successor trustee, pursuant
to the trust agreement.
(3) Prospective allottee’s policy on holding shares
In accordance with the above-mentioned trust agreement, the prospective
allottee, Trust & Custody Services Bank, Ltd. (Trust E), will possess
the shares of the Company in order to provide the trust assets (such as
shares of the Company) to the beneficiaries during the Trust Period, in
accordance with the Regulations on Stock Compensation.
If the prospective allottee, Trust & Custody Services Bank, Ltd. (Trust
E), transfers all or part of the allotted shares within two years from
the payment date (July 18, 2017), the Company will obtain from the
prospective allottee informal consent to concluding a pledge agreement
with the Company, under which the prospective allottee shall immediately
report to the Company, in writing, the purchaser’s name and address, the
number of shares transferred, the transfer date, transfer price,
transfer reason, transfer method, etc., thereof, and the Company shall
report the details of the report to the Tokyo Stock Exchange, Inc.; and
the details of the report shall be made available for public inspection.
(4) Confirmation that the prospective allottee has the funds required
for payment
The Company has confirmed through the J-ESOP Trust Agreement that with
respect to the monetary equivalent to the funds required for payment by
the prospective allottee, the initial trust money to be contributed by
the Company to the Plan will exist within the trust assets as of the
allotment date, as stated in the “Notice Regarding Introduction of
Employee Stock Ownership Plan (Determination of the Details)” announced
today.
For details, please refer to the “Notice Regarding Introduction of
Employee Stock Ownership Plan (Determination of the Details)” announced
today.
7. Major shareholders and shareholding ratios after the offering
Before the offering (as of May 31, 2017) | After the offering | |||||
NAVER CORPORATION | 79.80% | NAVER CORPORATION | 79.43% | |||
MOXLEY & CO LLC | 5.13% | MOXLEY & CO LLC | 5.11% | |||
| 0.72% |
| 0.71% | |||
| 0.45% |
| 0.46% | |||
| 0.37% |
| 0.45% | |||
| 0.32% |
| 0.37% | |||
| 0.25% |
| 0.32% | |||
| 0.24% |
| 0.25% | |||
THE BANK OF NEW YORK 134168 | 0.24% |
| 0.24% | |||
| 0.22% | THE BANK OF NEW YORK 134168 | 0.24% | |||
Note) | 1. | The major shareholders and shareholding ratios after the offering are based on the register of shareholders as of May 31, 2017. | ||
2. | The foregoing shareholding ratios are the ratios of voting rights held against the total number of voting rights. | |||
8. Outlook for the future
There will be a minor impact on the business prospect for the current
fiscal year.
9. Procedures under the Business Code of Conduct
Since the Third-Party Allotment (i) results in share dilution of less
than 25%, and (ii) does not cause a change in controlling shareholder,
obtaining an opinion from an independent third party and confirming the
intention of the shareholders as set forth in Article 432 of the
Securities Listing Regulations established by the Tokyo Stock Exchange,
Inc. are not required.
10. Business results and equity finance position for the past three
fiscal years
| ||||||
Fiscal year ended | December 31, 2014 | December 31, 2015 | December 31, 2016 | |||
Revenue | 86,366 million yen | 120,405 million yen | 140,704 million yen | |||
| 6,262 million yen | △530 million yen | 17,989 million yen | |||
| 2,004 million yen | △7,972 million yen | 7,103 million yen | |||
| 4,206 million yen | △7,581 million yen | 6,762 million yen | |||
| 24.05 yen | △43.33 yen | 34.84 yen | |||
Dividends per share | - yen | - yen | - yen | |||
| 71.41 yen | 101.39 yen | 738.53 yen | |||
Note) | The consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS). |
| ||||
Number of shares | Percentage of issued and outstanding shares | |||
Number of issued and outstanding shares | 219,309,500 | 100.0% | ||
Number of potential shares at current conversion price (strike price) | 21,371,500 | 9.74% | ||
Number of potential shares at lower-limit conversion price (strike price) | - | - | ||
Number of potential shares at upper-limit conversion price (strike price) | - | - | ||
Note) | “Potential shares” refers to shares convertible from stock options. | |
(3) Recent stock prices
| ||||||
Fiscal year ended | December 31, 2014 | December 31, 2015 | December 31, 2016 | |||
Opening price | - yen | - yen | 4,900 yen | |||
High | - yen | - yen | 5,230 yen | |||
Low | - yen | - yen | 3,780 yen | |||
Closing price | - yen | - yen | 4,010 yen | |||
Note) | The Company listed on Tokyo Stock Exchange on July 15, 2016, therefore there are no applicable stock prices before that. |
| ||||||||||||
| January 2017 |
|
|
|
| |||||||
Opening price | 4,450yen | 3,990yen | 3,590yen | 3,830yen | 4,245yen | 3,810yen | ||||||
High | 4,465yen | 4,195yen | 3,950yen | 4,320yen | 4,370yen | 3,935yen | ||||||
Low | 3,930yen | 3,530yen | 3,490yen | 3,805yen | 3,795yen | 3,655yen | ||||||
Closing price | 4,010yen | 3,625yen | 3,870yen |
| 3,865yen | 3,810yen | ||||||
3) Stock prices on the transaction day immediately preceding the date of
resolution to issue new shares
| ||
Opening price | 4,000yen | |
High | 4,035yen | |
Low | 3,980yen | |
Closing price | 3,995yen | |
(4) Equity finance position during the most recent three years
Issuance of new shares by public offering (domestic offering and
overseas offering)
Payment date | For overseas offering: July 14, 2016
| |
Amount of funds to be procured | 109,402,000,000 yen (estimated net amount after expenses) | |
Issue price | 2,295 yen | |
Number of shares issued at the time of offering | 174,992,000 shares | |
Number of shares issued through such offering | 35,000,000 shares
| |
Total number of shares issued after the offering | 209,992,000 shares | |
Initial plan regarding use of funds upon issuance | For repayment of short-term borrowings and corporate bonds;
| |
Planned timing of use of funds at the time of issuance | Repayment of short-term borrowings: FY ended December 2016
| |
Current status regarding use of funds | As originally planned, the funds are being used for the repayment of short-term borrowings and corporate bonds, capital investment, operating funds, investment in and financing for LINE Mobile Co., Ltd. and LINE MUSIC Co., Ltd., and investment under the growth strategy. | |
Issuance of new shares through third-party allotment in accordance
with domestic and overseas offering via over-allotment
Payment date | August 16, 2016 | |
| 16,545,375,000 yen (estimated net amount after expenses) | |
Issue price | 2,295 yen | |
| 209,992,000 shares | |
| 5,250,000 shares | |
| 215,242,000 shares | |
Allottees | (i) Nomura Securities Co., Ltd. 1,950,000 shares
| |
| For investment under the growth policy via the LINE business portal service | |
| The timing was not determined. | |
| The funds are being used for investment under the growth strategy regarding the LINE business portal segment. | |
11. Terms and Conditions of Issuance
(1) | Type and number of shares to be issued | 1,007,810 shares of common stock | ||
(2) | Issuance price | 3,969 yen per share | ||
(3) | Total issuance price | 3,999,997,890 yen | ||
(4) | Amount of stated capital to be increased | 1,999,998,945 yen | ||
(5) | Amount of capital reserve to be increased | 1,999,998,945 yen | ||
(6) | Payment date | Tuesday, July 18, 2017 | ||
(7) | Method of offering or allotment | Third-Party Allotment | ||
(8) | Prospective allottees | Trust & Custody Services Bank, Ltd. (Trust E) | ||
(9) | Other | The issuance is subject to notification in accordance with the Financial Instruments and Exchange Act being effective. | ||
Contacts
LINE
Icho Saito, +81-3-4316-2104
Global PR
dl_gpr@linecorp.co
Sumitomo Heavy Industries, Ltd. Completes Share Acquisition… 2017年06月26日 22時31分
New global CFB company – Sumitomo SHI FW
Highly competitive global delivery network proven by hundreds of
successful projects
AMSTERDAM--(BUSINESS WIRE)--With reference to Sumitomo Heavy Industries, Ltd. (SHI)
announcement of 26th June, 2017
(attached), SHI completed the share acquisition of FW Energie
B.V. culminating in the combination of SHI and Amec Foster Wheeler’s
fluidized bed business to become Sumitomo SHI FW, a new global leader in
sustainable energy solutions.
Sumitomo SHI FW will become part of the Energy and Environment Group
within SHI where we will dedicate our talent, energy and quality of
service on CFB and BFB steam generators and gasifiers, CFB scrubbers,
metallurgical waste heat boilers and aftermarket services.
Tomas Harju-Jeanty, CEO, Sumitomo SHI FW, said:
“Combining our strong Foster Wheeler heritage with Sumitomo’s
world-wide recognized name and skill will create a strong brand within
and outside our traditional markets. Sumitomo SHI FW will have a deep
commitment to technology innovation. Our goal is to provide
clients with sustainable value that will endure for the longer term.”
Notes to editors:
Sumitomo SHI FW (www.shi-fw.com)
is a world leader in combustion and steam generation technology. The
company has sold over 450 CFB steam generating units around the world,
bringing high-value technology solutions to utilities, independent power
generators and industrial clients. Our leadership position in CFB
combustion has resulted from our commitment to deliver superior designs
providing high efficiency, fuel flexibility and low emissions. Our power
solutions expand beyond fluidized bed technologies, covering a full
range of environmental products, waste heat boilers and a spectrum of
aftermarket services.
Contacts
Sumitomo SHI FW
Jan Rogers
Director of Forecasting & Analysis,
Strategy & Business Development
D +1-908-713-3288
Takeda and Seattle Genetics Announce Positive Results from … 2017年06月26日 19時45分
-Randomized Phase 3 Clinical Trial with ADCETRIS Met Primary
Endpoint, Demonstrating a Statistically Significant Improvement in
Modified Progression-Free Survival-
-Abstract to be Submitted for Presentation at the 2017 ASH Annual
Meeting; Regulatory Submissions Planned-
-Seattle Genetics to Host Conference Call and Webcast Today at 8:30
a.m. ET-
CAMBRIDGE, Mass., OSAKA, Japan & BOTHELL, Wash.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502)
and Seattle Genetics, Inc. (NASDAQ:
SGEN) today announced that the Phase 3 ECHELON-1 clinical trial met
its primary endpoint of a statistically significant improvement in
modified progression-free survival (PFS) versus the control arm.
ECHELON-1 is a randomized, multicenter trial evaluating ADCETRIS
(brentuximab vedotin) as part of a frontline combination chemotherapy
regimen in 1,334 patients with previously untreated advanced classical
Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed
to CD30, a defining marker of classical Hodgkin lymphoma. ADCETRIS is
currently not approved as a frontline therapy for Hodgkin lymphoma.
Patients in ECHELON-1 were randomized to receive either a combination of
ADCETRIS+AVD (Adriamycin, vinblastine, dacarbazine) or ABVD (Adriamycin,
bleomycin, vinblastine, dacarbazine), a recognized standard of care for
frontline Hodgkin lymphoma. The results of the ECHELON-1 trial
demonstrated that combination treatment with ADCETRIS resulted in a
statistically significant improvement in modified PFS versus the control
arm as assessed by an Independent Review Facility (hazard ratio=0.770;
p-value=0.035). The two-year modified PFS rate for patients in the
ADCETRIS arm was 82.1 percent compared to 77.2 percent in the control
arm. Interim analysis of overall survival (OS), the key secondary
endpoint, also trended in favor of the ADCETRIS+AVD arm. An abstract
will be submitted for data presentation at the American Society of
Hematology (ASH) annual meeting, December 9-12, 2017, in Atlanta, Ga.
The safety profile of ADCETRIS+AVD in the ECHELON-1 trial was consistent
with that known for the single-agent components of the regimen. There
was an increased incidence of febrile neutropenia and peripheral
neuropathy in the ADCETRIS+AVD arm. Febrile neutropenia was reduced
through the use of prophylactic growth factors in a subset of patients,
and peripheral neuropathy was managed through dose modifications. The
control arm had an increased rate and severity of pulmonary toxicity.
“We are excited about the positive result which shows a statistically
significant improvement in the primary endpoint of modified PFS,” said
Dirk Huebner, M.D., Executive Medical Director, Oncology Therapeutic
Area Unit, Takeda Pharmaceutical Company. “The results of this trial
signify an important step forward in the development of ADCETRIS and
have the potential to change the treatment approach of frontline
advanced Hodgkin lymphoma.”
“The outcome of the Phase 3 ECHELON-1 trial represents a significant
milestone for the Hodgkin lymphoma community,” said Clay Siegall, Ph.D.,
President and Chief Executive Officer of Seattle Genetics. “Seattle
Genetics’ goal is to establish ADCETRIS as the foundation of care for
CD30-expressing lymphomas, including Hodgkin lymphoma. Notably, this is
the first clinical trial in frontline advanced Hodgkin lymphoma to show
superior efficacy of a regimen that eliminates bleomycin.”
Takeda and Seattle Genetics plan to submit these results to regulatory
authorities for approval in their respective territories.
ECHELON-1 Phase 3 Clinical Trial Design
The randomized, open-label, Phase 3 trial is investigating ADCETRIS+AVD
versus ABVD as frontline therapy in patients with advanced classical
Hodgkin lymphoma. The primary endpoint is modified progression-free
survival per Independent Review Facility assessment using the Revised
Response Criteria for Malignant Lymphoma. Modified PFS is defined as the
time to progression, death or receipt of additional anticancer therapy
for patients who are not in complete response after completion of
frontline therapy per Independent Review Facility. This endpoint was
chosen as it provides a clearer picture of the efficacy of frontline
chemotherapy and eliminates the confounding impact of salvage and
consolidation chemotherapies and radiotherapy. Secondary endpoints
include overall survival, complete remission and safety. The
multi-center trial was conducted in North America, Europe, South
America, Australia, Asia and Africa. The study enrolled 1,334 patients
who had a histologically-confirmed diagnosis of Stage III or IV
classical Hodgkin lymphoma and had not been previously treated with
systemic chemotherapy or radiotherapy. The ECHELON-1 trial is being
conducted under a Special Protocol Assessment (SPA) agreement from the
U.S. Food and Drug Administration (FDA) and the trial also received
European Medicines Agency (EMA) scientific advice.
Please see Important Safety Information at the end of this press
release.
Seattle Genetics Conference Call Details
Seattle Genetics' management will host a conference call and webcast to
discuss this announcement. The event will be held today at 5:30 a.m.
Pacific Time (PT) / 8:30 a.m. Eastern Time (ET). The live event will be
available from Seattle Genetics' website at http://www.seattlegenetics.com,
under the Investors section, or by calling 877-723-9521 (domestic) or
719-325-2138 (international). The access code is 9916080. A replay of
the discussion will be available beginning at approximately 8:30 a.m. PT
/ 11:30 a.m. ET today from Seattle Genetics' website or by calling
888-203-1112 (domestic) or 719-457-0820 (international), using access
code 9916080. The telephone replay will be available until 5:00 p.m. PT
/ 8:00 p.m. ET Wednesday, June 28, 2017.
About Classical Hodgkin Lymphoma
Lymphoma is a general term for a group of cancers that originate in the
lymphatic system. There are two major categories of lymphoma: Hodgkin
lymphoma and non-Hodgkin lymphoma. Classical Hodgkin lymphoma is
distinguished from other types of lymphoma by the presence of one
characteristic type of cell, known as the Reed-Sternberg cell. The
Reed-Sternberg cell expresses CD30.
About ADCETRIS
ADCETRIS is being evaluated broadly in more than 70 clinical trials in
CD30-expressing lymphomas, including three Phase 3 studies: the
completed ECHELON-1 trial in frontline classical Hodgkin lymphoma, the
completed ALCANZA trial in cutaneous T-cell lymphoma, and the ongoing
ECHELON-2 trial in frontline mature T-cell lymphomas.
ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached
by a protease-cleavable linker to a microtubule disrupting agent,
monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary
technology. The ADC employs a linker system that is designed to be
stable in the bloodstream but to release MMAE upon internalization into
CD30-expressing tumor cells.
ADCETRIS for intravenous injection has received approval from the FDA
for three indications: (1) regular approval for the treatment of
patients with classical Hodgkin lymphoma after failure of autologous
hematopoietic stem cell transplantation (auto-HSCT) or after failure of
at least two prior multi-agent chemotherapy regimens in patients who are
not auto-HSCT candidates, (2) regular approval for the treatment of
classical Hodgkin lymphoma patients at high risk of relapse or
progression as post-auto-HSCT consolidation, and (3) accelerated
approval for the treatment of patients with systemic anaplastic large
cell lymphoma (sALCL) after failure of at least one prior multi-agent
chemotherapy regimen. The sALCL indication is approved under accelerated
approval based on overall response rate. Continued approval for the
sALCL indication may be contingent upon verification and description of
clinical benefit in confirmatory trials. Health Canada granted ADCETRIS
approval with conditions for relapsed or refractory Hodgkin lymphoma and
sALCL.
ADCETRIS was granted conditional marketing authorization by the European
Commission in October 2012 for two indications: (1) for the treatment of
adult patients with relapsed or refractory CD30-positive Hodgkin
lymphoma following autologous stem cell transplant (ASCT), or following
at least two prior therapies when ASCT or multi-agent chemotherapy is
not a treatment option, and (2) the treatment of adult patients with
relapsed or refractory sALCL.
In June 2016, the European Commission extended the current conditional
approval of ADCETRIS and approved ADCETRIS for the treatment of adult
patients with CD30-positive Hodgkin lymphoma at increased risk of
relapse or progression following ASCT.
ADCETRIS has received marketing authorization by regulatory authorities
in 67 countries for relapsed or refractory Hodgkin lymphoma and sALCL.
See important safety information below.
Seattle Genetics and Takeda are jointly developing ADCETRIS. Under the
terms of the collaboration agreement, Seattle Genetics has U.S. and
Canadian commercialization rights and Takeda has rights to commercialize
ADCETRIS in the rest of the world. Seattle Genetics and Takeda are
funding joint development costs for ADCETRIS on a 50:50 basis, except in
Japan where Takeda is solely responsible for development costs.
ADCETRIS (brentuximab vedotin) Global Important Safety Information
CONTRAINDICATIONS
ADCETRIS is contraindicated for patients with hypersensitivity to
brentuximab vedotin and its excipients. In addition, combined use of
ADCETRIS with bleomycin is contraindicated as it causes pulmonary
toxicity.
SPECIAL WARNINGS & PRECAUTIONS
Progressive multifocal leukoencephalopathy (PML): John Cunningham
virus (JCV) reactivation resulting in PML and death can occur in
patients treated with ADCETRIS. PML has been reported in patients who
received ADCETRIS after receiving multiple prior chemotherapy regimens.
Patients should be closely monitored for new or worsening neurological,
cognitive, or behavioral signs or symptoms, which may be suggestive of
PML. Suggested evaluation of PML includes neurology consultation,
gadolinium-enhanced magnetic resonance imaging of the brain, and
cerebrospinal fluid analysis for JCV DNA by polymerase chain reaction or
a brain biopsy with evidence of JCV. ADCETRIS dosing should be held for
any suspected case of PML and should be permanently discontinued if a
diagnosis of PML is confirmed.
Pancreatitis: Acute pancreatitis has been observed in patients
treated with ADCETRIS. Fatal outcomes have been reported. Patients
should be closely monitored for new or worsening abdominal pain, which
may be suggestive of acute pancreatitis. Patient evaluation may include
physical examination, laboratory evaluation for serum amylase and serum
lipase, and abdominal imaging, such as ultrasound and other appropriate
diagnostic measures. ADCETRIS should be held for any suspected case of
acute pancreatitis. ADCETRIS should be discontinued if a diagnosis of
acute pancreatitis is confirmed.
Pulmonary Toxicity: Cases of pulmonary toxicity, some with fatal
outcomes, have been reported in patients receiving ADCETRIS. Although a
causal association with ADCETRIS has not been established, the risk of
pulmonary toxicity cannot be ruled out. New or worsening pulmonary
symptoms should be promptly evaluated and treated appropriately.
Serious infections and opportunistic infections: Serious
infections such as pneumonia, staphylococcal bacteremia, sepsis/septic
shock (including fatal outcomes), and herpes zoster, and opportunistic
infections such as Pneumocystis jiroveci pneumonia and oral
candidiasis have been reported in patients treated with ADCETRIS.
Patients should be carefully monitored during treatment for emergence of
possible serious and opportunistic infections.
Infusion-related reactions (IRR): Immediate and delayed IRR, as
well as anaphylaxis, have occurred with ADCETRIS. Patients should be
carefully monitored during and after an infusion. If anaphylaxis occurs,
administration of ADCETRIS should be immediately and permanently
discontinued and appropriate medical therapy should be administered. If
an IRR occurs, the infusion should be interrupted and appropriate
medical management instituted. The infusion may be restarted at a slower
rate after symptom resolution. Patients who have experienced a prior IRR
should be premedicated for subsequent infusions. IRRs are more frequent
and more severe in patients with antibodies to ADCETRIS.
Tumor lysis syndrome (TLS): TLS has been reported with ADCETRIS.
Patients with rapidly proliferating tumor and high tumor burden are at
risk of TLS. These patients should be monitored closely and managed
according to best medical practice.
Peripheral neuropathy (PN): ADCETRIS treatment may cause PN, both
sensory and motor. ADCETRIS-induced PN is typically cumulative and
reversible in most cases. Patients should be monitored for symptoms of
PN, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a
burning sensation, neuropathic pain, or weakness. Patients experiencing
new or worsening PN may require a delay and a dose reduction or
discontinuation of ADCETRIS.
Hematological toxicities: Grade 3 or Grade 4 anemia,
thrombocytopenia, and prolonged (equal to or greater than one week)
Grade 3 or Grade 4 neutropenia can occur with ADCETRIS. Complete blood
counts should be monitored prior to administration of each dose.
Febrile neutropenia: Febrile neutropenia has been reported.
Patients should be monitored closely for fever and managed according to
best medical practice if febrile neutropenia develops.
Stevens-Johnson syndrome (SJS): SJS and toxic epidermal
necrolysis (TEN) have been reported with ADCETRIS. Fatal outcomes have
been reported. If SJS or TEN occurs, treatment with ADCETRIS should be
discontinued and appropriate medical therapy should be administered.
Gastrointestinal (GI) Complications: GI complications, some with
fatal outcomes, including intestinal obstruction, ileus, enterocolitis,
neutropenic colitis, erosion, ulcer, perforation and haemorragh, have
been reported. New or worsening GI symptoms should be promptly evaluated
and treated appropriately.
Hepatotoxicity: Elevations in alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) have been reported. Serious cases of
hepatotoxicity, including fatal outcomes, have also occurred. Liver
function should be tested prior to treatment initiation and routinely
monitored in patients receiving ADCETRIS. Patients experiencing
hepatotoxicity may require a delay, dose modification, or
discontinuation of ADCETRIS.
Hyperglycemia: Hyperglycemia has been reported during trials in
patients with an elevated body mass index (BMI) with or without a
history of diabetes mellitus. However, any patient who experiences an
event of hyperglycemia should have their serum glucose closely
monitored. Anti-diabetic treatment should be administered as appropriate.
Renal and Hepatic Impairment: There is limited experience in
patients with renal and hepatic impairment. Available data indicate that
MMAE clearance might be affected by severe renal impairment, hepatic
impairment, and by low serum albumin concentrations. The recommended
starting dose in patients with hepatic impairment or severe renal
impairment is 1.2 mg/kg administered as an intravenous infusion over 30
minutes every 3 weeks. Patients with renal or hepatic impairment should
be closely monitored for adverse events.
Sodium content in excipients: This medicinal product contains a
maximum of 2.1 mmol (or 47 mg) of sodium per dose. To be taken into
consideration for patients on a controlled sodium diet.
INTERACTIONS
Patients who are receiving a strong CYP3A4 and P-gp inhibitor,
concomitantly with ADCETRIS may have an increased risk of neutropenia
and should be closely monitored. Co-administration of ADCETRIS with a
CYP3A4 inducer did not alter the plasma exposure of ADCETRIS but it
appeared to reduce plasma concentrations of MMAE metabolites that could
be assayed. ADCETRIS is not expected to alter the exposure to drugs that
are metabolized by CYP3A4 enzymes.
PREGNANCY: Women of childbearing potential should be using two
methods of effective contraception during treatment with ADCETRIS and
until 6 months after treatment. There are no data from the use of
ADCETRIS in pregnant women, although studies in animals have shown
reproductive toxicity. ADCETRIS should not be used during pregnancy
unless the benefit to the mother outweighs the potential risks to the
fetus. If a pregnant woman needs to be treated, she should be clearly
advised on the potential risk to the fetus.
LACTATION (breast-feeding): There are no data as to whether
ADCETRIS or its metabolites are excreted in human milk, therefore a risk
to the newborn/infant cannot be excluded. With the potential risk, a
decision should be made whether to discontinue breast-feeding or
discontinue/abstain from therapy with ADCETRIS.
FERTILITY: In nonclinical studies, ADCETRIS treatment has
resulted in testicular toxicity, and may alter male fertility. Men being
treated with this medicine are advised not to father a child during
treatment and for up to 6 months following the last dose.
ADVERSE REACTIONS
Serious adverse drug reactions were: pneumonia, acute respiratory
distress syndrome, headache, neutropenia, thrombocytopenia,
constipation, diarrhea, vomiting, nausea, pyrexia, peripheral motor
neuropathy, peripheral sensory neuropathy, hyperglycemia, demyelinating
polyneuropathy, tumor lysis syndrome, and Stevens-Johnson syndrome.
In the clinical studies of ADCETRIS, adverse reactions defined as very
common (≥1/10) were: infection, upper respiratory tract infection,
neutropenia, PN (sensory and motor), cough, dyspneoa, diarrhea, nausea,
vomiting, constipation, abdominal pain, alopecia, pruritus, myalgia,
arthralgia, fatigue, chills, pyrexia, infusion-related reactions and
weight decreased. Adverse reactions defined as common (≥1/100 to <1/10)
were: Sepsis/septic shock, herpes zoster, pneumonia, herpes simplex,
anemia, thrombocytopenia, hyperglycemia, dizziness, demyelinating
polyneuropathy, ALT/AST increased, rash, and back pain.
ADCETRIS (brentuximab vedotin) U.S. Important Safety Information
BOXED WARNING
Progressive multifocal leukoencephalopathy (PML): JC virus infection
resulting in PML and death can occur in patients receiving ADCETRIS.
Contraindication
ADCETRIS is contraindicated with concomitant bleomycin due to pulmonary
toxicity (e.g., interstitial infiltration and/or inflammation).
Warnings and Precautions
Peripheral neuropathy (PN): ADCETRIS treatment causes a PN that is
predominantly sensory. Cases of motor PN have also been reported.
ADCETRIS-induced PN is cumulative. Monitor patients for symptoms of
neuropathy, such as hypoesthesia, hyperesthesia, paresthesia,
discomfort, a burning sensation, neuropathic pain or weakness and
institute dose modifications accordingly.
Anaphylaxis and infusion reactions: Infusion-related reactions,
including anaphylaxis, have occurred with ADCETRIS. Monitor patients
during infusion. If an infusion-related reaction occurs, interrupt the
infusion and institute appropriate medical management. If anaphylaxis
occurs, immediately and permanently discontinue the infusion and
administer appropriate medical therapy. Patients who experienced a
prior infusion-related reaction should be premedicated for subsequent
infusions. Premedication may include acetaminophen, an antihistamine,
and a corticosteroid.
Hematologic toxicities: Prolonged (≥1 week) severe neutropenia and
Grade 3 or 4 thrombocytopenia or anemia can occur with ADCETRIS.
Febrile neutropenia has been reported with ADCETRIS. Monitor complete
blood counts prior to each dose of ADCETRIS and consider more frequent
monitoring for patients with Grade 3 or 4 neutropenia. Monitor
patients for fever. If Grade 3 or 4 neutropenia develops, consider
dose delays, reductions, discontinuation, or G-CSF prophylaxis with
subsequent doses.
Serious infections and opportunistic infections: Infections such as
pneumonia, bacteremia, and sepsis or septic shock (including fatal
outcomes) have been reported in patients treated with ADCETRIS.
Closely monitor patients during treatment for the emergence of
possible bacterial, fungal or viral infections.
Tumor lysis syndrome: Closely monitor patients with rapidly
proliferating tumor and high tumor burden.
Increased toxicity in the presence of severe renal impairment: The
frequency of ≥Grade 3 adverse reactions and deaths was greater in
patients with severe renal impairment compared to patients with normal
renal function. Avoid the use of ADCETRIS in patients with severe
renal impairment.
Increased toxicity in the presence of moderate or severe hepatic
impairment: The frequency of ≥Grade 3 adverse reactions and deaths was
greater in patients with moderate or severe hepatic impairment
compared to patients with normal hepatic function. Avoid the use of
ADCETRIS in patients with moderate or severe hepatic impairment.
Hepatotoxicity: Serious cases of hepatotoxicity, including fatal
outcomes, have occurred with ADCETRIS. Cases were consistent with
hepatocellular injury, including elevations of transaminases and/or
bilirubin, and occurred after the first dose of ADCETRIS or
rechallenge. Preexisting liver disease, elevated baseline liver
enzymes, and concomitant medications may also increase the risk.
Monitor liver enzymes and bilirubin. Patients experiencing new,
worsening, or recurrent hepatotoxicity may require a delay, change in
dose, or discontinuation of ADCETRIS.
Progressive multifocal leukoencephalopathy (PML): JC virus infection
resulting in PML and death has been reported in ADCETRIS-treated
patients. First onset of symptoms occurred at various times from
initiation of ADCETRIS therapy, with some cases occurring within 3
months of initial exposure. In addition to ADCETRIS therapy, other
possible contributory factors include prior therapies and underlying
disease that may cause immunosuppression. Consider the diagnosis of
PML in any patient presenting with new-onset signs and symptoms of
central nervous system abnormalities. Hold ADCETRIS if PML is
suspected and discontinue ADCETRIS if PML is confirmed.
Pulmonary toxicity
Events of noninfectious pulmonary toxicity
including pneumonitis, interstitial lung disease, and acute
respiratory distress syndrome, some with fatal outcomes, have been
reported. Monitor patients for signs and symptoms of pulmonary
toxicity, including cough and dyspnea. In the event of new or
worsening pulmonary symptoms, hold ADCETRIS dosing during evaluation
and until symptomatic improvement.
Serious dermatologic reactions: Stevens-Johnson syndrome (SJS) and
toxic epidermal necrolysis (TEN), including fatal outcomes, have been
reported with ADCETRIS. If SJS or TEN occurs, discontinue ADCETRIS and
administer appropriate medical therapy.
Gastrointestinal (GI) complications: Fatal and serious GI
complications, including perforation, hemorrhage, erosion, ulcer,
intestinal obstruction, enterocolitis, neutropenic colitis, and ileus
have been reported in ADCETRIS-treated patients. Lymphoma with
preexisting GI involvement may increase the risk of perforation.
Contacts
Takeda
Japanese Media:
Tsuyoshi Tada, +81 (0)
3-3278-2417
tsuyoshi.tada@takeda.com
or
Media
outside Japan:
Sara Noonan, 617-755-3683
sara.noonan@takeda.com
or
Seattle
Genetics
Investors:
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
or
Media:
Tricia
Larson, 425-527-4180
tlarson@seagen.com
Read full story here
東芝： 2016年度 人工知能学会 現場イノベーション賞・金賞を受賞 2017年06月26日 17時30分
－四日市工場における半導体生産性改善－
東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- 株式会社東芝（以下、東芝）と東芝メモリ株式会社（以下、東芝メモリ）はこのたび、「四日市工場における半導体生産性改善」の取り組みが評価され、2016年度人工知能学会現場イノベーション賞・金賞を受賞しました。本日贈呈式が行われました。
人工知能学会現場イノベーション賞は、実生活やビジネスの現場における問題に対して人工知能技術により解決した事例を評価し、その研究開発を遂行した個人や団体を表彰するものです。今回の受賞は、東芝メモリの製造拠点である四日市工場において、製造装置や検査装置から収集したビッグデータを人工知能で解析し、生産性を改善したことが、人工知能をビジネスにつなげた事例として高く評価されたものです。
両社は今後も、人工知能の技術を用いて半導体の品質改善と生産コスト削減を推し進め、さらなるメモリの大容量化・生産規模拡大を図っていきます。
背景
四日市工場では、従来、製造装置や検査装置から収集したデータを熟練の技術者が解析し、品質改善や生産コスト削減、生産規模の拡大を図ってきました。一方、メモリの急速な大容量化と、製造プロセスの複雑化や大規模化に伴い、人手によるデータ解析が困難になりつつあります。そこで当社は、近年著しい発展を遂げている人工知能と機械学習を用いて、これまで熟練の技術者が担ってきたデータ解析の一部を自動化する技術を開発しました。
受賞した取り組みの概要
不良原因の自動解析
最終工程の全数検査で得られた不良データから不良原因を自動的に解析する技術です。解析された不良原因は不良の発生状況とともに「歩留新聞」注（図１）として可視化され、この「歩留新聞」を頼りに技術者が不良原因を取り除きます。「歩留新聞」の作成にはクラスタリングとパターンマイニング技術を用いています。一度発生した不良はシステムに登録され、再発が常時監視されます。本技術により、不良1件当たりの解析時間が平均6時間から2時間に短縮されました。
欠陥検査画像の自動分類
工程間の抜き取り検査において、走査型電子顕微鏡で撮影された欠陥検査画像（図２）を、欠陥の種類ごとに自動的に分類する技術です。多様な種類の欠陥がある中で、従来の検査画像の自動分類技術では、49%の欠陥に留まっていたものが、深層学習を用いることにより、83%の欠陥の自動分類を実現しました。
製造プロセスの早期改善
製造プロセスに関わるさまざまな条件や、製造装置に取り付けられたセンサの値から、製造工程の途中段階で、品質や特性を予測する技術です。その予測結果に基づいて、製造プロセスの改善や制御を行います。従来、膨大なセンサデータから品質の予測モデルを構築するには熟練者の高度な知見が必要でしたが、機械学習手法の一つであるスパースモデリングを用いることによって、高精度な予測モデルを自動的に作成することが可能となりました。
装置保守時期の自動決定
製造装置を低コストで安定的に動作させるための保守時期を自動的に決定する技術です。装置の保守時期が遅すぎると故障リスクが高まり、早すぎると保守コストがかさんでしまいますが、装置ごとに適切な保守時期を計算するモデルを作るのは困難です。そこで、強化学習を用いて保守コストが小さくなるタイミングを短期間で学習し、適切な保守時期の決定を自動化しました。
現場イノベーション賞
人工知能学会現場イノベーション賞は、実生活やビジネスの現場における実問題に関して、人工知能技術により解決した事例を学会として評価した上で、その研究開発を遂行した個人や団体を表彰するものです。2009年に始まり、今回で8回目となります。現場から見出した問題と、それに対する解として開発した技術の独創性・有用性を基準に受賞者が選定されます。
URL： http://www.ai-gakkai.or.jp/about/award/#INNOVATION
注 歩留新聞：ビッグデータを活用し、ウエハー上の不良分布、発生トレンド、および不良発生装置の候補を一覧で確認できるシステムのこと。
Contacts
本資料に関するお問い合わせ先：
東芝メモリ株式会社
経営企画部
山路 航太
Tel:
03-3457-3473
e-mail: semicon-NR-mailbox@ml.toshiba.co.jp
Takeda and Biological E. Limited Announce Partnership to De… 2017年06月26日 16時06分
Two recently-signed agreements will transfer Takeda’s measles and
acellular pertussis vaccine technologies to India-based multi-national
company Biological E. Limited (“BE”) to develop low-cost combination
vaccines including diphtheria, tetanus and acellular pertussis (DTaP)
and measles-rubella (MR) vaccines
OSAKA, Japan & HYDERABAD, India--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) and
Biological E. Limited (“BE”) today announced that they have entered into
a collaboration whereby two licensing agreements to expedite the
development and delivery of affordable combination vaccines have been
executed. BE will commercialize the vaccine in India, China and low- and
middle-income countries where large, unmet public health needs exist.
Takeda has sold both the measles and pertussis vaccines in the Japanese
market for more than 20 years. In heavily populated countries like
India, where 25.7 million births occurred in 2015, substantial
opportunities remain to deliver critical vaccines to those who need
them. In the absence of access to vaccines in many parts of the world,
this partnership illustrates Takeda’s desire to forge the kind of
collaborations needed to overcome this public health challenge in low-
and middle-income countries.
“Access to medicines is one of Takeda’s core values, and these
agreements align with Takeda’s strategic goals to make high-impact
contributions to global public health, either alone or through
partners,” said Rahul Singhvi, Chief Operating Officer, Takeda Vaccine
Business Unit. “These two agreements along with our current vaccine
pipeline underscore our global commitment to address important
infectious diseases across the globe.”
Under these agreements, Takeda will conduct a transfer from Japan to BE
its existing measles and acellular pertussis vaccine bulk production
technology, including the provision of technical services such as
support in infrastructure review, training for production and quality
control, technical assistance in process development, preclinical study
design and production of clinical batch and the first commercial batches.
BE will scale up the bulk production technology transferred from Takeda
and will be solely responsible for conducting and funding development
activities for the combination vaccines. BE has rights to use Takeda’s
measles vaccine technology for a combination MR vaccine and the right to
use Takeda’s pertussis vaccine technology for any pertussis-containing
combination vaccine. BE will have commercialization rights for the MR
and pertussis vaccines in India, China and selected public markets
worldwide as defined in the agreements.
According to Mahima Datla, Managing Director at Biological E. Limited,
“At the core of our mission is to develop and commercialize affordable
vaccines. We have successfully demonstrated this through our DTwP
franchise in developing countries, and this collaboration allows us to
serve additional markets and diversify our geographic presence. In the
context of MR, we look forward to contributing to the measles
elimination goals and protection against rubella.”
Takeda’s Commitment to Vaccines
Vaccines prevent more than two million deaths each year and have
transformed global public health. For 70 years, Takeda has supplied
vaccines to protect the health of people in Japan. Today, Takeda’s
global vaccine business is applying innovation to tackle some of the
world’s most challenging infectious diseases, such as dengue, Zika,
norovirus, and polio. Our team brings an outstanding track record and a
wealth of knowledge in vaccine development, manufacturing and global
access to advance a pipeline of vaccines to address some of the world’s
most pressing public health needs.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research
and development-driven pharmaceutical company committed to bringing
better health and a brighter future to patients by translating science
into life-changing medicines. Takeda focuses its research efforts on
oncology, gastroenterology and central nervous system therapeutic areas
plus vaccines. Takeda conducts R&D both internally and with partners to
stay at the leading edge of innovation. New innovative products,
especially in oncology and gastroenterology, as well as its presence in
emerging markets, fuel the growth of Takeda. More than 30,000 Takeda
employees are committed to improving quality of life for patients,
working with our partners in health care in more than 70 countries. For
more information, visit http://www.takeda.com/news.
About Biological E. Limited
Biological E is a privately held company established in 1953. Biological
E. Limited (BE) is a globally focused biopharmaceutical company that
develops, manufactures and markets innovative vaccines and biologics
that respond to health care needs worldwide. The company’s product
development efforts are driven by an internationally experienced
management team and the company has several strategic partnerships with
leading biotechnology and pharmaceutical companies and research
institutes around the world.
Contacts
Takeda Contacts:
For media outside of Japan:
Elissa J.
Johnsen
TEL: + 1 224-554-3185
elissa.johnsen@takeda.com
or
For
Japanese media:
Tsuyoshi Tada
TEL: +81-3-3278-2417
tsuyoshi.tada@takeda.com
or
Biological
E. Limited Contact:
Divya Bijlwan
Head, Business
Development
TEL: +91-8008022323
divya.bijlwan@biologicale.com
Toyoda Gosei Enhances Production Capacity for Plastic Fuel … 2017年06月26日 15時00分
KIYOSU, Japan--(BUSINESS WIRE)--Toyoda Gosei Co., Ltd. will enhance production capacity for plastic fuel
filler pipes in Japan and the USA to meet growing demand for lightweight
parts that contribute to better environmental performance of automobiles.
Toyoda Gosei will invest about 2 billion yen (US$1.9 million*)
to expand production facilities in its Heiwacho Plant (Aichi, Japan) and
at one of its US manufacturing subsidiaries, TG Kentucky, LLC. The
production capacity of the two plants together will be increased to 2
million pipes annually by 2020, about four times the current level.
Similar investments are planned in China, Czech Republic, and other
locations to meet customer’s demand for the product.
Fuel filler pipes have long been made mainly of metal. Toyoda Gosei was
the first to succeed in making these pipes of plastic with its extrusion
production method, which are about 50% lighter than previous metal
pipes. The company received a Superior TNGA Promotion Award in
February 2015 from its main customer, Toyota Motor Corporation, for
developing a product that contributes to improved automobile fuel
efficiency.
Toyoda Gosei’s plastic fuel filler pipes also meet stricter emission
constraints in North America, China, and Europe, and are expected to
come into wider use for their contributions to combating environmental
pollution.
* Calculated with US$1 = 105 yen
About Toyoda Gosei
Established in 1949 and headquartered in Kiyosu, Aichi Prefecture,
Japan, Toyoda Gosei is a leading specialty manufacturer of rubber and
plastic automotive parts and LEDs. Today, the Toyoda Gosei Group
provides a variety of high-quality products internationally, with a
network of approximately 100 plants and offices in 18 countries and
regions. Through its flexible, integrated global supply system and
leading-edge technologies for automotive safety, comfort, and
environmental preservation, Toyoda Gosei is a global supplier that
aims to deliver the highest levels of quality, innovation, and
satisfaction to customers worldwide.
Contacts
Toyoda Gosei Co., Ltd.
Takatomo Abe
inquiry@mail.toyoda-gosei.co.jp
Genentech’s Emicizumab Showed Positive Results in Phase III… 2017年06月26日 14時00分
Emicizumab showed substantial and clinically meaningful reduction
in bleeds across two pivotal studies
Data from HAVEN 1 in adults and adolescents and interim data from
HAVEN 2 in children to be presented at the 26th International Society
on Thrombosis and Haemostasis (ISTH) Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),
announced today positive data from the primary analysis of the Phase III
HAVEN 1 study in adults and adolescents and interim analysis of the
Phase III HAVEN 2 study in children evaluating once-weekly subcutaneous
emicizumab prophylaxis (preventative) for the treatment of hemophilia A
with inhibitors to factor VIII. Data from both studies will be presented
on July 10 at the 26th International Society on Thrombosis and
Haemostasis (ISTH) Meeting in Berlin, Germany.
The Phase III HAVEN 1 study compared emicizumab prophylaxis with
on-demand (no prophylaxis; episodic use only) and prophylactic use of
bypassing agents (BPAs) in adults and adolescents with hemophilia A with
inhibitors. The primary endpoint was treated bleeds, and results showed
a statistically significant and clinically meaningful reduction in bleed
rate of 87 percent (RR [risk rate]=0.13, p<0.0001) with emicizumab
prophylaxis compared to on-demand treatment with BPAs.
After a median observation time of 31 weeks, 62.9 percent of patients
receiving emicizumab experienced zero treated bleeds compared to 5.6
percent of those receiving on-demand BPAs. Reduction in bleed rate with
emicizumab was consistent across all secondary endpoints, including all
bleeds (80 percent; RR=0.20, p<0.0001), treated spontaneous bleeds (92
percent; RR=0.08, p≤0.0001), treated joint bleeds (89 percent; RR=0.11,
p=0.0050) and treated target joint bleeds (95 percent; RR=0.05,
p=0.0002) compared to on-demand BPAs. Results also showed a
statistically significant and clinically meaningful improvement in
health-related quality of life (HRQoL) measured at 25 weeks, including
Hem-A-QoL physical health domain and total score and EQ-5D-5L visual
analog scale and total utility score.
In an additional study arm (Arm C, n=49), patients who had previously
received prophylaxis with BPAs received emicizumab prophylaxis. A subset
of patients in this arm (n=24) had previously participated in a
non-interventional study (NIS), allowing for a first-of-its-kind
intra-patient analysis. This analysis showed a 79 percent (RR=0.21,
p=0.0003) reduction in treated bleeds in people receiving emicizumab
compared to their prior prophylaxis with BPAs.
Adverse events (AEs) occurring in five percent or more of patients
treated with emicizumab were injection site reactions, headache,
fatigue, upper respiratory tract infection and arthralgia. As previously
reported, serious adverse events of thromboembolic events (TE) and
thrombotic microangiopathy (TMA) occurred in two patients and three
patients, respectively, while receiving emicizumab prophylaxis. One
event occurred after the clinical cut-off date for the primary analysis.
The TE and TMA events were associated with repeated high doses of a BPA,
activated prothrombin complex concentrate, when used to treat
breakthrough bleeds.
Interim results from the single-arm HAVEN 2 study in children younger
than 12 years of age with hemophilia A with inhibitors who received
emicizumab prophylaxis are consistent with the positive results from the
HAVEN 1 study. After a median observation time of 12 weeks, the study
showed that only one of 19 children receiving emicizumab reported a
treated bleed. There were no reported joint or muscle bleeds. An
intra-patient comparison (n=8) in patients who were previously enrolled
in the NIS showed that all patients experienced a 100 percent reduction
in treated bleeds following treatment with emicizumab (previous ABR
ranged from 0 to 34.24); this included seven children who had received
prior BPA prophylaxis and one who had received prior on-demand BPA. The
data also indicate that the same dose of emicizumab is appropriate for
children as for adults and adolescents, based on the levels of
emicizumab in the blood (pharmacokinetics) of the children compared with
the level of emicizumab in the blood of adults and adolescents. The most
common AEs with emicizumab in the HAVEN 2 study were mild injection site
reactions and common cold symptoms (nasopharyngitis).
About HAVEN 1 (NCT02622321)
HAVEN 1 is a randomized, multicenter, open-label, Phase III study
evaluating the efficacy, safety, and pharmacokinetics of emicizumab
prophylaxis compared to on-demand BPA (no prophylaxis; episodic use
only) in adults and adolescents with hemophilia A with inhibitors to
factor VIII. The study included 109 patients (12 years of age or older)
with hemophilia A with inhibitors to factor VIII, who were previously
treated with on-demand or prophylactic BPAs. Patients previously treated
with on-demand BPAs were randomized in a 2:1 fashion to receive
emicizumab prophylaxis (Arm A) or no prophylaxis (Arm B). Patients
previously treated with prophylactic BPAs received emicizumab
prophylaxis (Arm C). Additional patients previously on BPA (on-demand or
prophylaxis) were also enrolled in a separate arm (Arm D). On-demand
treatment of breakthrough bleeds with BPAs was allowed per protocol in
all arms.
The primary endpoint of the study is the number of treated bleeds over
time with emicizumab prophylaxis (Arm A) compared with no prophylaxis
(Arm B). Secondary endpoints include all bleed rate, joint bleed rate,
spontaneous bleed rate, target joint bleed rate, health-related quality
of life (HRQoL)/health status, intra-patient comparison to bleed rate on
their prior prophylaxis regimen with BPAs (Arm C) or no prophylaxis (Arm
A). The study also evaluated safety and pharmacokinetics.
A summary of the HAVEN 1 study results to be presented at ISTH is
included below.
| HAVEN 1 (NCT02622321) | |||||
|
| |||||
Patients |
| |||||
|
|
| ||||
Treated bleeds ABR (primary endpoint) | ||||||
|
|
| ||||
% reduction (RR, p-value) |
| |||||
|
|
| ||||
|
|
| ||||
| ||||||
Study group | Prior prophylaxis with a BPA | Emicizumab prophylaxis | ||||
|
|
| ||||
|
| |||||
Median ABR (IQR) |
|
| ||||
|
|
| ||||
| ||||||
About HAVEN 2 (NCT02795767)
HAVEN 2 is a single-arm, multicenter, open-label, Phase III study
evaluating the efficacy, safety, and pharmacokinetics of once-weekly
subcutaneous administration of emicizumab. The interim analysis after a
median of 12 weeks of treatment included 19 children younger than 12
years of age with hemophilia A with inhibitors to factor VIII, who
require treatment with BPAs. The objectives of the study are to evaluate
the number of treated bleeds over time with emicizumab prophylaxis,
safety, pharmacokinetics, health-related quality of life (HRQoL) and
proxy HRQoL with aspects of caregiver burden. The study will enroll a
total of 60 children for its final analysis planned after 52 weeks of
treatment with emicizumab.
About emicizumab (ACE910)
Emicizumab is an investigational bispecific monoclonal antibody designed
to bring together factors IXa and X, proteins required to activate the
natural coagulation cascade and restore the blood clotting process.
Emicizumab can be administered by an injection of a ready-to-use
solution under the skin (subcutaneously) once weekly. Emicizumab is
being evaluated in pivotal Phase III studies in people 12 years of age
and older, both with and without inhibitors to factor VIII, and in
children under 12 years of age with factor VIII inhibitors. Additional
trials are exploring less frequent dosing schedules. The clinical
development program is assessing the safety and efficacy of emicizumab
and its potential to help overcome current clinical challenges: the
short-lasting effects of existing treatments, the development of factor
VIII inhibitors and the need for frequent venous access. Emicizumab was
created by Chugai Pharmaceutical Co., Ltd. and is being co-developed by
Chugai, Roche and Genentech.
About hemophilia A
Hemophilia A is an inherited, serious disorder in which a person’s blood
does not clot properly, leading to uncontrolled and often spontaneous
bleeding. Hemophilia A affects around 320,000 people worldwide,
approximately 50-60 percent of whom have a severe form of the disorder.
People with hemophilia A either lack or do not have enough of a clotting
protein called factor VIII. In a healthy person, when a bleed occurs,
factor VIII brings together the clotting factors IXa and X, which is a
critical step in the formation of a blood clot to help stop bleeding.
Depending on the severity of their disorder, people with hemophilia A
can bleed frequently, especially into their joints or muscles. These
bleeds can present a significant health concern as they often cause pain
and can lead to chronic swelling, deformity, reduced mobility and
long-term joint damage. In addition to impacting a person’s quality of
life, these bleeds can be life threatening if they go into vital organs,
such as the brain. A serious complication of treatment is the
development of inhibitors to factor VIII replacement therapies.
Inhibitors are antibodies developed by the body’s immune system that
bind to and block the efficacy of replacement factor VIII, making it
difficult, if not impossible to obtain a level of factor VIII sufficient
to control bleeding. Most people with hemophilia A who develop
inhibitors will infuse BPA therapies, either on-demand (episodic) or as
prophylaxis, to control bleeding. This approach is known to be less
effective and less predictable than factor VIII replacement therapy in
people with hemophilia A without inhibitors.
About Genentech in hemophilia
In 1984, Genentech scientists were the first to clone recombinant factor
VIII in response to the contaminated hemophilia blood supply crisis of
the early 1980s. For more than 20 years, Genentech has been developing
medicines to bring innovative treatment options to people with diseases
of the blood within oncology, and is investigating emicizumab as a
potential treatment option for hemophilia A. Genentech is committed to
improving treatment and care in the hemophilia community by delivering
meaningful science and clinical expertise. For more information visit http://www.gene.com/hemophilia.
About Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology
company that discovers, develops, manufactures and commercializes
medicines to treat patients with serious or life-threatening medical
conditions. The company, a member of the Roche Group, has headquarters
in South San Francisco, California. For additional information about the
company, please visit http://www.gene.com.
Contacts
Genentech
Media Contact:
Kimberly Muscara, 650-467-6800
or
Advocacy
Contact:
Sonali Chopra, 650-467-0842
or
Investor Contact:
Neera
Dahiya Ravindran, M.D., 650-491-5281
Karl Mahler, 011 41 61 687 8503
Chugai's Bispecific Antibody Emicizumab to Present Results … 2017年06月26日 14時00分
TOKYO--(BUSINESS WIRE)--#ISTH--Chugai
Pharmaceutical Co., Ltd. (TOKYO:4519) announced results from two
global phase lll studies for Chugai’s bispecific antibody emicizumab
(ACE910): the primary analysis of HAVEN 1 study (NCT02622321) and the
interim analysis of HAVEN 2 study (NCT02795767). The data will be
presented on July 10 at the upcoming 26th International Society on
Thrombosis and Haemostasis (ISTH) Meeting in Berlin, Germany (July 8 to
13). Both studies were conducted in haemophilia A with inhibitors, while
HAVEN 1 is for adult and adolescent patients and HAVEN 2 is for
paediatric patients.
HAVEN 1 Study
Study description
HAVEN 1 is a randomised, multicentre, open-label, global phase III study
evaluating the efficacy, safety, and pharmacokinetics of emicizumab
once-weekly subcutaneous injection for 24 weeks or longer in adults and
adolescents (12 years of age or older) with haemophilia A with
inhibitors to factor VIII.
Study design n=109
Patients previously treated with on-demand bypassing agents (BPAs)
were randomised in a 2:1 fashion to Arm A or B
Arm A (n=35): | emicizumab once-weekly dosing | |||||||
Arm B (n=18): | no prophylaxis (on-demand BPA) |
Patients previously treated with prophylactic BPA
Arm C (n=49): | emicizumab once-weekly dosing |
Patients who participated in a forgoing Non-Interventional Study (NIS)
and previously on BPA (on-demand or prophylactic)
Arm D: | emicizumab once-weekly dosing |
On-demand use of BPAs was allowed to treat breakthrough bleeds per
protocol in all arms.
Summary of results
The primary endpoint was achieved with a statistically significant
reduction in bleed rate of 87% (risk rate [RR]=0.13, p<0.0001) in
treated bleeds with emicizumab (Arm A) compared with on-demand
treatment with BPAs (Arm B). All secondary endpoints were also
achieved with consistent reductions in bleed rates.
| ||||||||
All bleeds: | (80%, RR=0.20, p<0.0001) | |||||||
Treated spontaneous bleeds: | (92%, RR=0.08, p≤0.0001) | |||||||
Treated joint bleeds: | (89%, RR=0.11, p=0.0050) | |||||||
Treated target joint bleeds: | (95%, RR=0.05, p=0.0002) | |||||||
After a median observation time of 31 weeks, 62.9% of patients
receiving emicizumab experienced zero treated bleeds (Arm A) compared
to 5.6% of those receiving on-demand BPAs (Arm B).
Results also showed a statistically significant improvement in
health-related quality of life (HRQoL) measured at 25 weeks with
emicizumab (Arm A) compared to on-demand BPAs (Arm B).
Among patients who had previously received prophylactic use of BPAs
and then received emicizumab (Arm C), 24 patients had participated in
the foregoing NIS, which was conducted without emicizumab. An
intra-patient analysis in this group showed a 79% (RR=0.21, p=0.0003)
reduction in treated bleeds receiving emicizumab compared to their
prior prophylaxis with BPAs.
Adverse events (AEs) occurring in 5% or more of patients treated with
emicizumab were injection site reactions, headache, fatigue, upper
respiratory tract infection and arthralgia.
Serious adverse events were reported with thromboembolic events (TE)
in two patients and thrombotic microangiopathy (TMA) in three patients
(one patient experienced TMA after the clinical data cut off for
primary analysis) while receiving emicizumab prophylaxis. The TE and
TMA events were associated with repeated high doses of a BPA,
activated prothrombin complex concentrate, when used to treat
breakthrough bleeds.
HAVEN 2 Study
Study Description
HAVEN 2 is a single-arm, multicentre, open-label, global phase III study
evaluating the efficacy, safety, and pharmacokinetics of emicizumab once
weekly subcutaneous injection in paediatric patients with haemophilia A
with inhibitors to factor VIII.
Interim analysis
The interim analysis was conducted with 19 children younger than 12
years of age with haemophilia A with inhibitors who require treatment
with BPAs. The median observation time was 12 weeks.
Summary of results
Only one of 19 children receiving emicizumab reported a treated bleed.
There were no reported joint or muscle bleeds.
An intra-patient comparison (n=8) in patients who were previously
enrolled in the NIS showed that all patients experienced zero treated
bleeds or a 100% reduction after emicizumab treatment (previous
annualized bleeding rate ranged from 0 to 34.24); this included seven
children who had received prior BPA prophylaxis, and one who had
received prior on-demand BPA.
Data indicated that the same dose of emicizumab is appropriate for
children as for adults and adolescents, based on the levels of
emicizumab in the blood (pharmacokinetics) of the children compared
with the level of emicizumab in the blood of adults and adolescents.
The most common AEs with emicizumab in the HAVEN 2 study were mild
injection site reactions and common cold symptoms (nasopharyngitis).
| ||||
Study Description | Phase III randomised, multicenter, open-label study evaluating the efficacy, safety, and pharmacokinetics of emicizumab prophylaxis versus no prophylaxis in people with hemophilia A with inhibitors to factor VIII. | |||
Patients |
| |||
Study group |
|
| ||
Treated bleeds ABR (primary endpoint) | ||||
Annualized bleeding rate [ABR]*
|
|
| ||
% reduction (RR, p-value) |
| |||
Median ABR
|
|
| ||
% patients with zero bleeds (95% CI) |
|
| ||
| ||||
Study group | Prior prophylaxis with BPAs | Emicizumab prophylaxis | ||
ABR*
|
|
| ||
% reduction (RR, p-value) |
| |||
Median ABR (IQR) |
| 0.0 [0.00; 2.23] | ||
% patients with zero bleeds |
|
| ||
*Negative binomial regression model
About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are
collaborating to develop new pharmaceuticals and laboratories in Ukima
are conducting research for technology development for industrial
production. Overseas, Chugai
Pharmabody Research based in Singapore is engaged in research
focusing on the generation of novel antibody drugs by utilizing Chugai’s
proprietary innovative antibody engineering technologies. Chugai
Pharma USA and Chugai
Pharma Europe are engaged in clinical development activities in the
United States and Europe.
The consolidated revenue in 2016 of
Chugai totalled 491.8 billion yen and the operating income was 80.6
billion yen (IFRS Core basis).
Additional information is available
on the internet at https://www.chugai-pharm.co.jp/english.
Contacts
For Media
Chugai Pharmaceutical Co.,
Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki
Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For
US media
Chugai Pharma USA Inc.
Casey Astringer
Tel:
+1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For
European media
Chugai Pharma France SAS
Nathalie Leroy
Tel:
+33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For
Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel:
+886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For
Investors
Chugai Pharmaceutical Co., Ltd.
Investor
Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel:
+81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp
OKI Wins Silver Innovation Award from ATM Industry Associat… 2017年06月26日 11時00分
- Award recognizes contributions to advances in cash recycling
technology -
TOKYO--(BUSINESS WIRE)--OKI (TOKYO: 6703) today announced that, in recognition of its
contributions to cash recycling technology, it was presented with a
Silver Award at 2017 ATM & Cash Innovation Europe, an event held in
London on June 13. Organized by the ATM Industry Association (ATMIA),
the award commemorated the 50th ATM anniversary of the world’s first ATM
installation occurred in London in 1967.
OKI was well-regarded as a major vendor in this field since pioneering
the development of the world’s first cash recycling technology and
deploying cash-recycling ATMs in the Japanese market in 1982 as well as
leading the way in ATM technological innovations.
In 2009, OKI launched the ATM-Recycler G7, a cash-recycling ATM capable
of handling currencies of multiple countries. Since then, the
cash-recycling ATM has continued to be adopted in the global ATM market,
which until its introduction had been dominated by cash dispensers. The
ATM-Recycler G7 is currently used in 14 countries and regions around the
world.
Moving forward, leveraging its track record and the trust it has gained
in the field of cash recycling technology, OKI will continue driving
market growth and delivering solutions to increase ATM added value in
response to future changes in payment methods.
About OKI Electric Industry (OKI)
Founded in 1881, OKI Electric Industry is Japan's leading
telecommunications manufacturer in the Info-telecom field. Headquartered
in Tokyo, Japan, OKI provides top-quality products, technologies, and
solutions to customers through its info-telecom systems and printer
operations. Its various business divisions function synergistically to
bring to market exciting new products and technologies that meet a wide
range of customer needs in various sectors. Visit OKI's global website
at http://www.oki.com/.
Notes:
The names of the companies and products mentioned in this document are
the trademarks or registered trademarks of the respective companies
and organizations.
Contacts
Press contact:
Oki Electric Industry Co., Ltd.
Mayuko
Noto, +81-3-3501-3835
Public Relations Division
press@oki.com
Customer
contact:
Oki Electric Industry Co., Ltd.
Global Strategic
Planning Department
Global Mechatronics Systems Division
Mechatronics
Systems Business Division
Phone: +81-27-325-1111
Takata Corporation and Key Safety Systems Reach Agreement i… 2017年06月26日 09時06分
To Implement Sale and Address Costs and Liabilities Related to Airbag
Inflator Recalls, Takata Corporation and Its Japanese Subsidiaries
Commence Proceedings under Civil Rehabilitation Act in Japan, and TK
Holdings, Inc. and Certain North American Affiliates and Subsidiaries
File for Chapter 11 in U.S.
Company Working with Customer Group Composed of 14 Automotive Vehicle
Manufacturers to Provide Takata Corporation and TK Holdings with
Substantial Accommodations and Liquidity Enhancements to Finance
Restructuring
Global Operations and Customer Shipments Expected to Continue Without
Interruption and Company Will Continue to Produce Replacement Kits for
Recalled Vehicles
Proceeds from Sale Will Be Used to Meet Requirements of Plea
Agreement with U.S. Department of Justice, to Satisfy Administrative
Costs and Expenses of the Restructuring, and to Fund Unsecured Creditor
Recoveries
TOKYO & STERLING HEIGHTS, Mich.--(BUSINESS WIRE)--Takata Corporation (“Takata,” “TKJP” or the “Company”), a leading global
supplier of automotive safety systems such as seat belts, airbags and
child seats, and Key Safety Systems (“KSS”), a global leader in mobility
safety, headquartered in Sterling Heights, Michigan, USA, announced
today that they have reached an agreement in principle to sponsor a
restructuring plan for the sale of substantially all of Takata’s global
assets and operations to KSS for an aggregate purchase price of
approximately ¥175 billion ($1.588 billion), subject to certain
adjustments at closing.
Under the agreement, KSS will acquire substantially all of Takata’s
assets, except for certain assets and operations that relate to the
Company’s manufacturing and sale of phase-stabilized ammonium nitrate
(PSAN) airbag inflators (collectively, the “PSAN Assets”). It is
expected that Takata’s PSAN-related operations will be run by a
reorganized Takata following the transaction closing and eventually will
be wound down. Takata expects to continue to meet demand for airbag
inflator replacements without interruption.
By combining substantially all of Takata with KSS, the transaction would
form a leading global safety-supply auto parts company with
approximately 60,000 employees in 23 countries focused on serving
customers and providing superior products and innovation in the rapidly
evolving auto safety industry.
Jason Luo, President & CEO of KSS, said: “Takata has deep management
talent, a dedicated work force and a long history of exceptional
customer service. Although Takata has been impacted by the global airbag
recall, the underlying strength of its skilled employee base, geographic
reach, and exceptional steering wheels, seat belts and other safety
products has not diminished. We look forward to finalizing definitive
agreements with Takata in the coming weeks, completing the transaction
and serving both our new and long-standing customers while investing in
the next phase of growth for the new KSS.”
Shigehisa Takada, Chairman & CEO of Takata, said: “KSS is the ideal
sponsor as we address the costs related to airbag inflator recalls, and
an optimal partner to the Company’s customers, suppliers and employees.
The combined business would be well positioned for long-term success in
the global automotive industry. Throughout this process, our top
priorities have been providing a steady supply of products to our valued
customers, including replacement parts for recalls, and a stable home
for our exceptional employees. This agreement would allow that to
continue.”
The proposed structure for the potential transaction is intended to
minimize supply chain disruption concerns for Takata’s OEM customers.
The companies anticipate a quick and seamless integration, utilizing the
combined strengths of their respective management teams to implement a
smooth transition.
KSS will continue to support Takata’s customers, suppliers and employees
and embrace and honor Takata's Japanese heritage:
KSS plans to retain substantially all of Takata’s employees across the
world on comparable employment terms as currently provided.
KSS has held in-depth discussions with Takata’s major OEM customers
and has jointly developed a transaction structure and operating plan
to facilitate ongoing supply of Takata parts. This should provide
continuity of supply to Takata’s customers and confidence to Takata’s
employees, suppliers and other key stakeholders.
KSS plans to continue to support and utilize Takata’s presence in
Japan, and does not intend to shut down any of Takata’s manufacturing
facilities there. Furthermore, KSS intends to establish an Asia
regional headquarters in Tokyo, which should create new jobs in Japan,
and plans to retain Takata's existing non-PSAN supplier contracts to
maintain an uninterrupted supply chain. KSS also intends to invest in
many of Takata’s other worldwide manufacturing facilities and
technology and R&D centers.
KSS has substantially completed its due diligence, and Takata and KSS
are working toward finalizing a definitive agreement in the coming
weeks, with an expected transaction close in the first quarter of 2018.
Hideaki Sudo, Chairman of Takata’s Steering Committee and Partner at
Tokyo Fuji Law office, said, “Since February 2016, the Steering
Committee has been working diligently, with assistance from our
financial and legal advisors, to develop a path forward for Takata that
resolves the recall costs and liabilities on a consensual basis in
partnership with Takata’s automotive customers. After a rigorous global
process, the Committee has recommended KSS as the best sponsor candidate
based on a variety of factors including strategic fit, valuation, and
certainty of closing. We are pleased that Takata has accepted such
recommendation. We appreciate the cooperation of the affected automotive
manufacturers, who have worked closely with us to devise this
restructuring plan, which we firmly believe is in the best interests of
the Company and its stakeholders.”
Civil Rehabilitation and Chapter 11 Proceedings
Excluding recall-related costs and liabilities, Takata has continued to
produce healthy profits and cash flows from its existing businesses.
Nevertheless, Takata has determined that it is in the best interests of
the Company and its stakeholders to address the recall-related issues in
conjunction with the proposed sale. Accordingly, with the expected
support of a group of its OEM customers representing more than 80% of
Takata’s annual sales (the “Customer Group”) and KSS as plan sponsor,
TKJP and its Japanese subsidiaries have commenced proceedings under the
Civil Rehabilitation Act in Japan in the Tokyo District Court (the
“Tokyo Court”). In addition, TKJP’s main U.S. subsidiary, TK Holdings,
Inc. (“TKH”), and certain of its North America affiliates and
subsidiaries, filed for Chapter 11 in the United States Bankruptcy Court
for the District of Delaware (the “Delaware Court”).
The Japanese OEMs have committed to provide Takata with valuable
accommodations and liquidity enhancements during the Civil
Rehabilitation and the Company is working with the Customer Group on an
agreement to do so on a global basis. Takata intends to use the Civil
Rehabilitation Act and Chapter 11 processes to continue to work with its
Customer Group and KSS to finalize and execute restructuring support
agreements (each an “RSA”) that would include comprehensive terms of the
restructuring. The RSAs will reflect the commitment of the Customer
Group and KSS to the restructuring transactions to be effectuated
pursuant to the Chapter 11 Plan of Reorganization (the “Plan”) that
would be subject to approval of the Delaware Court, as well as the
business transfer to be implemented by the Tokyo Court. The transaction
with KSS would also be subject to approval by the Tokyo Court and the
Delaware Court, as well as a number of other conditions, including
regulatory and other third-party approvals.
It is contemplated that upon the anticipated effective date of the Plan,
Takata’s global PSAN Assets will be transferred to TKH or one of its
subsidiaries, as reorganized under the Plan (“RTK” or “Reorganized
Takata”), and all of the PSAN Assets, including PSAN contracts, will be
transferred to RTK. It is expected that RTK will emerge from the Chapter
11 process and operate independently from KSS under the supervision of a
Plan administrator and oversight board. RTK will continue to manufacture
PSAN airbag inflators for recalls and the ongoing production needs of
Takata’s customers.
It is expected that the proceedings under the Civil Rehabilitation Act
in Japan and Chapter 11 process in the U.S. will be completed in the
first quarter of 2018.
Proceeds of Sale to Be Used to Address PSAN
Related Costs and Liabilities and Capitalize RTK
As contemplated and as expected to be detailed in the Plan, Takata
intends to use the Civil Rehabilitation and Chapter 11 processes to
address the costs and liabilities related to airbag inflator recalls,
including to fund its remaining obligations under the terms of the plea
agreement with the U.S. Department of Justice (“DOJ”) that was announced
on January 13, 2017 (“the DOJ Plea Agreement”) and Consent Orders
entered into by Takata with the National Highway Traffic Safety
Administration (“NHTSA”).
Pursuant to the DOJ Plea Agreement, Takata paid $25 million as a fine to
the DOJ and was required to fund two restitution funds: (1) a fund of
$125 million to meet liabilities to current or future personal injury
claimants and (2) a fund of $850 million to satisfy a portion of the
claims of OEM customers who purchased airbags containing PSAN inflators.
Each of the restitution funds will be administered by a special master
in accordance with the DOJ Plea Agreement. The $125 million fund for
personal injury claimants was funded on March 29, 2017. Consistent with
the DOJ Plea Agreement, the agreements in principle with the Customer
Group and the proposed restructuring terms provide for the proceeds of
the sale to KSS to be used to fund the $850 million OEM restitution fund.
After setting aside sufficient funds to capitalize RTK following
completion of the Chapter 11 process, any remaining sale proceeds after
satisfaction of the foregoing obligations and the payment of other
claims entitled to priority or payment in full would be used to fund
recoveries to holders of general unsecured claims.
Mr. Takada said, “We believe taking these actions in Japan and the U.S.
is the best way to address the ongoing costs and liabilities of the
airbag inflator issues with certainty and in an organized manner while
ensuring that Takata’s operations worldwide continue in the ordinary
course and without interruption. During the Civil Rehabilitation
proceedings and Chapter 11 process and beyond, Takata remains fully
committed to supporting all actions that advance vehicle safety. We
deeply regret the circumstances that have led to this situation, but we
are grateful to have reached a resolution that will allow us to continue
to promote the safety of the driving public.”
The commencement of Civil Rehabilitation
proceedings in Japan and the Chapter 11 filing in the U.S. should have
no effect on the ability of drivers to get replacements for recalled
Takata airbag inflators free of charge. Vehicle owners in the
U.S. should continue to visit https://www.airbagrecall.com/
for more information on airbag inflator replacements.
Debtor-in-Possession (DIP) Financing and
Customer Accommodations
TKJP has obtained a commitment for up to a ¥25 billion (U.S. $227
million) revolving credit facility debtor-in-possession (“DIP”)
financing to be provided by Sumitomo Mitsui Banking Corporation.
Additionally, the Japanese OEMs have committed to provide Takata with
valuable accommodations and liquidity enhancements during the Civil
Rehabilitation and the Company is working with the Customer Group on an
agreement to do so on a global basis. Upon approval by the supervisor
appointed by the Tokyo Court and approval by the Delaware Court, the DIP
financing in Japan and the accommodations and additional liquidity
support from the Customer Group in both Japan and the U.S., along with
Takata’s cash flow from operations, are expected to provide Takata with
sufficient liquidity to continue to operate its business and serve
automotive customers globally in the ordinary course and without any
significant disruptions.
Uninterrupted Global Operations
Shigehisa Takada, said “We are committed to ensuring that the
restructuring process has as little impact as possible on our employees,
customers and suppliers across the world, as well as on drivers whose
safety is always our primary focus.”
The Company has requested Court approval in the U.S. to continue to pay
its employees without interruption and in the same manner as before the
filing and expects the request to be granted as part of the Court's
"first day" orders. Also, under the Civil Rehabilitation Act, the
salaries of the Company’s employees will be statutorily protected. As a
result, the Company’s salaried and hourly employees should continue to
be paid on the normal schedule. Additionally, there are expected to be
no changes to various employee benefit programs.
With the additional liquidity to be provided by the DIP financing in
Japan and the accommodations and other liquidity enhancements to be
provided globally by the Customer Group, the Company’s suppliers can be
assured that Takata has the ability to pay its post-petition obligations
on a timely basis and intends to do so as required under the Civil
Rehabilitation Act and the U.S. Bankruptcy Code, which grants priority
status to goods and services received after the Civil Rehabilitation and
Chapter 11 filing date.
Mr. Takada added, “I would like to thank all of our constituents for
their continued support during this process. In particular, I and the
rest of our management team recognize that the Company’s success is
dependent upon our talented and dedicated employees, and we are grateful
for their hard work and loyalty. We are taking these actions to ensure
that Takata remains a stable and financially secure employer for
thousands of workers in Japan, the U.S. and across the world.”
Information Resources
Additional information regarding TKJP’s restructuring is available at www.takata.com.
Additional information regarding TKH’s restructuring, including court
filings and information about the claims process, is available at www.TKrestructuring.com,
or by calling TKH’s claims agent, Prime Clerk, at 1-844-822-9229 (Toll
free in U.S. and Canada) or 1-347-338-6502 (International).
Nagashima Ohno & Tsunematsu and Weil, Gotshal & Manges LLP are serving
as legal counsel to Takata. PricewaterhouseCoopers is serving as
financial advisor, and Lazard is serving as investment banker to Takata.
Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel,
KPMG is serving as financial advisor, Jefferies LLC is acting as lead
financial advisor while UBS Investment Bank also provides financial
advice to KSS.
About Takata
Takata Corporation is a leading global innovator and supplier of
automotive safety systems, including airbag systems, seat belts,
steering wheels, electronics, sensors, and child restraint systems, and
supplies all major automotive manufacturers in the world. Headquartered
in Tokyo, Japan, it operates 56 plants in 20 countries with
approximately 46,000 global employees worldwide.
About Key Safety Systems
Key Safety Systems (KSS) is a global leader in mobility safety through
the system integration and performance of safety-critical components to
the automotive and non-automotive markets serving the active safety,
passive safety and specialty product sectors. Through highly specialized
design, development, and manufacturing, KSS’ technology is featured in
more than 300 vehicle models produced by over 60 well-diversified
customers worldwide. Since commencing business as a United States
start-up, serving Detroit automakers in 1916, KSS continues today with
an entrepreneurial and pioneering spirit. KSS is headquartered in
Sterling Heights, Michigan, with a global network of more than ~13,000
employees in 32 sales, engineering, and manufacturing facilities. The
company has 5 main technical centers located in the key regions of the
Americas, Europe and Asia. It is a wholly owned subsidiary of Ningbo
Joyson Electronic Corp. (SHA:600699) (“Joyson Electronics”).
Forward-Looking Statements
This press release contains, and oral statements made from time to time
by our representatives may contain, forward-looking statements that are
based upon our current expectations and assumptions concerning future
events, which are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those anticipated.
The words "expect," "anticipate," "estimate," "forecast," "initiative,"
"objective," "plan," "goal," "project," "outlook," "priorities,"
"target," "intend," "evaluate," "pursue," "commence," "seek," "may,"
"would," "could," "should," "believe," "potential," "continue," or the
negative of any of those words or similar expressions is intended to
identify forward-looking statements. All statements contained in this
press release, other than statements of historical fact, including,
without limitation, statements about our operations, financial condition
and liquidity, strategies, business initiatives, prospects, expectations
regarding future events and our financial performance and the
development of the industry in which we operate, are forward-looking
statements that involve certain risks and uncertainties. While these
statements represent Takata’s current judgment on what the future may
hold, and Takata believes these judgments are based upon reasonable
assumptions, these statements are not guarantees of any events or
financial results, and the Company’s actual results may differ
materially.
You should not place undue reliance on the forward-looking statements
contained in this press release. These forward-looking statements speak
only as of the date on which the statements were made. Takata undertakes
no obligation to update publicly or otherwise revise any forward-looking
statements, except where expressly required by law.
Contacts
Media
TAKATA:
U.S./U.K.
Sard
Verbinnen & Co
Jared Levy/Devin Broda/Kelsey Markovich
212-687-8080
media@takata.com
or
Japan
Ashton
Consulting
Dan Underwood, +81 (0) 3 5425-7220
media@takata.com
or
Germany/Europe
Hering
Schuppener Consulting
Georg Lamerz, +49.211.430.79-276
Takata-hs@heringschuppener.com
or
KEY
SAFETY SYSTEMS:
Global
KSS
Jean-Luc
Blancou, +1-586-726-4046
blancoj2@keysafetyinc.com
or
Edelman
Chad
Tendler, Nadia Damouni
+1-917-868-6899
+1-646-239-5723
chad.tendler@edelman.com
nadia.damouni@edelman.com
or
Japan
Edelman
Deborah
Hayden, +81 3 80-8741-0417
deborah.hayden@edelman.com
EIA: Leaked EU-Japan Trade Agreement Would Increase Illegal… 2017年06月24日 03時05分
WASHINGTON--(BUSINESS WIRE)--Draft documents
published today set the terms for a new trade agreement between the
European Union (EU) and Japan (JEFTA) that, in its current form, would
likely result in increased illegal logging and timber smuggling,
including within Europe’s last remaining virgin forests. The documents,
posted to the website trade-leaks.org by Greenpeace, indicate the JEFTA
could be the EU’s biggest ever trade deal, covering a trade volume twice
as large as the recent EU-Canada deal, known as CETA. An expert
report commissioned by the European Commission (EC) warns about
JEFTA’s adverse impacts on forests.
“New trade deals bring great risks for lowering environmental standards,
unless they contain strict safeguards,” said Alexander von Bismarck,
Executive Director of the Environmental Investigation Agency (EIA). “The
JEFTA is extremely weak in this regard, and threatens to derail the
global effort against illegal timber trade by placing Japan’s
ineffective voluntary measures on par with the mandatory EU Timber
Regulation.”
Illegal logging and associated trade is the world’s third
largest transnational crime after counterfeiting and drug
trafficking, and on par with human trafficking, generating estimated
criminal proceeds of up to 157 billion dollars annually.
Japan is the world’s fourth largest importer of wood products, importing
millions of cubic meters every year from countries with high rates of
illegal logging, including Malaysia, Indonesia, and Russia. While the
EU, the United States, and Australia have mandatory laws prohibiting the
imports of illegally harvested timber and requiring importers to trace
their wood back to the source of harvest, Japan has no comparable law.
Japan’s new Clean
Wood Act, which took effect in May 2017, comprises only a voluntary
registration system for companies and lacks penalties for violations.
In a 2016 report, EIA
revealed how Japan’s indiscriminate sourcing practices are already
fueling illegal logging within the EU itself. Based on undercover
investigations and trade analysis, EIA documented how an Austrian
timber company has for over a decade incentivized illegal logging in
Romania’s Carpathian Mountains, generating hundreds of millions of Euros
in profits through exports of lumber, primarily to Japan for housing
construction. The Forest Stewardship Council (FSC) recently
disassociated from the Austrian company, Holzindustrie Schweighofer,
citing “clear and convincing evidence” of illegal timber sourcing. Many
of Schweighofer’s largest European buyers, including Hornbach, Leroy
Merlin, SPAR and Brico Depot have committed to stop selling Schweighofer
products. However, the company’s Japanese buyers continue to prefer
Schweighofer’s timber to more expensive Swedish or Finnish lumber.
The EC report notes Japan’s role in undermining Europe’s efforts to
establish a Voluntary Partnership Agreement (VPA) with Malaysia, due to
Japan’s extensive sourcing of high-risk timber from Malaysia’s Sarawak
province. According to the assessment, “Japan’s failure so far to
effectively control its imports of illegal timber has arguably had an
inhibiting effect on the negotiations between the EU and Malaysia on a
VPA.”
The leaked draft JEFTA lacks any binding obligations for Japan to change
its wood sourcing practices, since it contains only vague promises to
“encourage” conservation and legal timber trade, to “contribute to
illegal logging and related trade” and “exchange information.”
The EC assessment notes with concern that JEFTA would put European
companies at a disadvantage vis-à-vis the Japanese counterparts in the
global market place. Malaysian companies, which export large amounts of
timber to Japan, “see no reason to place potential restrictions on their
own trade when their major export market requires no such controls. Any
expansion of Japan’s timber imports consequent upon the FTA could serve
to exacerbate this situation.”
“The European Commission’s own experts concluded that JEFTA will
increase trade in illegally sourced timber, with severe consequences for
the world’s forests and for legitimate forest producers in the EU,” said
von Bismarck. “Japan’s import laws need to be brought in line with
international standards – not the other way around.”
Contacts
Environmental Investigation Agency
Maggie Dewane, EIA Press Officer
+1
202-483-6621
mdewane@eia-global.org
or
Susanne
Breitkopf, EIA Policy Director,
+1 202-390-5586
sbreitkopf@eia-global.org
Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (i… 2017年06月23日 16時00分
– Early studies of weekly and twice-weekly ixazomib plus lenalidomide
and dexamethasone demonstrate deep responses after induction, with
deepening responses seen after single-agent ixazomib maintenance –
– Data to be presented during two oral sessions at the 2017 European
Hematology Association (EHA) Annual Meeting –
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:
4502) today announced that data from two Phase 1/2 clinical trials
evaluating NINLARO™ (ixazomib) in patients with newly diagnosed multiple
myeloma will be presented during oral sessions at the 2017 European
Hematology Association (EHA) annual meeting on Saturday, June 24, 11:45
a.m. – 12 p.m. CEST and Sunday, June 25, 8:15 a.m. – 8:30 a.m. CEST.
Both studies evaluated NINLARO plus lenalidomide and dexamethasone in
newly diagnosed patients with multiple myeloma who did not undergo stem
cell transplant (SCT), followed by maintenance with single-agent
ixazomib. NINLARO is currently not approved for the treatment of newly
diagnosed multiple myeloma or in the maintenance setting.
“Despite recent progress, multiple myeloma remains a rare, devastating
and incurable hematologic cancer. Data being presented at EHA
demonstrate Takeda’s ongoing commitment to exploring new ways to provide
effective and sustainable treatment for patients with multiple myeloma,
both at the time of diagnosis and for long-term use,” said Jesus Gomez
Navarro, M.D., Vice President, Head of Oncology Clinical Research and
Development, Takeda. “These Phase 1/2 data demonstrate the potential use
of ixazomib in combination with lenalidomide-dexamethasone in newly
diagnosed multiple myeloma and as a single-agent maintenance therapy,
which resulted in patients achieving deepening responses with continual
use of the treatment. Ixazomib’s efficacy and safety profile – coupled
with its administration as a completely oral regimen – potentially can
reduce some logistical burdens, and help patients be able to sustain a
multiple myeloma therapy.”
Deep and Durable Responses with Weekly Ixazomib, Lenalidomide and
Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma:
Long-Term Follow-up of Patients who did not Undergo SCT (Abstract S408,
oral presentation at 11:45 a.m. CEST on June 24, 2017 at IFEMA Madrid,
Hall A)
In this Phase 1/2 study, patients with newly diagnosed multiple myeloma
received weekly oral ixazomib (1.68 - 3.95 mg/m2 in Phase 1
and 4.0 mg in Phase 2) plus lenalidomide and dexamethasone for up to
twelve, 28-day induction cycles. Of the 65 enrolled patients, 42
continued on study treatment without withdrawing early for SCT. After
initial therapy, 25 patients went on to receive weekly, single-agent
ixazomib at the last tolerated dose given during induction until disease
progression or unacceptable toxicity.
Key findings, which will be presented by Dr. Shaji Kumar of the Mayo
Clinic, Rochester, Minnesota, include:
Patients who did not undergo SCT and were treated with ixazomib plus
lenalidomide and dexamethasone at induction achieved high response
rates, demonstrate the activity of this regimen
At a median follow-up of 55.2 months, the confirmed overall
response rate (ORR) was 80%, complete plus very good partial
response (CR+VGPR) rate was 63% and CR rate was 32%
Of the patients who achieved sCR/CR and were evaluated for minimal
residual disease (MRD), 6 of 7 (86%) were MRD-negative.
Median progression-free survival (PFS) was 29.4 months
Median overall survival (OS) was not reached at a median follow-up
of 55.2 months; four-year landmark OS estimate was 82%
A total of 86% of patients had grade ≥ 3 adverse events (AEs) and
52% of patients had serious AEs. The most common grade ≥ 3 AEs
were neutropenia, thrombocytopenia, diarrhea, back pain, vomiting,
rashes, eruptions and exanthems, peripheral neuropathy and nausea.
Of the two patients who died on study, one was considered to be
treatment-related and was due to respiratory syncytial viral
pneumonia
After completing 12 cycles of induction therapy with lenalidomide and
dexamethasone, 25 patients went on to receive maintenance single-agent
ixazomib
Increased depth of response occurred in a number of patients who
received maintenance therapy with single-agent ixazomib; 32% of
patients improved their response during maintenance
The occurrence of the most common grade ≥ 3 AEs and adverse drug
reactions (ADRs), which included neutropenia, thrombocytopenia,
back pain and rashes, eruptions and exanthems, was confined almost
exclusively to the induction period
Less toxicity was reported during the maintenance versus
induction periods
“Based on an increasing body of evidence that long-term therapy may
improve clinical outcomes, this Phase 1/2 trial focused on continuous
treatment of patients with newly diagnosed multiple myeloma,”
said lead investigator Shaji Kumar, M.D., Mayo Clinic, Rochester, Minn.
“The trial evaluated patients who received weekly ixazomib plus
lenalidomide and dexamethasone as an induction regimen followed by
maintenance with single-agent ixazomib. Data showed that patients had
deep responses on single-agent therapy and median progression-free
survival of more than two years. We remain committed to gathering
additional data of ixazomib in this investigational, maintenance
setting.”
Twice Weekly Ixazomib Plus Lenalidomide-Dexamethasone in Patients
with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Data for
Patients who did not Undergo Stem Cell Transplant (SCT) (Abstract S780,
oral presentation at 8:15 a.m. CEST on June 25, 2017 at IFEMA Madrid,
Hall D)
This Phase 1/2 study evaluated twice-weekly oral ixazomib (3.0 or 3.7
mg) plus lenalidomide and dexamethasone for up to sixteen, 21-day cycles
followed by maintenance therapy with single-agent twice weekly ixazomib
(at last tolerated dose). Of the 64 patients enrolled, 41 continued on
study treatment without early withdrawal for SCT.
Key findings, which will be presented by Deborah Berg, Senior Scientific
Director, Oncology Clinical Research, Takeda, on behalf of Dr. Paul
Richardson, Dana-Farber Cancer Institute, Boston, Mass., include:
In patients who did not undergo SCT, initial treatment with
twice-weekly ixazomib plus lenalidomide and dexamethasone was
associated with deep responses
At median follow-up of 47 months, the ORR was 92%, the CR + VGPR
rate was 69% and the CR rate was 31%
Of the patients who achieved sCR/CR and were evaluated for minimal
residual disease (MRD), 8 of 9 (89%) were MRD-negative
Median PFS for patients was 24.9 months and median OS was not
estimable; three-year landmark OS estimate was 86%
A total of 85% of patients had grade ≥ 3 AEs and 54% of patients
had serious AEs. The most common grade ≥3 AEs included rash,
eruptions and exanthems, hyperglycemia, peripheral neuropathy,
peripheral edema, thrombocytopenia and neutropenia. There was one
on-study treatment-related death due to cardio respiratory arrest.
After completing induction therapy, 18 patients went on to receive
maintenance with twice-weekly single-agent ixazomib
Patients on maintenance therapy received a median of 31.5
treatment cycles
22% patients improved their responses during maintenance
44% of patients who received maintenance therapy had an onset of a
grade ≥ 3 AE and ADRs in cycle 17 or beyond. The most common grade
≥ 3 AEs and ADRs were hyperglycemia, rashes, eruptions and
exanthems, diarrhea, vomiting, peripheral neuropathy, nausea and
neutropenia.
“The addition of ixazomib – a first in class oral proteasome inhibitor –
to doublet therapy has been shown to substantially improve efficacy in
newly diagnosed multiple myeloma patients,” said lead investigator Paul
Richardson, M.D., Dana-Farber Cancer Institute. “In this Phase 1/2 trial
in newly diagnosed multiple myeloma, ixazomib plus lenalidomide and
dexamethasone resulted not only in high quality of responses using a
twice a week schedule but also in an encouraging deepening of responses
over time in patients who did not receive a stem cell transplant. In
addition, impressive durable clinical benefit was seen as patients went
on to receive maintenance therapy with single-agent ixazomib after
successful induction/remission therapy using this all oral approach.”
About Multiple Myeloma
Multiple myeloma is a cancer of the plasma cells, which are found in the
bone marrow. In multiple myeloma, a group of monoclonal plasma cells, or
myeloma cells, becomes cancerous and multiplies. These malignant plasma
cells have the potential to affect many bones in the body, possibly
resulting in compression fractures, lytic bone lesions and related pain.
Multiple myeloma can cause a number of serious health problems affecting
the bones, immune system, kidneys and red blood cell count, with some of
the more common symptoms including bone pain and fatigue, a symptom of
anemia. Multiple myeloma is a rare form of cancer, with approximately
114,000 new cases globally per year.
About NINLAROTM (ixazomib) capsules
NINLAROTM (ixazomib) is an oral proteasome inhibitor which is
also being studied across the continuum of multiple myeloma treatment
settings as well as systemic light-chain (AL) amyloidosis. It was the
first oral proteasome inhibitor to enter Phase 3 clinical trials and to
receive approval. NINLARO was approved by the U.S. Food and Drug
Administration (FDA) in November 2015 following a priority review and by
the European Commission in November 2016. In the U.S. and Europe,
NINLARO is indicated in combination with lenalidomide and dexamethasone
for the treatment of patients with multiple myeloma who have received at
least one prior therapy.
Ixazomib was granted orphan drug designation in multiple myeloma in both
the U.S. and Europe in 2011 and for AL amyloidosis in both the U.S. and
Europe in 2012. Ixazomib received Breakthrough Therapy status by the
U.S. FDA for relapsed or refractory systemic light-chain (AL)
amyloidosis in 2014.
The comprehensive ixazomib clinical development program, TOURMALINE,
further reinforces Takeda's ongoing commitment to developing innovative
therapies for people living with multiple myeloma worldwide and the
healthcare professionals who treat them. TOURMALINE includes a total of
five ongoing pivotal trials – four, which together are investigating
every major multiple myeloma patient population, and one in light-chain
amyloidosis:
TOURMALINE-MM1, investigating ixazomib vs. placebo, in combination
with lenalidomide and dexamethasone in relapsed and/or refractory
multiple myeloma
TOURMALINE-MM2, investigating ixazomib vs. placebo, in combination
with lenalidomide and dexamethasone in patients with newly diagnosed
multiple myeloma
TOURMALINE-MM3, investigating ixazomib vs. placebo as maintenance
therapy in patients with newly diagnosed multiple myeloma following
induction therapy and autologous stem cell transplant (ASCT)
TOURMALINE-MM4, investigating ixazomib vs. placebo as maintenance
therapy in patients with newly diagnosed multiple myeloma who have not
undergone ASCT; this study is currently enrolling
TOURMALINE-AL1, investigating ixazomib plus dexamethasone vs.
physician choice of selected regimens in patients with relapsed or
refractory AL amyloidosis; this study is currently enrolling
TOURMALINE-MM5, investigating ixazomib plus dexamethasone vs.
pomalidomide plus dexamethasone in patients with relapsed and/or
refractory multiple myeloma who have become resistant to lenalidomide
TOURMALINE-MM6, investigating ixazomib vs. placebo, in combination
with lenalidomide and dexamethasone in patients with multiple myeloma
transitioning from a bortezomib-based triplet induction regimen
In addition to the TOURMALINE program, ixazomib is being evaluated in
multiple therapeutic combinations for various patient populations in
investigator initiated studies globally.
NINLAROTM (ixazomib): Global Important Safety
Information
SPECIAL WARNINGS AND PRECAUTIONS
Thrombocytopenia has been reported with NINLARO (28% vs. 14% in
the NINLARO and placebo regimens, respectively) with platelet nadirs
typically occurring between Days 14-21 of each 28-day cycle and recovery
to baseline by the start of the next cycle. It did not result in an
increase in hemorrhagic events or platelet transfusions. Monitor
platelet counts at least monthly during treatment with NINLARO and
consider more frequent monitoring during the first three cycles. Manage
with dose modifications and platelet transfusions as per standard
medical guidelines.
Gastrointestinal toxicities have been reported in the NINLARO and
placebo regimens respectively, such as diarrhea (42% vs. 36%),
constipation (34% vs. 25%), nausea (26% vs. 21%), and vomiting (22% vs.
11%), occasionally requiring use of antiemetic and anti-diarrheal
medications, and supportive care.
Peripheral neuropathy was reported with NINLARO (28% vs. 21%
in the NINLARO and placebo regimens, respectively). The most commonly
reported reaction was peripheral sensory neuropathy (19% and 14% in the
NINLARO and placebo regimens, respectively). Peripheral motor neuropathy
was not commonly reported in either regimen (< 1%). Monitor patients for
symptoms of peripheral neuropathy and adjust dosing as needed.
Peripheral edema was reported with NINLARO (25% vs. 18% in
the NINLARO and placebo regimens, respectively). Evaluate patients for
underlying causes and provide supportive care, as necessary. Adjust the
dose of dexamethasone per its prescribing information or the dose of
NINLARO for severe symptoms.
Cutaneous reactions occurred in 19% of patients in the NINLARO
regimen compared to 11% of patients in the placebo regimen. The most
common type of rash reported in both regimens was maculo-papular and
macular rash. Manage rash with supportive care, dose modification or
discontinuation.
Hepatotoxicity drug-induced liver injury, hepatocellular
injury, hepatic steatosis, and hepatitis cholestatic have been
uncommonly reported with NINLARO. Monitor hepatic enzymes regularly and
adjust dose for Grade 3 or 4 symptoms.
Pregnancy NINLARO can cause fetal harm. Advise male and females
patients of reproductive potential to use contraceptive measures during
treatment and for an additional 90 days after the final dose of NINLARO.
Women of childbearing potential should avoid becoming pregnant while
taking NINLARO due to potential hazard to the fetus. Women using
hormonal contraceptives should use an additional barrier method of
contraception.
Lactation It is not known whether NINLARO or its metabolites are
excreted in human milk. There could be potential adverse events in
nursing infants and therefore breastfeeding should be discontinued.
SPECIAL PATIENT POPULATIONS
Hepatic Impairment: Reduce the NINLARO starting dose to 3 mg in
patients with moderate or severe hepatic impairment.
Renal Impairment: Reduce the NINLARO starting dose to 3 mg in
patients with severe renal impairment or end-stage renal disease (ESRD)
requiring dialysis. NINLARO is not dialyzable and, therefore, can be
administered without regard to the timing of dialysis.
DRUG INTERACTIONS
Co-administration of strong CYP3A inducers with NINLARO is not
recommended.
ADVERSE REACTIONS
The most frequently reported adverse reactions (≥ 20%) in the NINLARO
regimen, and greater than in the placebo regimen, were diarrhea (42% vs.
36%), constipation (34% vs. 25%), thrombocytopenia (28% vs. 14%),
peripheral neuropathy (28% vs. 21%), nausea (26% vs. 21%), peripheral
edema (25% vs. 18%), vomiting (22% vs. 11%), and back pain (21% vs.
16%). Serious adverse reactions reported in ≥ 2% of patients included
thrombocytopenia (2%) and diarrhea (2%). For each adverse reaction, one
or more of the three drugs was discontinued in ≤ 1% of patients in the
NINLARO regimen.
For European Union Summary of Product Characteristics: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf
For
US Prescribing Information: https://www.ninlarohcp.com/pdf/prescribing-information.pdf
For
Canada Product Monograph: http://www.takedacanada.com/ninlaropm
About Takeda
Takeda Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing better
health and a brighter future to patients by translating science into
life-changing medicines. Takeda focuses its R&D efforts on oncology,
gastroenterology and central nervous system therapeutic areas plus
vaccines. Takeda conducts R&D both internally and with partners to stay
at the leading edge of innovation. New innovative products, especially
in oncology and gastroenterology, as well as our presence in Emerging
Markets, fuel the growth of Takeda. More than 30,000 Takeda employees
are committed to improving quality of life for patients, working with
our partners in health care in more than 70 countries. For more
information, visit http://www.takeda.com/news.
Additional information about Takeda is available through its corporate
website, www.takeda.com,
and additional information about Takeda Oncology, the brand for the
global oncology business unit of Takeda Pharmaceutical Company Limited,
is available through its website, www.takedaoncology.com.
Contacts
Takeda Pharmaceutical Company Limited
Japanese Media
Tsuyoshi
Tada, +81 (0) 3-3278-2417
tsuyoshi.tada@takeda.com
or
European
Media
Kate Burd, +44 7974 151510
kate.burd@takeda.com
or
Media
outside Japan/EU
Sara Noonan, +1-508-566-2408
sara.noonan@takeda.com
株式会社ピューズ・人とくるまのテクノロジー展2017 名古屋出展… 2017年06月23日 08時00分
東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- 電気自動車の車両開発、テクニカルコンサルティング、部品販売を行う(株)ピューズ(本社：東京、代表取締役社長：竹田清人、www.pues.co.jp)は、2017年6月28日（水）から30日（金）まで、ポートメッセなごや（名古屋市港区金城ふ頭）で開催される（公社）自動車技術会主催
自動車技術展「人とくるまのテクノロジー展2017名古屋」（画像：https://www.pues.co.jp/images/Pers2.jpg）にグループ会社の(株)東京アールアンドデー(www.tr-d.co.jp)、東京R&Dコンポジット工業(株)（www.trdc.co.jp）と3社で共同出展いたします。
本展示会では、「電気バス用バッテリパック（UN-ECE-R100.02の安全基準認証済）」（画像：http://www.pues.co.jp/release/nbc.jpg）、「電動小型車両用急速充電器(DC48V対応)」、「モータ」、「インバータ」、「バッテリ制御システム（BMS）」、「絶縁劣化検知センサー（CEL4）」「燃料電池試験モジュール」（画像：http://www.pues.co.jp/images/170519_fc-test-module01.jpg、http://www.pues.co.jp/images/170519_fc-test-module02.jpg）など次世代自動車技術に繋がる幅広い要素を展示いたします。
■会期：2017年6月28日（水）～30日（金）AM10:00 ～ PM6:00 （26日のみPM5:00）
■場所：ポートメッセなごや 名古屋市国際展示場（名古屋市港区金城ふ頭二丁目2番地）
■小間番号：(株)ピューズ【185】
■展示会オフィシャルサイト：http://expo-nagoya.jsae.or.jp/
【会社概要】
(株)ピューズは、お客様のご要求に合わせて、常に最新の情報・手法に基づき、自動車用電動駆動システム、制御システムの研究・開発・製作・評価を行い試作から量産まで対応します。
名称：株式会社ピューズ
代表取締役社長：竹田
清人
URL：http://www.pues.co.jp
Contacts
【本件に関する問い合わせ先】
株式会社ピューズ
担当：営業企画部 石川 智久
TEL：046-226-5501
FAX：046-226-5505
E-MAIL：ishikawa.tomohisa@pues.co.jp
Former Senator John Edwards Representing Thousands of Unite… 2017年06月23日 06時16分
Ninth Circuit Rules Sailors Will Get Their Day in U.S. Court
RALEIGH, N.C.--(BUSINESS WIRE)--Today, the United States Ninth Circuit Court of Appeals ruled in favor
of the U.S. sailors who were exposed to dangerous levels of radiation
assisting in humanitarian relief efforts to Japan following an
earthquake and tsunami in 2011. Based on the ruling, the sailors are
able to continue their suit against Tokyo Electric Power Co. Holdings
Inc. (TEPCO) allowing the sailors to pursue their case in the District
Court in San Diego. It is possible that the nuclear meltdown at the
Fukushima plant affected up to 75,000 U.S. citizens, even after TEPCO
deemed the conditions safe.
After meeting with attorneys from both sides last December, the United
States Government submitted an amicus curiae brief
expressing its belief that nothing should prevent the sailors from
litigating their case here in America. Today’s Court of Appeals ruling
reinforces the government’s desire that the sailors’ fight for justice
will take place in the United States and not Japan as TEPCO and the
Government of Japan had previously requested.
“These members of the United States Navy deserve their day in court, and
they will get it,” said former Senator Edwards. “These American heroes
served the United States and were innocent victims in a nuclear disaster
that never should have happened. This case has broad U.S. interests,
both because of our nation’s long-standing relationship with Japan, and
because plaintiffs in this case are members of the U.S. military harmed
while on a humanitarian mission.”
As recently as this week, three former executives from TEPCO were
charged criminally in Japan with contributing to deaths and injuries
stemming from the meltdown at the Fukushima nuclear power plant. In
addition, the Japanese government investigated the nuclear disaster and
found that TEPCO was grossly negligent.
In 2011, U.S. sailors aboard the aircraft carrier U.S.S. Ronald Reagan
were poisoned by radiation during Operation Tomodachi (“friend”). The
humanitarian mission was in response to a 9.0 magnitude earthquake which
triggered a tsunami in Japan that led to the Fukushima nuclear disaster.
Relief efforts included delivering food, supplies and clothing to the
people ravaged by the earthquake and tsunami.
The plaintiffs, led by Lindsay R. Cooper and other members of the U.S.
Navy and their dependents, have suffered and continue to be diagnosed
with extensive injuries including blindness, thyroid cancer, leukemia
and brain tumors. The lawsuit is not only against TEPCO, but several
other co-defendants, including General Electric, EBASCO, Toshiba Corp.
and Hitachi.
Former Senator Edwards, his daughter Cate Edwards and California-based
attorneys Charles Bonner, Cabral Bonner and Paul Garner are continuing
to expand their suit against TEPCO. If you are a U.S. Sailor affected by
this, you can reach attorneys working on this litigation at 844.283.9434
or http://fukushima.edwardskirby.com/
About Edwards Kirby:
Edwards Kirby is a national law firm, led by former U.S. Senator and
trial attorney John Edwards and David Kirby, with offices in Raleigh,
N.C. and San Diego, CA. The firm offers leading representation for
plaintiffs in matters of personal injury, public and product safety,
consumer protection, health care and medical liability, or civil rights
and discrimination. For more information on the firm or its attorneys,
please visit www.edwardskirby.com.
Contacts
Edwards Kirby
Natalie Best, media@edwardskirby.com
Global Diagnostic Catheters Market to Grow at a CAGR of 7.3… 2017年06月23日 04時50分
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global
Diagnostic Catheters Market Insights, Opportunity, Analysis, Market
Shares And Forecast 2017 - 2023" report to their offering.
The global diagnostics catheters market is estimated to grow with
approx. 7.3% CAGR during the year 2016 - 2023.
The key driver increasing the growth of the global diagnostic catheters
market is technological innovation, growing prevalence of cardiovascular
disorders, and increase in number of diagnostic and imaging centers.
However, lack of professionals in the diagnostic and imaging procedure,
reuse of disposable diagnostic catheters and growth of diagnostic
catheters in the developing countries such as India, China, etc., are
hampering the growth of the diagnostic catheters market.
The global diagnostics catheters market is segmented on the basis of
type, application area and end-user. On the basis of type of diagnostics
catheters market is sub segmented into imaging and non-imaging
diagnostic catheters. The imaging catheters product segment is
anticipated to share the largest size of the diagnostic catheters
market. Based on the application, the diagnostics catheters market is
sub divided into cardiology, urology, gastroenterology, neurology and
other. On the basis of end-users, the diagnostics catheters market is
sub-segmented into hospitals and diagnostic & imaging centers.
Companies Mentioned
Abbott Laboratories (U.S.)
B. Braun Melsungen AG (Germany)
Boston Scientific Corporation (U.S.)
C. R. Bard Inc. (United States)
Cardinal Health Inc. (U.S.)
Cardiomac India Pvt. Ltd. (India)
Edwards Lifesciences Corporation (U.S.)
Johnson & Johnson (U.S.)
Koninklijke Philips N.V. (Netherlands)
Medtronic Plc (Ireland)
Siemens AG (Germany)
St. Jude Medical Inc. (U.S.)
Stryker Corporation (U.S.)
Terumo Corporation (Japan)
Trimble Navigation (U.S.)
Key Topics Covered:
1. Introduction
2. Market Overview
3. Market Determinants
4. Market Segmentation
5. Competitive Landscape
6. Global Diagnostics Catheters Market By Region
7. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/6pxl2p/global_diagnostic.
Contacts
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Diagnostics,
Catheters
Global Automotive Variable Displacement Engine Market to Gr… 2017年06月23日 03時16分
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global
Automotive Variable Displacement Engine Market 2017-2021"
report to their offering.
The global automotive variable displacement market to grow at a CAGR of
27.09% during the period 2017-2021.
This report, Global Automotive Variable Displacement Market 2017-2021,
has been prepared based on an in-depth market analysis with inputs from
industry experts. The report covers the market landscape and its growth
prospects over the coming years. The report also includes a discussion
operating in this market.
According to the report, one of the major drivers for this market is
increase in fuel economy at lower additional price. DEAC is a technology
that is growing in high-performance vehicles because of the increasing
need for fuel economy and improved performance. The increasing demand
for luxury cars in APAC, in countries like China, Japan, and India, is a
key factor in market growth. The rise in popularity of different types
of automotive racing events around the world also helps to drive the
global automotive variable displacement engine market.
Key vendors:
Fiat Chrysler Automobiles (FCA)
Ford Motor
General Motors
Honda
Volkswagen
Other prominent vendors:
Daimler
Delphi
Eaton
Toyota
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Market landscape
Part 06: Market segmentation by vehicle type
Part 07: Geographical segmentation
Part 08: Key leading countries
Part 09: Decision framework
Part 10: Drivers and challenges
Part 11: Market trends
Part 12: Vendor landscape
Part 13: Key vendor analysis
For more information about this report visit https://www.researchandmarkets.com/research/npphw9/global_automotive.
Contacts
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Engines
and Engine Parts
ARMのサイモン・シガースCEOがソフトバンクグループの取締役会… 2017年06月22日 23時25分
英ケンブリッジ--(BUSINESS WIRE)--（ビジネスワイヤ） --
ARMホールディングスは本日、サイモン・シガース最高経営責任者（CEO）のソフトバンクグループ（SBG）取締会への任命が、東京で本日開催されたSBGの第37回年次株主総会で正式に承認されたと発表しました。
SBGは先頃、コーポレート・ガバナンスの強化と成長加速に向けて、取締役会の新たな候補を発表しました。シガースの任命は、ソフトバンクが2016年に実施したARMの歴史的買収（320億米ドル）に続くものです。
シガースは、次のように述べています。「この心躍る技術革新の次の段階でソフトバンクの取締役会に参加できて光栄です。ソフトバンクがチップからクラウドまでとその間のあらゆるポイントでモバイルコンピューティングを変革したのと同じ方法で、ARMは共通プラットフォーム全体でIOTのスマート接続された世界を形作っています。これがソフトバンクのビジョンの中心にあるものであり、私はそれを実現するためにそのチームと共に働きたいと思います。」
SBGの第37回年次株主総会に関する詳細は、こちらでご覧いただけます。
サイモン・シガースについて
サイモン・シガース最高経営責任者（CEO）は、25年間にわたり技術業界の変革の中心にいました。世界初となる初期のデジタル携帯電話向けARMプロセッサーの開発を主導し、現在はすべての人のためにより良い社会、経済、教育、健康の見通しを実現するスマート接続技術に向けたARMのビジョンを推進しています。2013年7月に最高経営責任者（CEO）に任命される前は、シガースはARMの技術・事業開発チームでいくつかの幹部職を経験しました。カリフォルニア州のシリコンバレーを拠点とし、米国、欧州、中国の世界的な技術の中心都市で影響力のある著名人に会うことに多くの時間を費やしています。
ソフトバンクグループ取締役会への参加に加えて、シガースは国際半導体連合（GSA）と電気システム設計連合（ESDアライアンス）の理事と、ドルビーラボラトリーズの非常勤取締役を務めています。
ARMについて
ARMの技術は、人々の暮らし方と企業の仕事の仕方を変革するコンピューティングと接続性の革命の中心に位置しています。当社の先進的でエネルギー効率の高いプロセッサーの設計は、1000億個のシリコンチップのインテリジェンスを可能にし、センサーからスマートフォンやスーパーコンピューターまでの製品を安全に支えています。世界最大の企業や消費財ブランドを含む1000社以上の技術パートナーと協力する当社は、チップ、ネットワーク、クラウドといった計算が発生するあらゆる領域にARMの技術革新を広げています。
ソフトバンクグループについて
ソフトバンクグループは、情報革命の推進を目指す世界的な技術企業です。ソフトバンクグループは、持株会社ソフトバンクグループ株式会社（東証：9984）と世界的な企業ポートフォリオで構成されています。企業ポートフォリオには、先進的な電気通信、インターネットサービス、AI、スマートロボット工学、IoT、クリーンエネルギー技術の提供企業が含まれます。2016年9月に、世界有数の半導体IP企業のARMホールディングスがソフトバンクグループに加わりました。詳細については、www.softbank.comをご覧ください。
本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。
Contacts
for ARM Holdings
Eliza Walsh
arm@allisonpr.com
Keio Plaza Hotel Tokyo Hosts "Princess Mermaid Sweets Buffe… 2017年06月22日 23時00分
TOKYO--(BUSINESS WIRE)--#art--Keio
Plaza Hotel Tokyo, one of Japan’s most prestigious international
hotels located in Shinjuku, Tokyo, will host the “Princess Mermaid
Sweets Buffet” to commemorate the fairy tale “The Little Mermaid”
written by the Danish author Hans Christian Andersen. This buffet will
offer specially prepared desserts patterned after various sea creatures
reminiscent of characters from The Little Mermaid fairy tale, and be
held at the All
Day Dining restaurant “Jurin” on the second floor of our Hotel from
July 1 to September 30, 2017.
This year’s desserts will represent an even wider variety of sea
creatures than last year’s event, and includes tarts reminiscent of cute
“hermit crabs” using waffle cones in the shape of conch shells, bread
made to look like seals, cream puffs patterned after fish, and moray eel
shaped rolled cakes amongst others. Also, special “Blue Mermaid Jelly”
using Blue Hawaii flavored gelee, and macaroons made to look like mother
of pearl oysters matching the mood of the summer season will be served
to guests.
During July, we will also prepare special foods made from watermelon,
which is one of the most popular fruits eaten in Japan during the
summer, for the enjoyment of our repeat guests. These seasonal desserts
and beverages include watermelon and strawberry tart, watermelon fruit
punch and other refreshing menu items.
Our All Day Dining restaurant “Jurin” is known for its specially
prepared seasonal meals based upon various fairy tales including
“Alice’s Adventures in Wonderland” and “Peter Rabbit”. Our patissiers
will display their talents by creating a wide variety of delicious
desserts divided into five different categories on our 15 meter long
counter for customers to enjoy every day from 3:00p.m. to 5:30p.m.
during the event. This buffet was also held last year, and the various
desserts reminiscent of characters from “The Little Mermaid” was very
well received. In addition, we also offer special wedding plans based
upon “The Little Mermaid” to expand the range of guests who can enjoy
participating in this themed event.
| ||
Date: | From July 1 to September 30, 2017 | |
Venue: |
| |
Time: | 3:00p.m. to 5:30p.m. | |
Fees: | JPY 3,800 per adult | |
| ||
Contacts
Keio Plaza Hotel Tokyo
Keiko Kawashima, +81-3-5322-8010
Public
Relations Manager
keiko-kawashima@keioplaza.co.jp
Cigarettes to Record US$7.7 Billion Loss by 2021 as Heated … 2017年06月22日 22時06分
LONDON--(BUSINESS WIRE)--Global market
research company Euromonitor International released today new
tobacco data. According to the new research, the cigarettes market will
record a US$7.7 billion loss by 2021, compensated by the US$13.2 billion
growth in heated tobacco products sales in the same period.
Euromonitor International’s new data show that in 2016, for the first
time in decades, the value of the global cigarettes category as a
proportion of total tobacco sales fell below 90 percent and by 2021 it
will reach 86 percent. While cigarettes sales decline, the new research
highlights growth in the use of vapour products but also further changes
within this segment.
Shane MacGuill, head of tobacco research at Euromonitor International
comments: “The continued growth in vapour products and in particular the
emergence of heated tobacco as a viable alternative mode of consumption,
represent the major element of disruption for the tobacco industry.”
The new research shows that heated tobacco will be the fastest-growing
tobacco category in the next five years to reach US$ 15.4 billion in
2021, up from 2 billion in 2016, recording a 691 percent growth.
According to the new data, in 2016:
Japan was the largest heated tobacco market, accounting for a share of
96 percent of heated tobacco products global sales
Germany was the second largest heated tobacco market but the USA will
take its place by 2021
The third and fourth largest markets for heated tobacco products were
Switzerland and Portugal respectively, which were also amongst the
fastest growing markets
MacGuill concludes: “We believe that heated tobacco will gain a solid
presence in at least 35 global markets by 2021, accounting for a share
of 3.5 percent of total global cigarettes and heated tobacco value.
Heated tobacco prospects are strong and strengthening. On this evidence,
it is a truly a coming force in global tobacco.”
For more information, please visit: http://blog.euromonitor.com/category/tobacco
About Euromonitor International
Euromonitor
International is the world’s leading provider for global business
intelligence and strategic market analysis. We have more than 40 years
of experience publishing international market reports, business
reference books and online databases on consumer markets.
Contacts
Euromonitor International
Violetta Scola
Global Media
Relations Specialist
Tel: +44 (0) 20 7251 8024 EXT 1360
violetta.scola@euromonitor.com
Prudential Financial to Host 2018 Tokyo Investor Day 2017年06月22日 22時00分
NEWARK, N.J.--(BUSINESS WIRE)--Prudential Financial, Inc. (NYSE:PRU) will host a conference for
analysts and investors in Tokyo, Japan on Thursday, September 27, 2018.
Details will be announced closer to the date of the meeting.
Questions may be directed to Investor Relations at investor.relations@prudential.com.
Prudential Financial, Inc. (NYSE:
PRU), a financial services leader with more than $1 trillion of
assets under management as of March 31, 2017, has operations in the
United States, Asia, Europe, and Latin America. Prudential’s diverse and
talented employees are committed to helping individual and institutional
customers grow and protect their wealth through a variety of products
and services, including life insurance, annuities, retirement-related
services, mutual funds and investment management. In the U.S.,
Prudential’s iconic Rock symbol has stood for strength, stability,
expertise and innovation for more than a century. For more information,
please visit news.prudential.com.
Contacts
MEDIA:
Prudential Financial, Inc.
Laura Burke,
973-802-9489
laura.burke@prudential.com
Prince Hotels and Resorts Provides You the Experience of th… 2017年06月22日 18時30分
Hotel Guests can enjoy stargazing, fireworks, hot springs, pools
and Mount Fuji
TOKYO--(BUSINESS WIRE)--#experience--Prince
Hotels and Resorts, the chain of hotels that best represents
Japanese hospitality, has hotels and entertainment facilities throughout
Japan. Beginning this year, Prince Hotels will offer delightful plans to
enable guests from overseas to experience summers in Japan.
Venue for Enjoying Stargazing - Karuizawa
Karuizawa Township, in Nagano Prefecture roughly 1,000 meters above sea
level, is one of the best places in Japan for escaping the summer heat.
During the day, ride a converted ski lift for stunning views of Mount
Asama and panoramas of Karuizawa, and then at night, breathe deeply of
the cool mountain air and enjoy the beautiful star-studded night skies
from atop those peaks.
LOCATION: Karuizawa
Prince Hotel
TIME FRAME: August 11 to August 16, 2017
Karuizawa Prince Hotel
The Karuizawa Prince Hotel is famous
as a resort within Japan that includes golf courses, skiing, hot
springs, and a shopping plaza. Recent renovations of Karuizawa Prince
Hotel East, including guest rooms, the lobby, and restaurants will
reopen on July 12.
ADDRESS: Karuizawa, Karuizawa Township, Kita-Saku County, Nagano
Prefecture
RESERVATIONS & INQUIRIES: +81-(0)267-42-1111
http://www.princehotels.com/karuizawa-east/
Venues to Enjoy Fireworks, Hot Springs, and Mount Fuji - Hakone
The Hakone region, one of several famous locations within Japan for hot
springs, is also home to a fireworks festival. The fireworks festival
that occurs alongside the beautiful lake. Ashinoko, in Hakone, with
lovely views of Mount Fuji, is best when viewed from the lake’s surface,
aboard a pleasure craft. In addition to the three Prince Hotels in
Hakone, there is also a hot springs inn, Ryuguden,
where you can view the fireworks from the comfort of a Japanese-style
guest room.
FACILITY: Ryuguden (Ryokan)
Fireworks Viewing and Summer Evening Cruise
TIME FRAME: July 31 to
August 5, 2017
Fireworks Viewing from Guest Rooms
TIME FRAME: August 2 and 3, 2017
Ryuguden (Ryokan)
Ryuguden, a historical Japanese inn dating
back roughly 80 years, will be reopened on July 22 as a hot springs
facility, enabling guests to fully enjoy the delights of Hakone.
ADDRESS: 139 Moto-Hakone, Hakone Township, Ashigarashimo County,
Kanagawa Prefecture
RESERVATIONS & INQUIRIES: +81-(0)460-83-1121
http://www.princehotels.com/ryuguden/
Venue to Enjoy Pools, Hot Springs, and Mount Fuji - Oiso
Prince Hotels offers a variety of arrangements that combine pools with
lodgings. Among them is Oiso Prince Hotel, which includes multiple
different pools at the facility, with a 140 meter-long water slide, a
relaxing lazy river pool, and a wave pool, among many more attractions.
Located at the famous Oiso
Long Beach, your enjoyment includes stunning views of the Shonan
seacoast and Mount Fuji. Oiso is also close to Tokyo, Kamakura, and
Hakone, making it a convenient central location for various different
tourism opportunities.
FACILITY: Oiso Long Beach : http://www.princehotels.com/oiso/facilities/oiso-long-beach/
TIME
FRAME: July 8 to September 18
Oiso Prince Hotel
Roughly an hour from Tokyo, the
Oiso Prince Hotel is a resort hotel with a vantage point that looks
out over the expansive Shonan seacoast and, on clear days, Mount Fuji. A
new hot springs and spa facility, THERMAL SPA S.WAVE, will open on July
15, taking maximum advantage of a location where visitors can view the
entire Shonan seacoast. Mount Fuji will be visible as well.
ADDRESS: 546 Kokufu Hongo, Oiso Township, Naka County, Kanagawa
Prefecture
RESERVATIONS & INQUIRIES: +81-(0)463-61-1111
http://www.princehotels.com/oiso/
For Reservations:
Prince Hotels Inc.
+81-3-6741-9155
Contacts
For Media Inquiries:
Prince Hotels, Inc.
Satoshi Kasai / Yuka
Hagiwara, +81-3-5928-1154
PR Department
ph-media@princehotels.co.jp
Toshiba Tec Demonstrates Sustainable Business Excellence by… 2017年06月22日 17時00分
TOKYO--(BUSINESS WIRE)--#BSI--Toshiba
Tec Corporation (TOKYO:6588) announced today that BSI (British
Standards Institution) in Japan, the business standards company, has
verified Toshiba Tec’s new eco-friendly multi-functional peripheral
(MFP) the e-STUDIO3508LP, e-STUDIO4508LP, e-STUDIO5008LP, and the paper
reusing device e-STUDIO RD301 meets the stringent requirements of the
Life Cycle Assessment (LCA) standards ISO 14040 and ISO 14044.
The e-STUDIO3508LP, e-STUDIO4508LP, and e-STUDIO5008LP are Toshiba Tec’s
unique and eco-conscious product which prints regular black prints as
well as erasable blue prints within one device. These products will
reduce environmental burden such as CO2 emission from paper production
by erasing the erasable blue prints and reusing the paper hence reducing
the paper consumption. BSI - the third party organization’s verification
ensured that Toshiba Tec’s calculation method of LCA for its
eco-friendly MFP is based on ISO 14040 and ISO 14044 which provides a
robust framework for assessing the environmental impact of a product or
service from the time of production through to product disposal. The
verification process reviewed the LCA calculation method of these new
MFPs for a five year period and compared it with that of Toshiba Tec’s
regular MFP. From this calculation method, printing the paper in
erasable blue five times and erasing them to reuse will reduce the CO2
emission by 57% compared to that of five black prints.*
Toshiba Tec strives to be one of the world’s leading eco-conscious
companies based on the company's Three Greens philosophy: Greening of
Products, Greening of Process, and Green Management. Complying with
rigorous verification standards is demonstration of Toshiba Tec’s
commitment to sustainable business improvement. By verifying its
products to ISO 14040 and ISO 14044, Toshiba Tec is taking major steps
towards addressing the environmental aspects and potential impacts
throughout a product's life - from initial raw material acquisition
through to final disposal.
* Conditions:
- Basic Electricity unit for CO2 in Japan
-
Basic Paper unit for CO2 in Japan
About Toshiba Tec
Toshiba Tec Corporation is a Toshiba’s group company, a leading provider
of technology solutions, operating across multiple industries – ranging
from retail, education and business services to hospitality and
manufacturing. With headquarters in Japan and over 80 subsidiaries
worldwide, Toshiba Tec Corporation helps organizations transform the way
they create, record, share, manage and display information.
Please visit http://www.toshibatec.co.jp/en/
For
Global site please visit http://www.toshibatec.com/global/
About BSI
BSI (British Standards Institution) is the business standards company
that equips businesses with the necessary solutions to turn standards of
best practice into habits of excellence. Formed in 1901, BSI was the
world’s first National Standards Body and a founding member of the
International Organization for Standardization (ISO). Over a century
later it continues to facilitate business improvement and organizational
resilience across the globe by helping its clients drive performance,
manage risk and grow sustainably through the adoption of international
management systems standards, many of which BSI originated. Renowned for
its marks of excellence including the consumer recognized BSI Kitemark™,
BSI’s influence spans multiple sectors with a particular focus on
Aerospace, Automotive, Built Environment, Food, Healthcare and IT. With
81,000 clients in 181 countries, BSI is an organization whose products
and services inspire excellence across the globe.
To learn more, please visit www.bsigroup.com
Unless otherwise specified and/or credited all images, artwork, text and
graphics, logos and logotypes are the copyright and/or trademark of the
respective owners. All rights reserved.
Contacts
Media Contact
Toshiba Tec Corporation
Toshihiko “Tommy”
Minato, +81-(0)50-3681-5528
Marketing Department
Products,
Marketing & Service Division
Printing Solutions Business Group
Toshihiko_Minato@toshibatec.co.jp
東芝：三相ブラシレスモータドライバICの製品化について 2017年06月22日 16時18分
― 小型モータ、高速回転を実現するモータドライバIC ―
東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- 株式会社東芝ストレージ＆デバイスソリューション社は、家電・産業機器で使われる小型ファンモータ向けに、高速回転に対応した三相ブラシレスモータドライバIC、12V電源対応の「TC78B015FTG」と24V電源対応の「TC78B015AFTG」を製品化し、本日から量産出荷を開始します。
サーバーファンなどの冷却用ファンは、省スペースのための小型化、冷却能力を高めるための高速回転化が求められています。
新製品は、小型モータの限られた基板スペースへの実装に対応するため、小型パッケージを採用するとともに、外付け部品の省スペース化を実現する１センサ駆動と電流検出抵抗レスシステムを採用しています。１センサ駆動システムでは、センサレス駆動に比べモータ動作の信頼性が向上し、ホールセンサの部品数を３センサ駆動の３つから１つに削減できます。また、電流検出抵抗レスシステムでは、従来必要であった、定格電力とサイズが大きい抵抗部品を無くすことができ、基板の省スペース化に貢献します。
高速回転への対応では、正弦波通電方式に比べ高速回転で安定した動作を実現できる150度通電方式を採用し、従来の120度通電方式より低振動化を実現しています。また、低出力オン抵抗(上下和0.24Ωtyp)の採用により、高速回転時に増加するモータ電流に対して、モータ動作時の発熱を抑え、3Aまでの大電流駆動に対応します。
新製品の主な特長
小型パッケージ
WQFN36（5mm×5mm×0.8mm）パッケージを採用し、小型ファンの限られた基板スペースへの実装が可能です。
基板の省スペース化
１センサ駆動と電流検出抵抗レスシステムを採用し、外付け実装部品の省スペース化に貢献します。
高速回転に対応
正弦波通電方式より高速回転で安定した動作を実現できる150度通電方式を採用し、従来の120度通電方式より低振動化を実現しています。
低損失
出力オン抵抗が0.24Ω(typ)と小さいためモータ動作時のIC自身の損失を低く抑えることができます。
| ||||
品番 | TC78B015FTG | TC78B015AFTG | ||
電源電圧 （動作範囲） |
|
| ||
出力電流 （動作範囲） | 3A | |||
駆動方式 | 150度通電方式 | |||
ホールセンサ | 1センサ | |||
電流検出抵抗 | 無し | |||
その他・特長 | ホール素子／ホールIC対応 | |||
速度制御入力：PWM信号入力／アナログ電圧入力対応 | ||||
異常検出機能：過熱検出、過電流検出、モータロック検出 | ||||
出力オン抵抗（上下和）：0.24Ωtyp | ||||
パッケージ | WQFN36(5mm×5mm×0.8mm) | |||
新製品のさらに詳しい仕様については下記ページをご覧ください。
TC78B015FTG
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TC78B015FTG®ion=jp&lang=ja
TC78B015AFTG
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TC78B015AFTG®ion=jp&lang=ja
お客様からの製品に関するお問い合わせ先：
ミックスドシグナルIC営業推進部
Tel: 044-548-2821
https://toshiba.semicon-storage.com/jp/contact.html
＊本資料に掲載されている情報（製品の価格／仕様、サービスの内容及びお問い合わせ先など）は、発表日現在の情報です。予告なしに変更されることがありますので、あらかじめご了承ください。
Contacts
報道関係の本資料に関するお問い合わせ先：
株式会社東芝 ストレージ＆デバイスソリューション社
デジタルマーケティング部
長沢千秋
Tel:
03-3457-4963
e-mail: semicon-NR-mailbox@ml.toshiba.co.jp
Toshiba's New Three-phase Brushless Motor Drivers Realize H… 2017年06月22日 16時18分
TOKYO--(BUSINESS WIRE)--Toshiba
Corporation's (TOKYO:6502) Storage & Electronic Devices Solutions
Company today announced the launch of the three-phase brushless motor
drivers “TC78B015FTG” for 12V power supply and “TC78B015AFTG” for 24V
power supply. The new ICs support high speed rotation of small fan
motors suited to home appliances and industrial equipment. Mass
production starts today.
Ideally, cooling fans, such as server fans, combine minimized size with
a high rotation speed that ensures a high cooling capability. Toshiba’s
new products adopt small packages that can be mounted on the limited
board space of small motors. They also reduce the external component
count with a one-sensor drive and current detection resistor-free
system. One-sensor driving secures more reliable motor operation than a
sensorless drive and reduces the number of hall sensors from three
(required for a 3-sensor drive) to one. The current detection
resistor-free system can reduce rated power supply and eliminate the
large resistors previously required. These all contribute to reduced
demand for space on wiring boards.
High speed rotation is achieved with a 150-degree commutation system.
Rotation is faster and more stable than with a sine-wave commutation
system, and vibration is lower than in a conventional 120-degree
commutation system. Adoption of low on-resistance (upper + lower: 0.24Ω
(typ.)) ensures suppression of heat generated from increased motor
current by a high frequency drive, realizing support of a large current
drive of up to 3A.
Main Features of New Products
Small package
WQFN 36 (5mm x 5mm x 0.8mm) package that can be
mounted on the limited board space of small fans.
Space saving for boards
One-sensor drive and current detection
resistor-less system save space previously required for mounting
external components.
High speed rotation
A 150-degree commutation system realizes
faster and more stable rotation than a sine-wave commutation system
and lower vibration than a 120-degree commutation system.
Low loss
IC loss during motor operation can be suppressed by low
on-resistance of 0.24 Ω (typ.).
| ||||
Part number | TC78B015FTG | TC78B015AFTG | ||
| 6 V to 22 V | 6 V to 30 V | ||
| 3 A | |||
Driving system | 150-degree commutation system | |||
Hall sensor | One sensor | |||
Current detection resistor | Unnecessary | |||
Other features | Support Hall devices and Hall ICs | |||
Speed control input: PWM input or analog voltage input | ||||
Abnormal detection functions: Thermal shutdown,
| ||||
Output on-resistance (upper + lower): 0.24 Ω (typ.) | ||||
Package | WQFN36 (5 mm × 5 mm × 0.8 mm) | |||
For more information about the new products, please visit:
TC78B015FTG
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TC78B015FTG®ion=apc&lang=en
TC78B015AFTG
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TC78B015AFTG®ion=jp&lang=ja
For more information about Toshiba motor drivers, please visit:
https://toshiba.semicon-storage.com/ap-en/product/linear/motordriver.html
Customer Inquiries:
Mixed Signal IC Sales and Marketing Department
Tel:
+81-44-548-2821
https://toshiba.semicon-storage.com/ap-en/contact.html
Information in this document, including product prices and
specifications, content of services and contact information, is correct
on the date of the announcement but is subject to change without prior
notice.
About Toshiba
Toshiba Corporation, a Fortune Global 500 company,
channels world-class capabilities in advanced electronic and electrical
product and systems into three focus business fields: Energy that
sustains everyday life, that is cleaner and safer; Infrastructure that
sustains quality of life; and Storage that sustains the advanced
information society. Guided by the principles of The Basic Commitment of
the Toshiba Group, “Committed to People, Committed to the Future”,
Toshiba promotes global operations and is contributing to the
realization of a world where generations to come can live better lives.
Founded in Tokyo in 1875, today’s Toshiba is at the heart of a global
network of 550 consolidated companies employing 188,000 people
worldwide, with annual sales surpassing 5.6 trillion yen (US$50
billion). (As of March 31, 2016.)
To find out more about Toshiba,
visit www.toshiba.co.jp/index.htm
Contacts
Media Inquiries:
Toshiba Corporation
Storage & Electronic
Devices Solutions Company
Digital Marketing Department
Chiaki
Nagasawa, +81-3-3457-4963
semicon-NR-mailbox@ml.toshiba.co.jp
ファインデックス、訪問看護データの集積とAI分析に関する取り… 2017年06月22日 11時00分
「在宅アセスメントシステム」で集められる訪問看護データとAIを活用し、訪問看護の質の向上と高齢化社会を見据えた在宅ケアの充実、医療・介護費用削減を支援
東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- 株式会社ファインデックス（東証一部：3649
本社：東京 代表取締役：相原輝夫、以下ファインデックス）は、全国の訪問看護事業所へ「在宅アセスメントシステム
※1」のサービス提供を開始いたします。このサービスを通じて全国の訪問看護データを集積しAIなどを活用して分析を行っていきます。
ファインデックスの在宅アセスメントシステムは、アセスメントによる客観的な状態把握と根拠に基づく看護計画の立案を支援するクラウド型サービスです。このサービスを通じて集められる全国の訪問看護のデータをAIで分析することにより、異常の早期発見や重症化の予測を行い治療の変更や観察の強化を行うことで病気や介護の予防へとつなげていくことができます。訪問看護だけでなく医療や介護も含めた在宅ケア全体の評価をシステムとデータが支援することで、国の抱える在宅ケアの充実や医療費及び介護保険費用の削減にも貢献できると考えます。
団塊世代が75歳以上となる超高齢社会を迎えるにあたり、在宅ケアの充実や医療・介護に係る費用削減は喫緊の課題となっています。国民一人一人の自立と尊厳を支えるケアを将来に渡って持続的に実現する為には、医療及び介護の一体化を図り切れ目のない提供体制を構築することが必要不可欠です。既に地域包括ケアシステムなどの新たな仕組みが構築され始めていますが、在宅ケアにおける連携をより強固にしていく為にはICTを活用して医療と介護のデータを集積し活用していくことが重要になります。
在宅ケアにおいては、医師、ケアマネージャー、ヘルパーなど様々な関係者が療養生活を支援しています。その中にあっても、医療の専門知識を持ち頻繁に患者宅を訪問して医療と介護の両方にわたる幅広いケアを提供しているのは訪問看護師です。ICTを利用して訪問看護のデータを集めることができれば、訪問看護だけでなく在宅ケア全体の基礎データとして様々な用途に活用していくことができます。
現在、訪問看護の現場においても、質の向上や均等化を図るために訪問看護計画の重要性が問われていますが、在宅アセスメントシステムで集められる客観的なデータをAIが学習することで、最適な看護計画の自動立案と自己成長を図り、訪問看護事業所における業務の効率化と質の向上を支援することも可能になります。
今後は在宅アセスメントシステムを全国へと広めていくことで、訪問看護事業所の業務を支援するだけでなく各事業所のサービス向上や国の施策にも役立てられる有益なデータを集めていきます。連結子会社のイーグルマトリックスコンサルティング株式会社はAIなどを活用したデータ分析の実績を多く有していることから、双方の強みを活かして価値あるデータの集積と分析を行うことで、超高齢化社会を迎える国の課題解決を支援していきます。
※1 在宅アセスメントシステム
ITを利用した定期的なアセスメント、客観的な評価を根拠とした訪問看護計画の立案、評価により、訪問看護における業務の効率化と質の向上を支援するシステムです。
詳しくはファインデックスHPのプレスリリース資料および製品紹介ページをご覧下さい。
〇2016年11月11日 在宅アセスメントシステム開発に関するプレスリリース発表
http://findex.co.jp/news_release/2016/nr_20161114.html
〇在宅アセスメントシステム製品ページ
http://findex.co.jp/products/medical/assessment/index.html
株式会社ファインデックスについて
ファインデックスは、医療システムのスペシャリストとして常に革新的なソリューションを創り出し、診療の効率化やデータ活用による研究や病院経営を支援してきました。ファインデックスの医療ソリューションは、全国の大学病院から診療所まで幅広い医療機関で利用されており、国立大学病院の70％以上、大規模病院の50%以上という高いシェアを獲得しています。医療以外の分野においても文書管理を中心とした業務効率化ソリューションを展開しており、AIを利用したデータ活用ビジネスにも取り組んでいます。
Contacts
株式会社ファインデックス
事業戦略室 横田千明
089-947-3388
chiaki.yokota@findex.co.jp
Global $2.86 Billion 3D Metal Printing Market Analysis 2014… 2017年06月22日 03時32分
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "3D
Metal Printing Market Analysis By Product (Titanium, Nickel, Steel,
Aluminum), By Application (Aerospace & Defense, Automotive, Medical &
Dental), By Form (Powder, Filament), By Region, By Country, And Segment
Forecasts, 2014 - 2025" report to their offering.
The global 3D metal printing market is expected to reach USD 2.86
billion by 2025.
Metals are the fastest-growing 3D printing materials worldwide on
account of high application scope coupled with increasing demand from
the medical and dental application.
The market has witnessed advancements, both in terms of technologies and
materials, in order to facilitate low cost and mass production of the
products. This would also lead to flexibility in designs and ease of
manufacturing of products for a wide range of applications.
Numerous companies including GE have been utilizing metal 3D printing
for the development of aerospace parts. In December 2016, Sigma Labs
entered into a new contract with Honeywell aerospace. The Defense
Advanced Research Project Agency (DARPA) selected the company for
completion of phase III of the Open Manufacturing (OM) program. It is
aimed at reducing the barriers involved in the metal 3D printing process
including speed, cost, and repeatability.
Further key findings from the report suggest:
Powder segment is expected to witness the fastest CAGR of over 30%
from 2016 to 2025 on account of significant technological development
in the field of metal printers
Aerospace & defense sector dominated the industry in 2015 with a share
of over 35% and is anticipated to witness significant growth on
account of high application scope in military aircraft, aircraft
engine, commercial aircraft, complex weapon systems, high volume
weapons, and munition components
The medical sector accounted for a share of over 30%, in terms of
revenue, in 2015 on account of increasing use of the technology in
medical implants, medical devices, and surgical equipment including
crowns & bridges, model castings, and abutments
Titanium is expected to witness rapid growth from 2016 to 2025 on
account of superior mechanical properties, accuracy in production, and
early adoption of the product in aerospace & defense and medical
industry
Asia Pacific is anticipated to witness the fastest growth of over 30%
from 2016 to 2025 on account of rapid industrial development,
supportive government policies, and high R&D investment in China,
Japan, and South Korea
New product development is one of the major strategies being adopted
by the industry players in order to strengthen their global position
Key Topics Covered:
1. Methodology and Scope
2. Executive Summary
3. 3D Metal Printing Market Variables, Trends & Scope
4. 3D Printing Metals Application Estimates & Trend Analysis
5. 3D Printing Metals Form Estimates & Trend Analysis
6. 3D Printing Metals Product Estimates & Trend Analysis
7. 3D Printing Metals Regional Estimates & Trend Analysis
8. Company Profiles
Arcam AB
ExOne GmbH
3D Systems Corporation
Materialise NV
Renishaw plc
Hoganas AB
Voxeljet AG
Carpenter Technology Corporation
Equispheres
GKN plc
Sandvik AB
LPW Technology Inc.
Optomec Inc.
EOS GmbH Electro Optical Systems
Concept Laser GmbH
For more information about this report visit https://www.researchandmarkets.com/research/7fzq9f/3d_metal_printing.
Contacts
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Metals
and Minerals, 3D
Printing
LeSportsac and Super Mario Power up for a New Travel Collec… 2017年06月21日 22時00分
Various Super Mario Items and Styles Coming This Holiday Season
REDMOND, Wash.--(BUSINESS WIRE)--LeSportsac and Nintendo have teamed up to celebrate one of the most
recognizable video game icons, Mario, with a special collection of
totes, backpacks and accessories – launching in time for the holiday
travel season.
Holding a treasured place in the hearts of millions, Mario’s adventures
have brought him to many strange places, including the far corners of
the Mushroom Kingdom and galaxies beyond. Working with Nintendo,
LeSportsac took Mario’s passion for exploration and translated it into
the brand’s best-selling, on-the-go styles. These include crossbodies,
totes, backpacks and weekenders, as well as small cosmetics and
accessories that even the Mushroom Kingdom’s most celebrated hero can
run away with on his many adventures.
The collaboration features two unique designs created exclusively for
the LeSportsac X Nintendo collection. Power-Up Burst is a colorful
homage to Mario’s iconic power-up items and classic foes, including Fire
Flowers, Super Mushrooms, 1-Up Mushrooms, Super Stars, coins, Goombas
and Koopas. The Mario Travel print portrays playful Mushroom
Kingdom-inspired travel memorabilia, such as luggage tags, passport
stamps and postcards on a bright red background.
Complementing the collection are five additional items, including an
authentic pouch shaped like the Game Boy system, a round Piranha Plant
pouch, and a Super Mario Bros. cosmetic. All styles will showcase
a custom Super Mario coin zipper pull – because it is all about
collecting those coins!
The LeSportsac X Nintendo collection launches in Japan on July 19 and
will be available in other countries, including the United States, this
fall.
For more information about Nintendo, visit http://www.nintendo.com/.
For more information about LeSportsac, visit https://www.lesportsac.com/.
About Nintendo: The worldwide pioneer in the creation of
interactive entertainment, Nintendo Co., Ltd., of Kyoto, Japan,
manufactures and markets hardware and software for its Nintendo Switch™
system and the Nintendo 3DS™ family of portable systems.
Since 1983, when it launched the Nintendo Entertainment System™,
Nintendo has sold more than 4.4 billion video games and more than 703
million hardware units globally, including Nintendo Switch and the
Nintendo 3DS family of systems, as well as the Game Boy™,
Game Boy Advance, Nintendo DS™ family of systems, Super NES™,
Nintendo 64™, Nintendo GameCube™, Wii™
and Wii U™ systems. It has also created industry icons that
have become well-known, household names, such as Mario, Donkey Kong,
Metroid, Zelda and Pokémon. A wholly owned subsidiary, Nintendo of
America Inc., based in Redmond, Wash., serves as headquarters for
Nintendo’s operations in the Americas. For more information about
Nintendo, please visit the company’s website at http://www.nintendo.com.
About LeSportsac: An iconic lifestyle brand with a global
outlook, LeSportsac was founded in 1974 by Melvin and Sandy Schifter,
who invented the original ripstop parachute nylon bags and luggage.
Today, the company (acquired by Itochu Corp. in 2011) has become known
worldwide for its lightweight, high quality accessories, combining
whimsical colors and prints with on-the-go functionality and enduring
quality. Designed in the USA and made to travel (whether just around the
block or around the globe), LeSportsac is a leader and innovator in the
accessories market, committed to creating stylish, versatile bags that
are made for the modern, mobile lifestyle and packed with possibilities.
Note to editors: Nintendo press materials are available at http://press.nintendo.com,
a password-protected site. To obtain a login, please register on the
site.
Contacts
GOLIN
Justin Aclin, 212-373-6004
jaclin@golin.com
or
Lisa
McKendall, 310-641-1556
lmckendall@golin.com
Selection of Preferred Bidder for the Sale of Toshiba Memor… 2017年06月21日 21時00分
TOKYO--(BUSINESS WIRE)--Toshiba Corporation (TOKYO:6502) hereby announces that its board of
directors today resolved to select the consortium of Innovation Network
Corporation of Japan, Bain Capital Private Equity LP, and Development
Bank of Japan (“the Consortium”) a preferred bidder in respect of the
sale of Toshiba Memory Corporation (“TMC”).
TMC was split from Toshiba Corporation on April 1, 2017, as a wholly
owned subsidiary responsible for Toshiba’s memory business. This was
done toward securing further management resources essential for the
continued growth of the memory business, and to support Toshiba in
enhancing its financial structure.
Toshiba has determined that the Consortium has presented the best
proposal, not only in terms of valuation, but also in respect to
certainty of closing, retention of employees, and maintenance of
sensitive technology within Japan.
Following this decision, Toshiba’s intention is to reach a mutually
satisfactory definitive agreement with the Consortium by the date of its
annual ordinary general meeting of shareholders, scheduled for June 28,
and to close the transaction within March 2018, upon clearance of all
the required processes, including competition law approvals in key
jurisdictions.
Related News: http://www.toshiba.co.jp/about/press/2017_06/pr0201.htm
About Toshiba
Founded in Tokyo in 1875, Toshiba Corporation is a Fortune Global 500
company that contributes to a better world and better lives with
innovative technologies in Energy, Infrastructure and Storage. Guided by
the philosophy of “Committed to People, Committed to the Future,”
Toshiba promotes operations through a global network of 551 consolidated
companies employing 188,000 people, with annual sales surpassing 5.6
trillion yen (US$50 billion; March 31, 2016).
Find out more about Toshiba at www.toshiba.co.jp/index.htm
Contacts
Press Contact
Toshiba Corporation
Kaori Hiraki, +81-3-3457-2100
Public
Relations & Investor Relations Div.
Media Relations Group
media.relations@toshiba.co.jp
ARM CEO Simon Segars Joins SoftBank Group Board of Directors 2017年06月21日 13時19分
CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--ARM Holdings plc today announced that CEO Simon Segars’ appointment to
the SoftBank Group Corp. (SBG) Board of Directors was formally approved
at SBG’s 37th Annual General Meeting of Shareholders held
today in Tokyo.
SBG earlier
announced new board candidates to strengthen corporate governance
and accelerate growth. Mr. Segars’ appointment comes following
SoftBank’s historic 2016 acquisition of ARM for US$32 billion.
“I’m honored to join the SoftBank Board at this exciting next stage of
innovation,” said Segars. “In the same way it transformed mobile
computing from chip to cloud and all points in between, ARM shapes the
smart, connected world of IOT across a common platform. This is at the
heart of the SoftBank vision and I look forward to working with the team
to make it a reality.”
More information on SBG’s 37th Annual General Meeting of Shareholders
can be found here.
About Simon Segars
Simon Segars, CEO, has been at the heart of transformational change in
the technology industry for 25 years. He led the development of early
ARM processors for the world’s first digital mobile phones and now
spearheads ARM’s vision for smart and connected technologies that create
better social, economic, education and health prospects for all. Before
being appointed CEO in July 2013, Simon held several leadership
positions within ARM’s engineering and business development teams. He is
based in California’s Silicon Valley, and spends much of his time
meeting leading influencers in the world’s technology hubs in the US,
Europe and China.
In addition to joining the Board of SoftBank Group, Simon serves on the
Boards of the Global Semiconductor Alliance (GSA), the Electric System
Design Alliance (ESD Alliance), and as a non-executive director at Dolby
Laboratories, Inc.
About ARM
ARM technology is at the heart of the computing and connectivity
revolution that is transforming the way people live and businesses
operate. Our advanced, energy-efficient processor designs are enabling
the intelligence in 100 billion silicon chips and securely powering
products from the sensor to the smartphone to the supercomputer. With
more than 1,000 technology partners including the world's
largest business and consumer brands, we are driving ARM innovation into
all areas compute is happening inside the chip, the network and the
cloud.
About SoftBank Group
The SoftBank
Group is a global technology player that aspires to drive the
Information Revolution. The SoftBank Group is comprised of the holding
company SoftBank Group Corp. (TOKYO: 9984) and its global portfolio of
companies, which includes advanced telecommunications, Internet
services, AI, smart robotics, IoT and clean energy technology providers.
In September 2016, ARM Holdings plc, the world's leading semiconductor
IP company, joined the SoftBank Group. To learn more, please visit www.softbank.com.
Contacts
for ARM Holdings
Eliza Walsh
arm@allisonpr.com
KKR Names Head of KKR Capital Markets Japan 2017年06月21日 12時32分
TOKYO--(BUSINESS WIRE)--Leading global investment firm KKR today announced the appointment of Go
Yamashita as Head of KKR Capital Markets (“KCM”) Japan.
In his role, Mr. Yamashita oversees a team of professionals who support
KKR, the Firm’s portfolio companies and other clients by providing
tailored capital markets advice and manage relationships and business
development with institutional investors in Japan.
Worldwide, the KCM team develops and implements traditional and
nontraditional capital solutions for investments and companies seeking
financing. In Japan, KCM arranged financing for key transactions
including KKR’s acquisitions of Panasonic Healthcare, Pioneer DJ,
Calsonic Kansei and Hitachi Koki, as well as Panasonic Healthcare’s
acquisition of Ascensia Diabetes Care.
“Japan is an integral part of our Asia strategy as Japanese companies
have the tremendous potential to expand and compete internationally.
Providing strong Japanese companies with the capital market resources to
fulfil their growth potential is an integral part of the equation,” said
Hiro Hirano, Member & CEO of KKR Japan. “Go’s extensive experience and
relationships with Japanese institutional investors helps strengthen our
capital markets solutions for Japanese companies and our institutional
partners. We are pleased to welcome him to the KKR Japan team.”
Mr. Yamashita joins KKR with nearly 20 years of professional experience,
including more than a decade in the financial services and investment
banking sector. He is a graduate of Keio University and holds an MBA
from Harvard Business School.
“KKR is at the forefront of Japan’s private equity industry and has
established a track record of helping Japanese companies carve out
non-core businesses and expand both organically and through accretive
mergers and acquisitions,” said Mr. Yamashita. “KKR Capital Markets
plays a key role in the success of KKR’s portfolio companies, and I am
very excited to be a part of the team.”
KKR has been investing in Japan through its pan-regional private equity
funds since 2010. Japan has been and continues to be a key focus for KKR
in the region, and the Firm has invested or committed approximately US$2
billion in the market. KKR has completed five acquisitions in the
market: Intelligence, Panasonic Healthcare, Pioneer DJ, Hitachi Koki,
and Calsonic Kansei as of March 31, 2017. KKR has also announced its
investment in Hitachi Kokusai Electric.
About KKR
KKR is a leading global investment firm that manages investments across
multiple asset classes including private equity, energy, infrastructure,
real estate, credit and hedge funds. KKR aims to generate attractive
investment returns by following a patient and disciplined investment
approach, employing world-class people, and driving growth and value
creation at the asset level. KKR invests its own capital alongside its
partners' capital and brings opportunities to others through its capital
markets business. References to KKR's investments may include the
activities of its sponsored funds. For additional information about KKR
& Co. L.P. (NYSE:KKR), please visit KKR's website at www.kkr.com and
on Twitter @KKR_Co.
Contacts
Media:
KKR Asia Pacific
Anita Davis, +852 3602-7335
Anita.Davis@kkr.com
or
Ashton
Consulting (For KKR Japan)
Brendan Jennings, +81 03 5425-7220
KKRJapanPR@ashton.jp
株式会社東京アールアンドデー・人とくるまのテクノロジー展201… 2017年06月21日 08時30分
東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- 株式会社東京アールアンドデー（本社：東京都千代田区、代表取締役社長：岡村了太、www.tr-d.co.jp）は、2017年6月28日（水）から30日（金）まで、ポートメッセなごや（愛知県名古屋市）で開催される「人とくるまのテクノロジー展2017
名古屋」にグループ会社の株式会社ピューズ（www.pues.co.jp）、東京R&Dコンポジット工業株式会社(www.trdc.co.jp)と共同出展いたします。
本展示会では、環境省事業「燃料電池小型トラックの開発」のご紹介、EV・FCV向け車両遠隔監視&データ分析ソリューション「Visual
M2M（最新版）」、ピューズ社によるUN-ECE-R100.02対応の「電気バス用バッテリパック」、DC48Vで充電可能な「電動小型車両用急速充電器」、東京R&Dコンポジット工業による「CFRP製自転車フレーム」など、次世代自動車技術に繋がる幅広い要素を展示致します。
■会期： 2017年6月28日（水）～30日（金）AM10:00 ～ PM6:00 （30日のみPM5:00）
■場所：
ポートメッセなごや（愛知県名古屋市港区金城ふ頭2丁目2）
■小間番号： ㈱東京アールアンドデー【185】
■展示会オフィシャルサイト：
http://expo-nagoya.jsae.or.jp/
Contacts
本件の問合せ先
株式会社東京アールアンドデー
広報部
担当：
水野 景太（みずの けいた）
Tel： ０４６－２２７－１１０１
Cotchett, Pitre & McCarthy Investigating Sharp Corporation … 2017年06月21日 03時40分
SAN FRANCISCO--(BUSINESS WIRE)--Cotchett, Pitre & McCarthy is currently investigating potential claims
on behalf of consumers who purchased a Sharp television that may have
been falsely advertised and which may not comply with federal safety
regulations. The false advertising may include the size of the picture,
the brightness of the television and UL standards for certain
televisions.
Sharp Corporation has filed a lawsuit against Hisense Electric Company,
which licensed the Sharp brand for televisions sold in the U.S.,
accusing Hisense of putting the Sharp brand name on poor-quality
televisions and deceptively advertising them.
The affected TV models include:
LC-32N4000U | LC-40N3000U | LC-40LB480U | LC-40N5000U | ||||||
LC-43N4000U | LC-43N6100U | LC-43N610CU | LC-43N7000U | ||||||
LC-50N3100U | LC-50N4000U | LC-50N5000U | LC-50N6000U | ||||||
LC-50N7000U | LC-55LB481U | LC-55N4000U | LC-55N5300U | ||||||
LC-55N6000U | LC-55N620CU | LC-55N7000U | LC-60N5100U | ||||||
LC-60N6200U | LC-60N7000U | LC-65N5200U | LC-65N7000U | ||||||
LC-65N9000U | LC-70N7lOOU | LC-75N620CU | LC-75N8000U | ||||||
If you purchased a Sharp television with one of the above model numbers
after June 2015, you may be impacted by our firm’s investigation. If you
would like to learn more about our investigation or have any questions,
please contact Alexandra Summer by email at asummer@cpmlegal.com,
by telephone at (650) 697-6000 or by filling out
this form.
Contacts
Cotchett, Pitre & McCarthy, LLP
Alexandra Summer, 650-697-6000
asummer@cpmlegal.com
Fax:
650-697-0577
840 Malcolm Road
Burlingame, CA 94010
